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ABSTRACT 
MECHANISMS OF CHROMATE-INDUCED SUPPRESSION OF RAD51: A ONE 
ENVIRONMENTAL HEALTH APPROACH 
Rachel M. Speer 
June 25, 2020 
Lung cancer is the leading cause of cancer death. Lung cancer is commonly 
associated with smoking, however, 1 in 5 women and 1 in 12 men who develop 
lung cancer are never-smokers. Environmental exposures, therefore, account for 
a significant portion of lung cancer cases. Hexavalent chromium [Cr(VI)] is a global 
environmental contaminant and known human lung carcinogen. Cr(VI) and other 
carcinogenic metals induce chromosome instability, an early event in lung cancer. 
Structural chromosome instability arises in part due to failed DNA repair. 
Particulate Cr(VI), the most potent form of Cr(VI), induces DNA double strand 
breaks and inhibits the high-fidelity DNA repair mechanism, homologous 
recombination. Specifically, the effector step of homologous recombination is 
affected shown by RAD51 failure. 
RAD51 failure is due to inhibited expression, inhibited localization to double 
strand breaks, or a combination of these two mechanisms. Little is known about 
the mechanisms of Cr(VI)-inhibited expression. However, Cr(VI) exposure results 
in downregulation of global expression, and it has been suggested epigenetic 
changes affect expression profiles after Cr(VI) exposure. Studies show changes in 
viii 
acetylation of the RAD51 promoter affect E2F1-mediated RAD51 transcription by 
altering the “histone code” as potential epigenetic mechanisms of inhibited 
expression. Studies also show changes in microRNAs are an additional epigenetic 
mechanism of Cr(VI)-altered expression, and this may provide an additional 
mechanism of inhibited RAD51 expression. 
The mechanisms of particulate Cr(VI)-induced RAD51 failure were 
investigated in a human lung cells, and key events were confirmed in a wildlife 
model, leatherback sea turtle (Dermochelys coriacea) cells. The leatherback 
model was included as a part of the One Environmental Health Approach to 
investigate particulate Cr(VI) carcinogenesis across species. This type of analysis 
is used to identify how two species with different environmental adaptations may 
have alternative responses to chemical exposures. Therefore, the hypothesis of 
this dissertation is: Prolonged exposure to particulate Cr(VI) inhibits RAD51 
expression through E2F1-inhibited transcription and alteration of microRNA 
expression profiles, and these effects are paralleled in a leatherback sea turtle 
model. 
We found particulate Cr(VI) inhibits RAD51 and E2F1 nuclear and whole 
cell protein and mRNA levels in human lung cells. Therefore, we aimed to show 
E2F1 modulates the RAD51 response to particulate Cr(VI). We found E2F1 
overexpression did not rescue particulate Cr(VI)-induced RAD51-failure after 
prolonged (120 h) exposure. However, when we knocked down E2F1 we found 
E2F1 knockdown does not inhibit RAD51 mRNA or protein expression but does 




RAD51 is normally functional. These results suggest E2F1 may affect RAD51 
localization to double strand breaks, but not expression after Cr(VI) exposure. As 
an alternative mechanism of inhibited RAD51 expression we next performed RNA 
sequencing (RNAseq) analysis to asses Cr(VI)-altered microRNA (miRNA) 
expression. This study showed Cr(VI) significantly affected global miRNA 
expression, a subset of which target homologous recombination genes and RAD51 
expression directly. These data advance our understanding of how Cr interferes 
with a critical cellular pathway that contributes to carcinogenesis.  
We previously reported particulate Cr(VI) induces structural chromosome 
instability in leatherback lung cells similarly to data in human lung cells with some 
differences. In this dissertation we confirmed particulate Cr(VI) induces DNA 
double strand breaks in leatherback lung cells. In analysis of DNA repair we found 
lower levels RAD51 foci after prolonged particulate Cr(VI) exposure compared to 
acute exposure in leatherback lung cells. However, the sister chromatid exchange 
assay showed homologous recombination is functional after prolonged particulate 
Cr(VI) exposure. These results are dissimilar to results in human lung cells 
indicating there are significant differences in the mechanistic response to 
particulate Cr(VI) exposure between human and leatherback lung cells.  
x 
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 CHAPTER 1: INTRODUCTION 
 
Part I: Chromium background 
Metals are associated with both industrial uses and biological processes. 
Some metals like iron (Fe), copper (Cu) and magnesium (Mg) are essential and 
have well characterized roles in biology. Other metals such as mercury (Hg) and 
lead (Pb) have no known biological functions but have been widely used in 
industry. Chromium (Cr) has extensive commercial uses and used to be 
considered an essential nutrient (Vincent, 2017). Cr has been used in a diverse 
range of applications for more than 200 years leading to industrial and societal 
advancements. The physical and chemical properties of Cr including its varying 
degrees of solubility, valence states and bright colors make it a desirable and 
useful resource. Consequently, the ever increasing and ubiquitous use of Cr has 
led to global environmental contamination and associated increased health risks. 
Negative health risks have been documented and associated with Cr exposure for 
well over a century dating back to the 1800s (IARC, 1980; Newman, 1980). 
However it wasn’t until 1980 that Cr was classified as a human carcinogen, and 
since then there have been several large assessments that aimed to better identify 






Chemical and physical properties 
Cr is a transition metal that occurs in the environment from natural and 
anthropogenic sources. The EPA’s Toxics Release Inventory Program reported in 
2016 12,259,441 lbs of Cr and 50,433,180 lbs of Cr compounds were released into 
the environment by anthropogenic means accounting for approximately 90% of the 
total release of Cr in the environment (TRI, 2016). Anthropogenic sources of Cr 
consist of the burning of fossil fuels and industrial processes notably the chrome 
plating industry, electroplating, cement work, leather tanneries and the production 
of dyes and pigments.  
Cr comes in many different forms ranging in solubility and valence state 
forming compounds with other elements including potassium (K), sodium (Na), Pb, 
zinc (Zn), barium (Ba) among others.  The valence states of Cr range from (-2) to 
(+6) with trivalent [Cr(III)] and hexavalent Cr [CrVI)] being the most prevalent and 
stable valence states (Kotas and Stasicka, 2000). Cr is found in the environment 
predominantly in the trivalent state. However, the desirable properties of Cr are 
associated with Cr(VI). Therefore, Cr(III) from the environment is converted into 
Cr(VI) compounds through a chemical process using sodium ash to produce 
soluble sodium chromate (ATSDR, 2012; Barnhart, 1997). Then, sodium chromate 
is converted to other particulate or soluble chromate compounds. As a result Cr(VI) 
in the environment is predominantly anthropogenic and is found in air, water and 
soil.  
Studies show the major form of Cr in water is hexavalent, in soil is trivalent, 




and Millero, 1990). However, the ratio of different valence states of Cr in the 
environment vary depending on pH and the presence of reducing agents (Cespon-
Romero et al., 1996). When considering human health, Cr(III) and Cr(VI) are 
considered to be the physiologically relevant forms due to their stability and 
widespread exposure to them.  
Chromate-worker exposures and regulations 
Cr is mined from the Earth’s crust predominantly in the trivalent form and is 
then processed into Cr(VI). Exposure in the Cr industry begins with the processing 
where the high temperatures required to convert Cr(III) to Cr(VI) create inhalation 
exposures (IARC, 1990; Langard and Norsheth, 1975). However, exposure to 
Cr(VI) extends far beyond this where it is used in many other industrial 
applications. The United States remains one of the largest chromate producers 
and users (Papp, 2015). Thus, there are occupational regulations aimed to 
decrease health risks associated with Cr(VI) exposure.  
The Occupational Safety and Health Administration's (OSHA) permissible 
exposure level for Cr(VI) is 5 ug/m3 as an 8‐hour time weighted average (OSHA, 
2006). OSHA assumes a working lifetime is 45 years. In sum, this evaluation 
means over the course of a working lifetime a chromate worker would experience 
225 ug/m3 work years of exposure. These health standards were last updated in 
2006 leaving 14 years of Cr(VI) research unaccounted for in the OSHA health 
assessment. It is important to also remember different types of Cr(VI) occupations 
have different levels and types of risk of exposure. Additionally, worldwide 




countries like Pakistan and China, which have less regulations than the United 
States posing significant health risk to Cr workers. For example, in China total 
atmospheric Cr emissions has grown at an average rate of 8.8% from 1990 to 2009 
(Cheng et al., 2014). This growth also creates an elevated worldwide health risk. 
Health risks have been associated with Cr exposure since the early 19th 
century when a Scottish chrome pigment worker was identified with nasal tumors 
(Bagchi et al., 1995). Since then, over 80 Cr occupations have arisen leading to 
extensive occupational exposure (IARC, 1990). Accordingly, there have been 
many epidemiology studies indicating high incidences of cancers associated with 
chromate workers (Davies, 1984; Davies et al., 1991; Gibb et al., 2015; Gibb et al., 
2000; Langard and Vigander, 1983; Machle and Gregorius, 1948; Mancuso and 
Hueper, 1951). It is important to note these studies include only male subjects, 
which is a factor of societal limitations as men were and still are the primary 
employees of the chromate industry.  
Methods for evaluating Cr exposure 
Assessing Cr exposure in chromate workers can be challenging, however 
there have been many studies investigating the different methods used for these 
analyses (Table 1.1).  There are currently several methods to track Cr exposure in 
workers including assessing exhaled breath condensate and measuring Cr in red 
blood cells, plasma, and urine. However, each of these methods has limitations 
and we will discuss these limitations with each method. In general, it can be difficult 
to compare between studies that evaluate Cr exposure due to the lack of detail in 




masks throughout the day may not be reported or specific details on the collection 
methods may be vague.   
Exhaled breath condensate has been used to assess Cr speciation in 
chromate workers and to assess biomarkers that might be used in exposure 
assessments. Goldoni et al., 2006 aimed to evaluate soluble Cr(VI) in exhaled 
breath condensate from chromate workers and in environmental air (Goldoni et al., 
2006). Previous studies suggest Cr(VI) could be reduced to Cr(III) in the respiratory 
tract extracellularly, but a Cr(VI)/Cr(III) equilibrium was not determined (Caglieri et 
al., 2005; De Flora et al., 1996; Petrilli et al., 1986). Therefore, this study aimed to 
determine if Cr(VI) persists in the lung. They found 15 h post workplace exposure 
Cr(VI) was detectable in the exhaled breath condensate of chromate workers 
indicating Cr(VI) does persist in the lung.  
Studies evaluating Cr speciation in exhaled breath condensate are limited 
in their ability to stabilize Cr in its different valence states and the sensitivity of the 
analysis. Leese et al., 2016 aimed at establishing methodologies to improve this 
type of exposure assessment and implemented their methods in a 2017 study 
evaluating exhaled breath condensate in chromate and non-chromate workers 
(Leese et al., 2016). They measured the differences in Cr(VI) in exhaled breath 
condensate at the beginning of the workweek (Monday morning) and again at the 
end of the workweek (Thursday afternoon) and found chromate workers had a 
significant increase of Cr(VI) and Cr(III) in their exhaled breath condensate 




in exhaled breath condensate has been successful, it still has experimental hurdles 
to overcome and is best used in conjunction with other monitoring methods.  
Another method for monitoring Cr(VI) exposure is by measuring Cr 
concentrations in red blood cells. Cr in red blood cells is representative of Cr that 
reaches the bloodstream in the hexavalent state whereas measuring Cr in plasma 
represents Cr that reached the blood stream in the reduced state, Cr(III) (Goldoni 
et al., 2010). Devoy et al., 2016 evaluated the selectivity of red blood cells 
accumulating Cr after Cr(VI) exposure using whole blood samples (Devoy et al., 
2016). They found Cr levels in red blood cells are a good candidate to indicate 
internal dosing from a recent exposure of approximately 8-10 weeks. However, 
this study used an in vitro system and was limited by its applicability of exposure 
periods. Minoia and Cavalleri, 1988 compared Cr levels in red blood cells between 
individuals who worked primarily with Cr(VI) and workers who worked primarily 
with Cr(III) compounds (Minoia and Cavalleri, 1988). They found Cr red blood cell 
and plasma concentrations were significantly higher in Cr(VI) workers whereas 
only plasma Cr concentrations increased in Cr(III) workers. This outcome confirms 
Cr(VI) can reach the bloodstream, Cr(VI) readily enters cells while Cr(III) does not 
and red blood cells can be used to monitor Cr(VI) exposure. 
Perhaps, the most widely used method to evaluate Cr exposure has been 
monitoring urine Cr levels. Unexposed reference ranges have been evaluated by 
several studies to find a range of 0.24 to 1.8 ug/L (OSHA, 2006). However humans 
exposed to 0.01 to 0.1 mg/m3 Cr(VI) for an 8-hour time-weighted average had 




found measuring Cr in the urine was an accurate predictor of short-term exposure 
to soluble Cr (Tola et al., 1977). Several other studies have evaluated Cr levels in 
urine over the years showing elevated levels in chromate industry workers (Pesch 
et al., 2018; Saner et al., 1984; Stridsklev et al., 2004).The type of chromate work 
has been shown to influence post-exposure levels of Cr in the urine as described 
by Lindberg and Vesterberg, 1989 (Lindberg and Vesterberg, 1989). They found 
reported urinary Cr levels did not decrease in chrome platers to the same extent 
as other studies urinary levels decrease in welders of Cr-alloyed stainless steel 
(Tossavainen et al., 1980). This result further highlights differences between 
occupational exposures. Despite widespread use of monitoring Cr exposure by Cr 
urine levels it has its limitations including it is relatively unreliable for chronic 
exposure measurements and it cannot be used to discern between Cr(III) and 
Cr(VI) exposure. 
Non chromate-worker exposures 
Cr(VI) is ubiquitous in the environment due to its widespread use and the 
lack of regulations concerning Cr(VI) waste and air pollution for many decades 
after the industrial revolution began. Today, Cr(VI) is continually released in to the 
environment through the burning of fossil fuels and regulated release from many 
different industrial sources (IARC, 1990). Regulation of Cr(VI) waste in some 
countries is not as strict as it is in the United States further increasing the risk of 
exposure.  
Studies show Cr released into the atmosphere can travel through air 




been monitored for Cr levels in ambient air and found to range from 0.001 to 0.1 
ug/m3. Levels of Cr taken over the Atlantic have ranged from 0.007 to 1.1 ng/m3, 
in Hawaii were measured to be 67 ug/m3 and in the Baltimore harbor 226 ug/m3 
(Bowen, 1979; Fishbein, 1976; IARC, 1990). Additionally, Cr travels through 
groundwater and is found throughout the world’s oceans (Fishbein, 1976). Cr(VI) 
has been shown to be the predominant form of Cr in sea water (Pettine and Millero, 
1990). Further, many studies in urban areas have assessed Cr(VI) in air 
considering the proximity of factories that use Cr(VI) and indicate elevated levels 
of Cr(VI) in these areas (Khlystov and Ma, 2006). Nonetheless, Cr(VI) is also found 
far removed from industry-heavy regions where air pollution is expected to be 
relatively low (Rowbotham et al., 2000). A recent study in Korea found particulate 
lead chromate is a specific source of atmospheric Cr(VI) pollution due to its 
widespread use in traffic paint and other applications, and the use of lead chromate 
was a specific source of concern for public health (Lee et al., 2006). These studies 
confirm Cr(VI) is ubiquitous in the environment and exposure to it is widespread 
and can contribute to co-exposures.  
The environmental contamination of Cr(VI) raises concern of exposure to 
non-chromate workers and as such there is an urgent need to investigate the 
effects of low, long term exposures. Currently, many low-dose, long-term Cr(VI) 
studies focus on Cr(VI) in drinking water. However, inhalation is considered to be 
primary route of Cr(VI) exposure. Few studies have measured the effects of Cr(VI) 
in non-chromate  workers. However, Hwang et al., 2017 measured Cr in the blood 




their mean Cr levels to be 3.8 ug/L which is above estimated levels in other studies 
which range from 0.12 ug/L to 2.37 ug/L (Hwang et al., 2017; Kim, 2004; Nisse et 
al., 2017). Nonetheless, much more research needs to be done evaluating the 



















Table 1.1. Studies on Methods for Evaluating Cr Exposures 
Study 
Population 
Methodology Study Findings Reference 
24 chrome-
plating workers  
Exhaled breath 
condensate collected 
before and after a 
Friday work shift and 
before the work shift 
the following Monday. 
Cr- exhaled breath condensate 
levels increased from before 
shift to after shift (5.3 ug/L to 6.4 
ug/L) on Friday but were 
considerably lower the following 





Whole blood was 
incubated with Cr(VI) 
or Cr(III) then Cr was 
measured in red blood 
cells. 
Cr(VI) but not Cr(III) 
accumulated in red blood cells 
and there was a strong 
correlation between Cr(VI) 
added to a blood sample the red 








and 15 h later. 
Cr(VI) was reduced by 50% in 
airway lining fluid at the end of 
exposure and there was a 
further 50% reduction after 









condensate and urine 
were collected at the 
beginning and end of 
working shifts. 
Urine-Cr correlated with plasma-
Cr at the end of the working 
shift, red blood cell-Cr correlated 
with exhaled breath condensate 










Urine and Exhaled 
breath condensate 
samples were 
collected at the start 
of a shift Monday 
morning (pre-work 
week) and on 
Thursday afternoon 
(post-work week). 
Exhaled breath condensate from 
workers has higher levels of 
Cr(III) and Cr(VI) than the 
control group and higher levels 
of total Cr in their urine. There 
was no significant difference 
between pre- and post-work 
week exhaled breath 





platers over a 
weekend and 23 
chrome platers 
over 31 days of 
vacation 
Urine was collected in 
the weekend group 
and from the last 
working day before 
vacation and on the 
first working day after 
vacation in the 
vacation group. 
Urine-Cr was  >0.5 ug/L in all 
individuals. The half-time of Cr in 
the weekend group was 65 h. 
Urine-Cr in the vacation group 
decreased from 4.2 ug/L at the 
beginning of exposure break to 






Fifty male steel 
welders from 14 
companies 
Respirable welding 
fume was collected in 
the breathing zone of 
the welders during a 
working shift and urine 
Cr content in pre-shift urine was 
a stronger determinant than 
airborne shift exposure when 
correlating with post-shift urinary 







collected before and 
after the work shift. 
total Cr varied considerably in 
the welding fumes collected. 
12 normal 
adults; 
34 male tannery 
workers 
Hair samples were 
taken from the 
suboccipital area of 
the head. 24 h urine 
samples were 
obtained 
Compared with normal adult 
values, urine-Cr concentration, 
Cr/Creatinine ratio, daily Cr 
excretion, and hair-Cr were 









was collected pre- and 
post-work Monday, 
Wednesday and 
Friday. Urine was 
collected 3 times 
daily.  
Air concentrations had a mean 
of 200 ug/m
3
 total Cr and 11.3 
ug/m
3
 Cr(VI). Mean levels of Cr 
after work in whole blood, 
plasma and erythrocytes were 
1.25, and 1.68 and 0.9 ug/L, 
respectively. The mean level for 
Cr in urine after work was 3.96 
ug/g creatinine. 
Stridsklev 
et al., 2004 
6 high alloy Cr-
Ni steel welders 
Air was collected each 
day in the morning 
and afternoon (5 
days). Urine samples 
were collected 3 times 
per day (5 days). 
Blood was collected 2 
days. 
The proportion of Cr(VI) in the 
air was higher than 50% of total 
Cr during welding with coated 
electrodes and less than 10% 
produced during metal-inert gas 
welding was Cr(VI). Cr in urine 
correlated with air exposures. 














Cr(VI) and respiratory cancer  
The lung is considered to be a primary target of Cr(VI) carcinogenesis and 
there are many studies supporting the carcinogenic risks associated with inhalation 
of Cr(VI). In 1948 an epidemiology study evaluating chromate workers found 
21.8% of chromate worker deaths were attributed to respiratory cancers; 16 times 
higher than expected in the control population (Machle and Gregorius, 1948). 
Since then numerous epidemiology studies on chromate workers have shown 
increased incidences of respiratory cancers associated with Cr(VI) exposure 
(Davies, 1984; Davies et al., 1991; Gibb et al., 2015; Gibb et al., 2000; Languard 
and Vigander, 1983). While many of these studies specifically found lung cancer 
to be the carcinogenic endpoint, some studies also revealed an increased risk for 
nasal and sinus cancers (ATSDR, 2012).  
It is well known the solubility of Cr(VI) plays a role in the carcinogenic 
potential of chromate compounds. The less soluble forms persist in the lung 
leading to lung cancers and are believed to be the more potent form of Cr(VI) 
(Ishikawa et al., 1994a; Ishikawa et al., 1994b). There have been few epidemiology 
studies that have been able to target a specific chromate compound due to the 
complexity of occupational exposures. However, a factory that worked specifically 
with zinc chromate pigments found an increased incidence of chromate tumors in 
its workers (Langard and Vigander, 1983). Further, a zinc chromate production 
factory where workers were exposed to sodium chromate (a raw material to 
produce zinc chromate) and zinc chromate found an increase in the incidence of 




support Cr(VI)-induced lung cancer and are further supported by animal models 
and cell culture studies.  
Inhalation and intratracheal deposition studies in mice and rats have 
confirmed the carcinogenicity of Cr(VI) in the lung (Levy and Vennitt, 1986; 
Takahashi et al., 2005; Toya et al., 1999). Levy and Venitt, 1986 found only 
particulate and not soluble Cr(VI) intrabronchial implantation increased tumors in 
rats (Levy et al., 1986). Cell culture studies further confirm the carcinogenicity of 
particulate and soluble Cr(VI). Wise et al., 2002 and Wise et al., 2006a found 
particulate lead chromate was more cytotoxic and genotoxic to human lung cells 
than soluble sodium chromate. Similarly, lead chromate induced neoplastic 
transformation of C3H10T1/2 mouse embryo cells while soluble calcium chromate 
did not further supporting the conclusion less soluble chromate compounds are 
more carcinogenic (Patierno et al., 1988). More recently lung epithelial BEAS-2B 
cells have been shown to be transformed with Cr(VI) compounds in several studies 
(Azad et al., 2010; Park et al., 2016; Sun et al., 2011; Wise et al., 2006a). These 
studies indicate Cr(VI) has carcinogenic potential, but further insight into 
mechanistic information is ongoing. 
To date most studies have assessed Cr(VI) carcinogenicity using soluble 
chromate compounds despite the evidence that the particulate form is more 
carcinogenic creating a clear information gap. Therefore, Cr(VI) research requires 
the expansion of studies using particulate forms of Cr(VI) in addition to including 
more mechanistic data concerning Cr(VI) carcinogenesis. Other data gaps lie in 




contain Cr(VI). While the studies above directly evaluated Cr(VI) compounds, other 
types of studies involving welding fumes that are known to contain Cr(VI) as a 
primary component have also been evaluated. A recent study investigated metal 
arc-stainless steel welding fume found increased lung tumorigenesis in A/J mice 
(Falcone et al., 2017). The welding fume in this study was collected from the actual 
welding process characterized to predominantly contain metal-rich particulate 
matter of which a main constituent is Cr(VI). Further, this exposure closely models 
exposures that chromate workers in stainless steel welding may experience. 
These data have been valuable in the risk assessment for Cr(VI). However, risk 
assessment has more recently been requiring mechanistic data to better 
understand risk.  
Mechanisms of Cr(VI) carcinogenesis 
Investigation into the mechanisms underlying Cr(VI) carcinogenesis have 
been ongoing for decades. However, due to the complexities of carcinogenesis 
and the dynamisms of Cr inside cells much remains to be understood about the 
overall mechanism and its details. While some of the processes of Cr(VI) 
carcinogenesis align with well understood mechanisms of carcinogenesis, others 
are specific to metals and others unique interactions between Cr and cellular 
components. There are three drivers of carcinogenesis that are well accepted 
among researchers: mutations, epigenetic changes, and genomic instability. There 
is scientific evidence that the key drivers of Cr(VI) carcinogenesis most likely are 
epigenetic changes and genomic instability. Cr(VI) is known to be a weak mutagen 




mutations are not a strong driver of Cr(VI) carcinogenesis (Ewis et al., 2001; 
Holmes, et al., 2008; Kondo et al., 1997; Wise, 2012). We will discuss key features 
that have been investigated in these drivers of carcinogenesis and the events that 
lead to their development. Additionally, we will briefly consider malignant cell 
transformation and second stage carcinogenesis that are hypothesized to 
contribute to the progression of Cr(VI)-induced tumors. 
Physical-chemical mechanisms 
The specific valence states of Cr play a significant role in the toxicity of Cr 
compounds. First, consideration is given to the exposure route of Cr(VI). Cr(VI) 
can enter the body through ingestion, dermal absorption and inhalation. If ingested 
Cr(VI) is largely reduced in the gut to Cr(III), which is poorly absorbed through the 
mucosal membranes and poses little health risk (De Flora et al., 1997; Donaldson, 
1966). However, this topic is controversial. Dermal absorption and inhalation of 
Cr(VI) both result in the internalization and cellular exposure to Cr(VI).  
Studies show Cr(VI) compounds dissolve extracellularly and the chromate 
oxyanion enters cells using anion transport channels (Wise et al., 1993; Xie et al., 
2004). Once inside the cell Cr(VI) is rapidly reduced to Cr(III) by Nicotinamide 
adenine dinucleotide phosphate (NAPDH), ascorbate, glutathione (GSH), and thiol 
groups on cysteine (Figure 1.1) (Quievryn et al., 2003, Quievryn et al., 2006; Cai 
et al., 2012, Zhitkovich et al., 2002). If Cr(VI) is reduced by ascorbate the Cr(V) 
intermediate is not formed and only Cr(IV) forms as an intermediate. However, 
other reducing agents result in both Cr(V) and Cr(IV) intermediates. The reduction 




damage to critical molecules in the cell including DNA, RNA, protein, and lipids 
(Leonard et al., 2004; Wang et al., 2011). It is widely accepted that the reduction 
process is a key process in Cr(VI) carcinogenesis. However, if a chromate particle 
enters the cell through phagocytosis there appears to be no toxic effect and no 
apparent effect of the cation (Xie et al., 2004).  
There have been considerable studies into whether and how Cr (in any 
valence state) can interact or bind with the major constituents of the body (i.e. 
lipids, proteins, and nucleic acids) resulting in damage. For example, several in 
vitro studies where DNA molecules are combined with Cr in test tubes show Cr(III) 
and Cr(V) can bind to DNA molecules (Standeven et al., 1992; Stearns et al., 
1995). However, cell model systems and in vivo studies are less clear. This 
ambiguity is due to the difficultly in measuring the Cr intermediates as they are 
short lived and assays to measure them are insensitive.  
Several studies showed Cr can bind to DNA directly altering its 
conformation or in the event of DNA replication lead to a DNA breaks (Borges et 
al., 1991; Cupo and Wetterhahn, 1985; Madhusudanan et al., 1999; Tsapakos et 
al., 1983; Standeven et al., 1992; Zhitkovich et al., 1996). Studies on the binding 
of Cr with DNA reveal there are inconsistencies in the binding mechanism and 
exactly where Cr can bind is uncertain.  Recently, Zhou et al., 2016 sought to 
investigate the binding of Cr(III) with both the phosphate backbone of DNA and the 
nucleobases. They found Cr(III) could weakly bind to the DNA phosphate 
backbone in a reversible interaction likely through electrostatic forces. However, 




to note when neutral or high pH was restored in these experiments Cr(III) gradually 
lost its binding ability likely due to hydrolysis. This study reveals some binding 
kinetics about Cr to DNA, but whether it is physiologically relevant remains elusive. 
There has been little other research into the direct interaction of Cr with cellular 













Figure 1.1. Mechanisms of intracellular Cr(VI) reduction. This figure 
shows the mechanisms by which Cr(VI) is reduced to Cr(III) inside the cell. 
Glutathione can reduce Cr(VI) in a one- or two-electron reaction whereas 
cysteine is almost exclusively considered to reduce Cr(VI) in a one-electron 
reaction with NADPH providing electrons. Ascorbate reduces Cr(VI) in a two-
electron reaction skipping the Cr(V) intermediate and immediately forming 
Cr(IV). As a result of all these reductions reactive oxygen species are formed 







The range in the solubility of Cr compounds further affects how Cr interacts with 
biological systems. Particulate forms of Cr(VI) are considered to be the more 
hazardous form because Cr(VI) is first and foremost considered a lung carcinogen 
(Holmes et al., 2010; Patierno et al., 1988; Xie et al., 2004). When soluble Cr(VI) 
is inhaled it can be cleared by the lung whereas inhalation of Cr(VI) particles leads 
to their deposition at bifurcation sites (Ishikawa et al., 1994a; Ishikawa et al., 
1994b). Here, the Cr(VI) particles slowly dissolve over time releasing Cr(VI) 
oxyanions leading to prolonged exposures. While soluble and particulate chromate 
compounds can both induce respiratory cancers solubility plays a significant role 
in potency.  
DNA damage and chromosome instability 
One of the key results of intracellular Cr(VI) reduction is the induction of 
DNA damage. DNA breaks may result from direct or indirect oxidative damage and 
DNA double strand breaks are well documented following Cr(VI) exposure (Qin et 
al., 2014; Wise et al., 2003; Wise et al., 2002; Xie et al., 2009). DNA double strand 
breaks can arise due to the collapse of a replication fork or the conversion of a 
single strand break to a double strand breaks during the replication process. Cr(VI) 
has been shown to affect mismatch repair which is used to repair Cr-DNA adducts 
(Zecevic et al., 2009). Failure of this process can lead to a stalled replication fork 
and ultimately double strand breaks (Barbour, 2003). DNA double strand breaks 
can lead to chromosomal instability if left unresolved (Masuda and Takahashi, 
2002). Chromosome instability is known to occur in a majority of lung cancers and 




2004). Chromosome instability can occur in the form of numerical chromosome 
instability as a change in the number of chromosomes or as structural 
chromosome instability in the form of translocations or DNA breaks contributing to 
Cr(VI) carcinogenesis (Albertson et al., 2003). First, we will focus on structural 
chromosome instability and the current known mechanisms of Cr(VI)-induced 
structural chromosome instability and then follow with a discussion of numerical 
structural chromosome instability.  
Cr(VI) causes DNA double strand breaks. Interestingly, Cr(VI)-induced 
DSBs develop in late S and G2 of the cell cycle resulting in a G2 arrest Luczak et 
al., 2015; Reynolds et al., 2004; Xie et al., 2009). If these breaks were repaired 
structural chromosome instability would not occur. Therefore, investigators have 
been researching how Cr(VI) interferes with DNA repair mechanisms. There are 
two primary DNA double strand break repair pathways; homologous recombination 
and non-homologous end joining. non homologous end joining is considered a low 
fidelity pathway due to the loss of genetic material in the repair process. Further, 
a study by Camyre et al., 2007 found non homologous end joining is not critical in 
protecting cells against Cr(VI) exposure. Homologous recombination is considered 
a high-fidelity repair mechanism and has been shown to be critical in preventing 
chromosome instability. Additionally, several studies have shown homologous 
recombination is impaired following Cr(VI) exposure and is critical in maintaining 
genomic stability (Bryant et al., 2006; Stackpole et al., 2007; Tamblyn et al., 2009; 
Tian et al., 2016). This effect occurs after prolonged exposures and there is a 
specific loss of the effector step of homologous recombination through the loss of 




homologous recombination, the underlying mechanisms in this pathway remain to 
be determined.  
Numerical chromosome instability has been well documented in lung 
tumors with 70 to 80% of tumors exhibiting severe aneuploidy (Masuda and 
Takahashi, 2002). Many cell culture studies support this finding especially 
following chronic exposures to Cr(VI) and were characterized by hypodiploidy, 
hyperdiploidy, polyploidy and tetraploidy (Guerci et al., 2000; Holmes et al., 2010, 
Rodrigues et al., 2009; Seoane et al., 2002). Since these findings, investigation 
into the mechanisms of numerical chromosome instability have also been 
investigated. Numerical chromosome instability can arise because of improper 
segregation during mitosis and impaired centrosome regulation. Specifically, the 
spindle assembly checkpoint is critical in maintaining proper division. Spindle 
assembly checkpoint bypass has been observed in Cr(VI) exposed cells and is 
associated with aneuploidy (Holmes et al., 2010; Seoane et al., 2002). Cr(VI) 
exposure caused a decrease in MAD2, which is a key component in regulating the 
spindle assembly checkpoint (Wise et al., 2006b).  
Another key component required for correct chromosome separation during 
cell division are centromeres. Centromeres are responsible for pulling the 
chromosomes to the two poles of a cell during division to ensure proper 
chromosomal segregation. However, Holmes et al., 2010 found chronic Cr(VI) 
resulted in an increase in supernumerary centromeres. Ultimately, this outcome 
means during segregation chromosomes can be pulled to multiple poles resulting 




al., 2015 found there was a correlation between supernumerary centrosomes and 
numerical chromosome instability and critical proteins in centrosome regulated 
were impaired following Cr(VI) exposure. This study further demonstrated key 
structural components required to prevent premature centromere separation are 
also compromised following prolonged Cr(VI) exposure. 
Taken together there is significant evidence both structural and numerical 
chromosome instability play a role in the mechanism of Cr(VI)-induced 
carcinogenesis. Ultimately, abnormal numbers of chromosomes or deletions or 
insertions in whole chromosomes or genes can result in aberrant gene expression 
that leads to carcinogenic outcomes. While the specific pathways involved in 
maintaining fidelity in these mechanisms are still being investigated, there is 
significant evidence genomic instability is a key driver of Cr(VI) carcinogenesis. 










Figure 1.2. Mechanisms of numerical and structural chromosome 
instability in Cr(VI) carcinogenesis. This figure shows some of the major 
mechanisms underlying chromosome instability in our proposed mechanism 
of Cr(VI) carcinogenesis. Particulate Cr(VI) dissolves extracellularly and if the 
cation enters the cell there is no contribution to the effect. Similarly, if the 
Cr(VI) particle enters the cell by phagocytosis there is also no contribution to 
the effect. When the Cr(VI) oxyanion enters the cell it is reduced to Cr(III) and 
ROS are produced. The reactive oxygen species can induce oxidative 
damage which base excision repair (BER) attempts to repair. However, if it 
fails double strand breaks form. Positively charged Cr intermediates and 
Cr(III) form as result of the intracellular reduction process potentially binding 
to cellular elements including the formation of DNA-Cr adducts or crosslinks 
and consequentially stalled replication forks and the formation of a DNA 




to resolve these effects, but if they fail will result in double strand breaks. The 
formation of double strand breaks results in a G2 arrest as the attempts to 
repair the damage. Cr(VI)-impaired homologous recombination repair leads 
to the use of a low fidelity repair mechanism and structural chromosome 
instability. At the same time, Cr(VI) induces spindle assembly checkpoint 
bypass and premature centriole disengagement leading to centrosome 
amplification and numerical chromosome instability. Underlying structural 
and numerical chromosome instability are Cr(VI)-induced epigenetic 
alterations, which have yet to be elucidated. Finally, taken together structural 
and numerical chromosome instability contribute to the neoplastic 














Alterations in epigenetics and gene expression 
Another major driver of carcinogenesis is epigenetic changes. Changes in 
the epigenome can result in gene expression changes and ultimately 
carcinogenesis. Epigenetic modifications are involved in the upregulation and 
downregulation of genes though DNA methylation, histone modifications, histone 
variants, miRNA expression and nucleosome repositioning (Sharma et al., 2010). 
Gene expression and epigenetic studies are ongoing in Cr(VI) carcinogenesis. 
There is limited information about changes in gene expression in Cr(VI)-induced 
tumors and epigenetic alterations, but cell culture analysis has uncovered complex 
alterations.  
Studies in chromate tumors have revealed limited information about 
changes in gene expression. Takahashi et al., 2005 found MLH1 and MLH2 
expression was decreased in chromate tumors. Similarly, other changes in gene 
expression in chromate tumors have been seen including increased cyclin D1 and 
decreased survivin (Halasova et al., 2010; Katabami, 2000). Interestingly, 61.3% 
of chromate tumors were found to have gene variants in the surfactant B gene in 
a study by Ewis et al., 2006.  
Cell culture studies have revealed numerous changes in gene expression 
following Cr(VI) exposure (Sun et al., 2009; Sun et al., 2011, Ye and Shi, 2001). 
Recently, BEAS-2B cells were evaluated using single-cell RNA sequencing for 
changes in gene expression following a chronic 2 month exposure to Cr(VI) (Park 
et al., 2017). This study found Cr(VI) with or without a CRISPR/cas9 deletion of 




over 80 genes. Interestingly, these genes were involved in cell adhesion, oxidative 
stresses, protein ubiquitination, epithelial-mesenchymal transition/metastasis and 
WNT signaling (Park et al., 2017).  
Gene expression is widely regulated by epigenetic mechanisms, however, 
studies on epigenetic changes in tumors has been limited and are focused on 
methylation changes. For example, Ali et al., 2011 found tumors from those 
exposed to Cr had increased aberrant methylation of tumor suppressor genes at 
a higher frequency than in tumors from unexposed individuals. Additionally, 
methylation in multiple tumor suppressor genes has also been found in tumors 
derived from ex-chromate workers (Kondo et al., 2006; Toya et al., 1999). A recent 
study found mitochondrial DNA isolated from the blood of chromate workers was 
hypomethylated, however, this study was focused on using this endpoint as a 
biomarker for Cr(VI) exposure (Linging et al., 2016). Hu et al., 2018 found 
hypermethylation of CpG sites in DNA repair genes, including RAD51, increased 
in Cr(VI) exposed workers compared to non-exposed workers and this outcome 
correlated with blood Cr levels. Further this study confirmed these results in 16HBE 
cells treated with Cr(VI). Methylation changes have also been observed in other 
cell culture studies. Hu et al., 2016 found hypermethylation of the CpG islands of 
the tumor suppressor p16 in 16HBE cells treated with Cr(VI) which correlated with 
decreased expression of p16. More broadly, both particulate and soluble Cr(VI) 
was investigated in genome-wide methylation of DNA in human B lymphoblastoid 




expression of a subset of genes indicating there are multiple mechanisms 
controlling their expression (Lou et al., 2015).  
Changes in histone modifications are also being investigated in Cr(VI) 
carcinogenesis. Wei et al., 2004 found Cr(VI) can crosslink a histone deacetylase 
to inducible promoters resulting in decreased gene expression. Additionally, 
acetylation of histone tails is commonly associated with increased gene 
expression. The acetylation of histone H4 of the stressor protein Nupr1 was found 
to be downregulated following Cr(VI) exposure in BEAS-2B cells and was 
associated with increased expression of Nupr1 protein, of which overexpression is 
associated with cancers (Chen et al., 2016). Another epigenetic histone 
modification is biotinylation. Xia et al., 2014 found differential histone biotinylation 
and differential distribution of biotinidase in 16HBE cells depending on the 
concentration of Cr(VI). Furthermore, they found histone deacetylation plays a role 
in histone biotinylation further adding to complexity of these mechanisms.  
No studies to date have investigated miRNAs in chromate tumors. However, 
one study evaluated miRNAs in the blood of chromate workers but found only 
decreased miR-3940-5p levels were associated with blood Cr (Li et al., 2014). 
There are limited but increasing numbers of cell culture studies that support the 
involvement of miRNAs in Cr(VI) carcinogenesis. Li et al., 2016 investigated miR-
3940-5p and its involvement in homologous recombination using 16HBE cells. This 
study found miR-3940-5p enhanced the homologous recombination response 
following treatment with Cr(VI). He et al., 2013 found changes in miRNA 




was associated with the upregulation of several proteins involved in proliferation 
and angiogenesis. A recent study in BEAS-2B cells found Cr(VI) exposure induced 
malignant cell transformation associated with increased miR-21 expression and 
the inhibition of a tumor suppressor (Pratheeshkumar et al., 2017). These studies 
highlight the complexities and connectedness between different mechanisms of 
carcinogenesis. Specifically, miRNAs and other epigenetic alterations affect gene 
expression and vital pathways that lead to proper cell homeostasis. 
Part II: Focus of this dissertation 
Repair of Cr(VI)-induced double strand breaks 
Cr(VI) induces DNA double strand breaks, and the predominant repair 
pathway for these breaks is homologous recombination. Several studies have 
shown the importance of homologous recombination repair following Cr(VI) 
exposure. One study investigated the protein Mus81, involved in resolving Holiday 
junctions, a final step in the homologous recombination pathway (Tamblyn et al., 
2009). They found in Mus81-deficient cells Cr(VI) induced higher levels of 
phosphorylated H2AX (gamma-H2AX) foci indicating resolution of double strand 
breaks was inhibited. Tamblyn et al., 2009 complemented this study showing 
delayed RAD51 foci removal in Mus81-deficient cells. Ultimately, exposure to a 
DNA double strand break-inducing agent and inhibition of homologous 
recombination repair results in structural chromosome instability. Two studies 
confirmed this mechanism showing Cr(VI) increased chromosome aberrations in 




These studies highlight the importance of homologous recombination repair in 
preventing structural chromosome aberrations following Cr(VI) exposure.  
There are three main steps in the homologous recombination pathway: the 
sensing step, transducing step, and the effecting step. Double strand breaks are 
sensed by the MRN complex (MRE11, RAD50, and NBS1), which acts to resect 
the ends of the break using the nuclease activity of MRE11 (D’Amours and 
Jackson, 2002; Williams et al., 2007). Studies show the sensing step of 
homologous recombination repair is activated after Cr(VI) exposure and remains 
active through prolonged exposures (Browning et al., 2016; Qin et al., 2014; Xie et 
al., 2008; Xie et al., 2009). The sensing step by MRN is initiated by the 
phosphorylation of H2AX on either side of a double strand break signaling 
downstream recruitment of repair factors (Li and Heyer, 2008). This signal is 
further transduced by ATM and ATR, which reciprocally leads to amplification of 
the gamma-H2AX signal (Li and Heyer, 2008). Studies show Cr(VI) increases 
signal transduction by gamma-H2AX, ATM, and ATR indicating these steps in the 
homologous recombination pathway are activated and remain functional after 
acute Cr(VI) exposure (Bryant et al., 2006, Luczak et al., 2015; Ha et al., 2004; Qin 
et al., 2014; Xie et al., 2008; Xie et al., 2009; Wakeman et al., 2004) and prolonged 
exposure (Browning et al., 2016; Qin et al., 2014; Xie et al., 2008; Xie et al., 2009). 
After end resection the single stranded DNA of the break is coated with RPA 
to protect the ends during downstream signaling and while further repair factors 
are recruited (Georgaki and Hubscher, 1992). In the effecting step of homologous 




replacing RPA (Baumann et al., 1996; Sung & Robberson, 1995). RAD51 
recruitment is facilitated by the BRCA2/BARD1 protein complex and RAD51C, 
which transport RAD51 into the nucleus and onto single stranded-DNA forming a 
RAD51 nucleofilament (Amunugama et al., 2013; Liu et al., 2010; Sigurdsson et 
al., 2001; Zhang et al., 2009). The RAD51 nucleofilament is then involved with the 
search for a homologous sequence of DNA with RAD54 and strand invasion 
resulting in high-fidelity repair of the double stranded break through Holiday 
junction resolution (Constantinou et al., 2001).  
We have shown while earlier steps in the homologous recombination 
pathway remain functional following prolonged Cr(VI) exposure the key effector, 
RAD51, is inhibited (Browning et al., 2016, Bryant et al., 2006; Qin et al., 2014). 
Specifically, these studies reveal three major RAD51 effects after prolonged 
particulate Cr(VI) exposure: 1) inhibited nuclear foci formation, 2) accumulation of 
RAD51 protein in the cytoplasm and 3) reduced RAD51 protein levels. Qin et al., 
2014 and Bryant et al, 2006 showed RAD51 nuclear foci increased after 24 h Cr(VI) 
exposure. However, Qin et al., 2014 further identified RAD51 nuclear foci was 
strongly inhibited after prolonged 72 and 120 h exposures and it accumulated in 
the cytoplasm. Similarly, RAD51 nuclear and whole cell protein levels decrease 
after prolonged exposure (Browning et al., 2016). Browning et al., 2017a 
investigated proteins involved in the transport and loading of RAD51 to form the 
nucleofilament essential to complete homologous recombination repair. They 
revealed one mechanism of inhibited-RAD51 function is through impaired RAD51 




nuclear localization and RAD51C deficiency resulted in cytoplasmic accumulation 
of RAD51. However, Cr(VI) did not affect the interaction of RAD51 with RAD51C 
or its other import partner, BRCA2. These results partially explain RAD51 
dysfunction, however, mechanism of Cr(VI)-inhibited RAD51 protein levels have 
yet to be elucidated.  
Expression of RAD51 
E2F1 is a primary transcription factor for RAD51 and is involved in 
homologous recombination repair. Studies show loss of E2F1 leads to RAD51 and 
homologous recombination failure inducing effects similar to those observed 
following prolonged Cr(VI) exposure (Chen et al., 2011; Choi and Kim, 2019; Wu 
et al., 2014). One study by Kachap et al., 2010 showed histone deacetylase 
inhibitors specifically inhibited E2F1-regulated transcription of RAD51 and induced 
RAD51 cytoplasmic accumulation, which is a phenotype observed after prolonged 
Cr(VI) exposure. However, no studies have investigated the effects of Cr(VI) on 
E2F1 or the transcriptional control of RAD51.  
The expression of RAD51 not only depends on the transcriptional control of 
the gene, but also post-transcriptional processes. miRNAs play an important role 
in the control of expression by targeting mRNA transcripts for degradation and 
inhibiting translation to protein. They are short non-coding RNA transcripts known 
to regulate about 60% of protein-coding transcripts (Friedman et al., 2009). It is 
well known multiple miRNAs target a single mRNA transcript, and each miRNAs 
has multiple transcript targets. However, the expression and balance of miRNAs 




Studies have investigated miRNAs targeting RAD51 that also lead to inhibition of 
homologous recombination repair (Gasparini et al., 2013; Huang et al., 2013; Lai 
et al,. 2016; Wang et al., 2012). While Cr(VI) is known to effect the expression of 
miRNAs no studies have investigated Cr(VI)-altered miRNAs that target RAD51 or 
homologous recombination in general.  
One Environmental Health approach 
To understand how environmental toxicants, affect health it is important to 
consider multiple perspectives. Environmental toxicants affect human health, 
wildlife health, and ecosystem health. Traditionally, research has focused on 
evaluating the effects of environmental toxicants from one of these three 
perspectives. However, important information can be identified by incorporating 
research perspectives from more than one area of health. This is especially true 
for risk assessment purposes and developing a comprehensive view of how 
environmental toxicants affect overall health. This idea of incorporating human, 
animal, and ecosystem health developed into the One Health initiative, which 
originally was termed based on comparing the study of infectious diseases in 
animals with humans (Gibbs, 2014; Zinsstag et al., 2011). The concept of One 
Health has expanded, and new subsets have emerged to accommodate a wide 
range of disciplines and goals.  
One Environmental Health is a subset of One Health specifically focused 
on the study of toxicants (Pérez and Wise 2018). As a global environmental 
pollutant, Cr(VI) is an excellent candidate for applying the One Environmental 




methods and model organisms. One advantage to the One Environmental Health 
approach is investigating molecular mechanisms across species. This is especially 
important in Cr(VI) research because the mechanisms of Cr(VI) carcinogenesis 
are currently not well understood. Throughout evolution individual species have 
developed adaptations to deal with different environments and challenges they 
have been exposed to. These adaptations, in part, explain why cancer rates do not 
always correlate with organism body size and life span. 
Cancer arises through the accumulation of mutations and other genomic 
alterations. Therefore, in theory, the larger an organism (i.e. the more cells they 
contain) the more likely it is they would develop cancer. Additionally, the longer the 
lifespan of an organism the more time there would be for these mutations and 
genomic alterations to occur (Caulin and Maley, 2011). While these theories hold 
true within species such as dogs and humans, it is not the case across species 
(Hawley et al., 2013; Mwacalimba et al., 2015). Instead, cancer is most seen in 
mammalian species with a wide range of sizes and lifespans (Hubbard et al., 
1983). These discoveries led to the concept of Peto’s Paradox, which says the 
incidence of cancer does not correlate with the number of cells in an organism 
(Leroi et al., 2003; Peto et al., 1975). One example of this is whales, which are 
much larger and have similar lifespans as humans but develop cancers at much 
lower rates (Nagy et al., 2007). Indeed, Li Chen et al., 2012 found Cr(VI) induced 
lower levels of genomic instability in whale cell lines compared to human cell lines. 
Further, Browning et al., 2017b found Cr(VI) does not inhibit homologous 




Other groups have investigated mechanisms of carcinogenesis based on these 
types of observations. For example, Sulak et al., 2016 identified copy number 
expansion of TP53 in elephants, another large and long-lived species with lower 
cancer rates than humans. TP53 plays an important role in the DNA damage 
response. Therefore, having multiple copies may serve as a protective mechanism 
against DNA damage-induced genomic alterations that lead to carcinogenesis.  
While much research is done in mammalian species to investigate how 
different organisms may be protected against carcinogenesis, reptiles offer unique 
research opportunities. Reptiles range widely in size and longevity and have 
unique physiological adaptations that may impact how they evolved protective 
mechanisms against carcinogenesis (Allen et al., 2017; Harris et al., 2017). Chiari 
et al., 2018 propose reptiles are an excellent parallel system to evaluate 
differences and similarities with humans regarding carcinogenesis. Therefore, we 
have included leatherback sea turtles (Dermochelys coriacea) as a reptilian model 
in our research to apply the One Environmental Health approach.  
Summary and dissertation aims 
It has been well established Cr(VI) is a global environmental pollutant and 
human lung carcinogen. Cr(VI) particles are inhaled and lodge at bifurcation sites 
in the lung resulting in the long term dissolution of chromate anions. These 
chromate anions enter cells and are reduced to the next stable valence state, 
Cr(III) leading to the induction of DNA double strand breaks. We have previously 
shown prolonged particulate Cr(VI) exposure inhibits the high-fidelity DNA repair 




The mechanisms of how Cr(VI) inhibits RAD51 expression have not been 
investigated. E2F1 is considered the predominant transcription factor for RAD51, 
however, the effects of Cr(VI) on E2F1-driven RAD51 expression are unknown. 
Expression of RAD51 may also be mediated by miRNAs. It is currently unknown 
how Cr(VI) affects miRNAs that target RAD51. Given the importance of RAD51 in 
protecting genomic stability it is critical to understand how Cr(VI) may be affecting 
RAD51 expression, and potential protective mechanisms to prevent this effect.  
To better understand mechanisms of Cr(VI) carcinogenesis key outcomes 
observed in human models can be explored in other organisms. Leatherback sea 
turtles provide a unique model to evaluate Cr(VI) toxicity and determine if Cr(VI) 
may pose a threat to leatherback health. Our previous studies show Cr(VI) is 
cytotoxic and genotoxic to leatherbacks cells at similar levels to human cells, 
however, there were some observable differences. Investigating the mechanisms 
of Cr(VI)-induced genotoxicity in leatherbacks may provide important information 
to better understand which mechanisms are conserved across species and 
adaptations that may provide a biological advantage in one species over another 
to cope with genotoxic insult.  
Therefore, the central hypothesis of this project is: Prolonged exposure to 
particulate Cr(VI) inhibits RAD51 expression through E2F1-inhibited transcription 
and alteration of miRNA expression, and key events are paralleled in a leatherback 





Aim 1: Determine if E2F1 modulates the RAD51 response to particulate Cr(VI) 
exposure. 
This aim seeks to determine if E2F1 is critical for facilitating the RAD51 
response to particulate Cr(VI) exposure. First, particulate Cr(VI) effects on RAD51 
mRNA levels and protein half-life will be investigated to confirm altered 
transcription is the predominant mechanism of reduced RAD51 protein. Next, 
particulate Cr(VI) effects on E2F1 will be investigated. Finally, we will test if E2F1 
overexpression can rescue particulate Cr(VI)-induced RAD51 failure after 
prolonged exposure and if knocking down E2F1 can induce RAD51 failure after 
acute particulate Cr(VI) exposure when RAD51 is normally functional. 
Aim 2: Identify particulate Cr(VI)-altered miRNAs involved in RAD51 regulation and 
homologous recombination repair. 
This aim focuses on miRNAs altered by particulate Cr(VI) exposure. First, 
global changes in miRNA expression patterns will be evaluated using RNAseq 
analysis. Second, differential expression of miRNAs will be investigated to 
determine their potential role in pathways of Cr(VI) carcinogenesis. Finally, Cr(VI)-
altered miRNAs involved in RAD51 and homologous recombination will be further 
investigated to determine which of these miRNAs may play a significant role in 






Aim 3: Characterize the effects of particulate Cr(VI) on homologous recombination 
in leatherback sea turtle lung cells. 
In this aim, the effects of particulate Cr(VI) exposure in leatherback lung 
cells will be evaluated. First, DNA damage will be measured following acute and 
prolonged Cr(VI) exposure. Second, the effects of particulate Cr(VI) on RAD51 will 
be determined. Finally, homologous recombination repair function will be assessed 




CHAPTER 2: MATERIALS AND METHODS 
 
This section contains the methods for all three aims of this dissertation. The 
methods are arranged in alphabetical order and include a brief background of each 
method. 
Cell Culture 
The lung is the primary target of particulate Cr(VI) with exposures occurring 
via inhalation. Epidemiology studies in chromate workers show chromate-induced 
tumors arise as cancers of the epithelium, primarily as squamous cell carcinomas 
(Hirose et al., 2002; Ishikawa et al., 1994a). While epithelial cells are the ultimate 
cell type transformed by Cr(VI) one study found Cr accumulates in fibroblasts in 
the stromal layer of the lung, not the epithelial cells from which Cr(VI)-induced 
cancers arise (Kondo et al., 2003). These data suggest fibroblasts accumulate Cr 
and create an unhealthy microenvironment for adjacent epithelial cells, which may 
contribute to their transformation into cancer cells. Indeed, the literature shows in 
many different types of cancers fibroblasts play a key role altering the 
microenvironment by releasing growth factors, chemokines, and other 
components that contribute to carcinogenesis.  
Epithelial cells are difficult to immortalize while maintaining normal 




of Cr(VI) on chromosomes as a primary target of Cr(VI) exposure and therefore 
the currently available immortalized epithelial cells are not suitable for this work. 
Additionally, primary epithelial cells cannot be maintained long enough to carry out 
the exposures required in this dissertation with consistency. Therefore, because 
of these issues with epithelial cell culture and because fibroblasts have been 
shown to be a key target of Cr(VI) exposure (Kondo et al., 2003), the primary cell 
line used in this study is an hTERT immortalized human lung fibroblast cell line. 
This cell line (from here on called WTHBF-6) was developed by the Wise 
Laboratory from primary lung fibroblasts derived from healthy lung tissue of a 67-
year old Caucasian male. These cells have a normal diploid karyotype (46 
chromosomes), normal growth parameters, and the same toxicological response 
to metals as their parent primary cell line (Wise, et al., 2004).  
WTHBF-6 cells were maintained in DMEM/F12 (Corning) supplemented 
with 15% cosmic calf serum (Hyclone Laboratories), 1% penicillin/streptomycin 
(Corning), 1% L-alanyl-L-glutamine (Corning), and 0.1 mM sodium pyruvate 
(Hyclone Laboratories). They were cultured as adherent monolayers in a 
humidified incubator at 37°C and 5% CO2. WTHBF-6 cells were fed every 2 days 
and split every 3-4 days using 0.25% trypsin/1 mM EDTA (Gibco). Experiments 
were performed on logarithmically growing cells.  
Leatherback sea turtle lung cells (PGDC9-1LU cells) were used in 
experiments where the One Environmental Health Approach was applied. These 
primary cells were established by the Wise Laboratory from a leatherback sea 




cells exhibit a normal diploid karyotype (56 chromosomes) and normal growth 
parameters. PGDC9-1LU cells were cultured in DMEM/F12 supplemented with 
10% fetal bovine serum (Avantor), 1 % penicillin/streptomycin, 1% L-alanyl-L-
glutamine, and 0.1 mM sodium pyruvate. Cells were cultured as adherent 
monolayers in a humidified incubator at 26°C and 5% CO2. Cells were fed every 
2-3 days and split at least once per week using 0.1% trypsin-EDTA. Experiments 
were performed on logarithmically growing cells.  
Cell authentication and validation was continuously carried out for both cell 
lines. Cells were confirmed to be mycoplasma negative monthly and monitored for 
any growth or morphological changes. All cells were karyotyped when thawed for 
use and again after every 3 months of continuous culture to ensure authenticity. 
WTHBF-6 cells underwent standard tandem repeat analysis yearly. Short tandem 
repeat analysis is currently not available for leatherback cells.  
Cell equivalent protein extractions 
Protein was extracted from cells for western blot analysis. It is well known 
Cr(VI) causes global changes in expression and this is reflected by differences in 
the amount of protein quantified in Cr(VI)-treated cells compared to control cells. 
Therefore, cell equivalents were used as a measure to load the same number of 
cells-worth of protein for each sample for western blot analysis. The extraction 
method below, therefore, includes counting the number of cells in each sample 




WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for 48 h 
before treating with zinc chromate for 24, 72, or 120 h. For protein half-life 
experiments, at the end of the zinc chromate treatment 10 ug/ml cycloheximide 
was added to all dishes and cells were harvested immediately (0 h) then 1, 2, 4, 6, 
8, 10, and 12 h following. At the end of treatment media was aspirated and cells 
were rinsed once with 1X PBS without calcium and magnesium. Cells were 
trypsinized and the reaction was neutralized using fresh media. Cells were 
centrifuged for 5 minutes at 1000 rpm (4ºC), the supernatant was aspirated, and 
cells were resuspended in cold-PBS. Cells were counted using a Beckman Coulter 
Multisizer 3 and centrifuged. The PBS was aspirated to 1 ml and 1 ml of cold-PBS 
was used to dislodge the pellet and transfer the cells to a microcentrifuge tube.  
Cells were centrifuged in a microcentrifuge 5 minutes at 3500 rpm (4ºC). The PBS 
was gently aspirated, and samples were placed on ice.  
Whole cell protein was extracted using cold Pierce RIPA buffer (Thermo 
cat: 89900) with 10% phosphatase and protease inhibitors added immediately 
before use. The volume of extraction buffer added to each sample was calculated 
based on cell number resulting in the same number of cells per volume extraction 
buffer. Extraction buffer was added to the cell pellet and pipetted up and down to 
resuspend the pellet. Samples were placed on ice for 20 minutes, vortexing every 
5 minutes at max speed for 5 seconds. Samples were then centrifuged at max 
speed (14 x g) for 10 minutes (4ºC). The supernatant with the protein sample was 
transferred to a fresh tube. Protein was quantified using the Pierce Rapid Gold 




Samples were boiled with 4X loading buffer + 10% 2-mercaptoethanol (Sigma 
Aldrich) 5 minutes at 95ºC and stored at -20ºC.  
Nuclear protein was extracted using the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents kits (Thermo cat: 78833) using the manufacturer’s 
instructions with some modifications. After treatment, cells were collected using 
the methods above to a cell pellet. Then, ice-cold cytoplasmic extraction buffer I 
(plus 10% phosphatase and protease inhibitors) was added to each sample, 
vortexed 15 seconds and placed on ice 10 minutes. Ice-cold cytoplasmic extraction 
buffer II was added, vortexed 5 seconds and placed on ice 1 minute. The samples 
were vortexed again 5 seconds and centrifuged at maximum speed (14 x g) 5 
minutes. The supernatant with cytoplasmic protein was transferred to a fresh tube. 
The pellet (nuclear fraction) was resuspended with ice-cold nuclear extraction 
buffer and vortexed every 10 minutes for 15 seconds for a total of 40 minutes. The 
samples were centrifuged at maximum speed (14 x g) 10 minutes and the 
supernatant (nuclear protein) was transferred to fresh tubes. The supernatant with 
the protein sample was transferred to a fresh tube. Protein was quantified using 
the Pierce Rapid Gold BCA kit and BSA standards on a Biotek microplate reader. 
Samples were boiled with 4X loading buffer + 10% 2-mercaptoethanol 5 minutes 
at 95ºC and stored at -20ºC. 
Cell equivalent western blot analysis 
Immunoblotting or western blot analysis is a technique used to separate and 
visualize specific proteins from a sample for quantification. In this method, proteins 




interferences. The proteins are transferred through a gel matrix using 
electrophoresis to separate the proteins based on size. Following electrophoresis, 
the proteins are transferred to a membrane, which is then probed using antibodies 
for a specific protein of interest. Fluorophores either directly attached to the primary 
antibody or through secondary antibodies are then applied to quantitate the protein 
of interest in the sample. We have specifically used cell-equivalent loading so that 
each sample per experiment has the same number of cells-worth of protein to 
accurately quantitate protein levels across samples. 
Protein was loaded using cell equivalents and resolved on 10% Bis-Tris 
SDS-PAGE gels (~1 h) and transferred to 0.45 uM nitrocellulose membranes 
(Thermo cat: 88018) (~1.5 h). Immunoblots were dried (~1 h), rehydrated with 1X 
tris buffered saline (TBS), and blocked with Odyssey blocking buffer (TBS) (Li-cor) 
diluted 1:1 with TBS 1 h. Immunoblots were probed with RAD51 (Santa Cruz sc-
8349; 1:1000), E2F1 (Santa Cruz sc-251; 1:500), EGR1 (Cell Signaling clone 15F7 
Cat: #4153, 1:1000), p130 (Santa Cruz clone A10 sc-374521, 1:500), phospho-
p130 (Invitrogen Cat: PA5-64769, 1:1000),  p53 (BD Pharm 554294, 1:500), 
phospho-p53 (Ser15) (Cell Signaling 9284, 1:500), or E2F4 (Cell Signaling clone 
E3G2G Cat: #40291, 1:1000) in odyssey blocking buffer (TBS) diluted 1:1 with 
TBS + 0.2% tween-20 (Sigma Adrich) overnight. Equal loading was confirmed by 
GAPDH (Genetex GT293; 1:500), H3 (Cell Signaling #9715, 1:500), or alpha-
tubulin (GeneTex GT114, 1:1000) in odyssey blocking buffer (TBS) diluted 1:1 with 
TBS + 0.2% tween-20. Immunoblots were incubated with IRDye secondary 




+ 0.2% tween-20 1 h and imaged on a Li-Cor Odyssey CLx. Results were 
normalized to their respective loading control and then represented relative to the 
untreated (0 ug/cm2 zinc chromate) control at each time point, respectively. 
 Cr(VI) preparation and treatment  
The particulate Cr(VI) compounds are considered to be the most toxic and 
carcinogenic. Zinc chromate was used as the representative particulate chromate 
compound in this dissertation. Zinc chromate is a partially soluble particulate 
chromate compound and epidemiology studies show it alone can induce lung 
cancer (Kano et al., 1993). It has wide industrial use, especially as a rust inhibitor 
and in pigment applications.   
Zinc chromate (99.7% purity; CAS# 13530-65-9) was prepared according 
to our published methods by washing twice with deionized H2O to remove water 
soluble contaminants, rinsed twice with acetone (99.5% purity, Sigma Aldrich) to 
remove organic contaminants, and thoroughly dried. Before use zinc chromate 
was suspended in cold, sterile deionized H2O and stirred overnight at 4°C. 
Dilutions were prepared the day of use and administered to cells as a suspension 
of particles using a vortex. Zinc chromate treatments are represented as ug/cm2 to 
account for particles treatment across different exposure vessels. Cells were 
treated with 0.1-0.3 ug/cm2 zinc chromate for WTHBF-6 cells and 0.1-0.4 ug/cm2 
zinc chromate for PGDC9-1LU cells, which represents a sub lethal range of 
cytotoxicity in each cell line, respectively. This range of concentrations also 
represents documented exposures in the literature (Danadevi et al., 2004; 






Analysis using immunofluorescence allows for visualization of native protein 
localization, quantity in specific compartments of the cell, and interactions between 
proteins among other applications. This technique involves using antibodies 
conjugated to fluorescent dyes to visualize the target of interest. 
Immunofluorescence was applied in this dissertation to identify protein foci and 
localization in the cytoplasm or nucleus of the cell.  
WTHBF-6 or PGDC9-1LU cells were seeded on glass chamber slides pre-
coated with FNC (Athenaes) and allowed to reenter logarithmic growth for 48 h 
before treating with zinc chromate for 24, 72, or 120 h. At harvest, cells were fixed 
with 4% paraformaldehyde for 10 minutes, permeabilized with 0.2% triton-X-100 
for 5 minutes and blocked with 10% goat serum and 1% BSA in PBS with calcium 
and magnesium for 1 h. Cells were incubated with RAD51 antibody (Santa Cruz 
sc-8349; 1:200) or gamma-H2AX antibody (Cell Signaling #2577) in 1% BSA 
overnight, washed with PBS 3 times 5 minutes each, and incubated with secondary 
Alexa Fluor 488 rabbit 1:2000 (RAD51) or Alexa Fluor 594 1:2000 (gamma-H2AX) 
1 h. Cells were washed with PBS 5 times for 5 minutes each and coverslips were 
mounted with DAPI diamond (Thermo cat: P36962). RAD51 or gamma-H2AX 
nuclear foci were scored visually in 100 cells per condition per time point using 
fluorescent microscopy. Results were expressed as the percentage of cells with 





RAD51 nuclear and cytoplasmic protein quantification was assessed using 
confocal microscopy. Images of 50 cells per condition per time point were obtained 
with a Nikon A1 confocal laser microscope. Z-stack images were taken with a 60X 
objective with a step size of 0.5 um. All camera settings were the same across all 
images per experiment. Images were processed using the Denoise.ai noise 
reduction technology in NIS-Elements software (Nikon) and maximum image 
projections (MaxIPs) were created. The MaxIP images were analyzed in NIS-
Elements software using the auto-detect (region of interest) ROI program to 
automatically detect nuclei. Then the outline of the cell was traced manually to 
compare nuclear and cytoplasmic RAD51 total intensity levels at the single cell 
level. Cells were considered positive for cytoplasmic accumulation if the 
cytoplasmic intensity was greater than 95% of control cells.  
Karyotype analysis 
Karyotype analysis is a cytogenetic technique used to assess chromosomal 
arrangements and can be used to confirm cell line authenticity or alterations made 
to chromosomes after exposure to chemicals. We used g-banding (Giemsa 
banding) karyotype analysis to confirm cell line authenticity throughout this project. 
This method results in dark staining of adenine and thymine-rich heterochromatic 
regions and light staining of euchromatic regions rich in guanine and cytosine 
resulting in a banding pattern.  
Cells were seeded immediately from a thawed cryovial or from growing 
cells. Colcemid was added to cells to arrest in metaphase 1 or 4 hours before 




collected to avoid loss of any loosely attached mitotic cells. Cells were washed 
with PBS (without calcium and magnesium) and trypsin was added to lift cells off 
the dishes. Cells were collected and centrifuged at 1000 rpm for 5 minutes at 4°C. 
The supernatant was aspirated, and the cell pellet was resuspended with 10 ml of 
0.75 M KCl for 17 minutes. One ml fixative (methanol:acetic acid; 3:1) was added 
and the cells were pelleted again by centrifugation 5 minutes at 4°C and 1000 rpm. 
The pellet was resuspended in 10 ml fixative 20 minutes at room temperature, the 
fixative was changed twice, and cells were dropped onto wet microscope slides.  
Slides were stained by digesting the cells with trypsin (1:250) in Gurr’s 
buffer approximately 30 seconds – 1 minute which was stopped by dipping 3-4 
times in 2% fetal bovine serum in Gurr’s buffer (Gibco). Slides were dipped 3-4 
times in Gurr’s buffer (pH 7.0) then 70% ethanol, 95% ethanol and Gurr’s buffer 
(pH 6.8) before staining approximately 3 minutes in Wright’s stain (Carolina 
Biological). Slides were cover-slipped and imaged using an Applied Spectral 
Imaging microscope and software. Ten metaphases were assessed per analysis. 
Neutral comet assay 
The comet assay is a method to measure DNA damage using single-cell 
gel electrophoresis. The neutral comet assay specifically measures double strand 
breaks. This assay is a sensitive measurement of DNA damage based on the 
principle negatively charged DNA fragments (created as a result of DNA damage) 
will migrate in an electrical current out of the cell creating a ‘comet tail’. Therefore, 
more DNA damage in a cell the results in longer and/or more intense comet tails. 




media was replaced with fresh, warm media and cells were treated with 0, 0.1, 0.2, 
0.3 and 0.4 ug/cm2 zinc chromate for 24 or 120 h.  
At harvest, media was aspirated, and cells were washed with PBS (without 
calcium and magnesium) before trypsin was used to collect cells. Cells were 
centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was aspirated, cells 
were resuspended in PBS and counted. Cells were diluted to 100,000 cells/ml in 
PBS and added to low melting point agarose at a ratio of 1:10. The cell-agarose 
mixture was added to CometAssay® slides (R&D Systems) and chilled at 4°C 20 
minutes. Slides were submerged in CometAssay® lysis solution (Trevigen) 30 
minutes, rinsed with distilled water and submerged in enzyme digestion solution 
with proteinase K (1 mg/ml) for 2 h at 37°C. Slides were rinsed and immersed in 
chilled neutral electrophoresis buffer for 10 minutes. Electrophoresis was carried 
out in CometAssay® units (Trevigen) at 21V in neutral electrophoresis buffer at 
4°C for 20 minutes. Slides were sensed with distilled water and immersed in DNA 
precipitation solution for 30 minutes at room temperature. Cells were brought into 
a single plane by immersing in freshly prepared 70% ethanol for 5 minutes at room 
temperature. Slides dried overnight and were stained with SYBR green (Sigma 
Aldrich) 30 minutes.  
Slides were analyzed using Comet Assay IV software (Instem). One 
hundred cells per concentration per time point were analyzed for tail intensity. Tail 






Under certain conditions cells may have loss of protein expression that 
affects other functions in the cell. Overexpression plasmids that contain high copy 
numbers of a specific gene of interest can be transfected into cells to assess the 
effects reconstituting or overexpressing a specific gene. Specifically, plasmid 
vectors contain the gene of interest, the regulatory sequences required for 
transcription (enhancer and promoter regions) and antibiotic resistance 
sequences. These antibiotic resistance sequences allow for the correct selection 
of bacteria for expansion and isolation of plasmids to transfect into cells. 
Additionally, antibiotic resistance can be used to select for cells that were 
successfully transfected.  
An E2F1 expression plasmid (HA-E2F1 wt-pRcCMV plasmid; Addgene-
21667) and CMV500 vector control (Addgene-33348) were acquired as bacterial 
stabs from Addgene. HA-E2F-1 wt-pRcCMV was a gift from William Kaelin 
(Addgene plasmid # 21667; http://n2t.net/addgene:21667; RRID: 
Addgene_21667) (Krek et al., 1994). CMV500 empty vector was a gift from 
Charles Vinson (Addgene plasmid # 33348; http://n2t.net/addgene:33348; RRID: 
Addgene_33348) (Rishi et al., 2004). Bacteria were streaked on agar plates and 
single colonies were selected for expansion in LB broth with ampicillin. The 
QIAGEN plasmid midi kit was used to isolate plasmids from bacteria according to 
the manufacturer’s instructions. Briefly, Bacteria cultures were centrifuged at 6,000 
x g for 15 minutes at 4°C. The pellet was resuspended in buffer, and DNA was 




NanoDrop ND-1000 spectrophotometer. Plasmids were assessed for appropriate 
size by resolution on a DNA gel.  
 
Figure 2.1. Exposure paradigm for E2F1 overexpression experiments following 
120 h particulate Cr(VI) exposure. 
WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for 
48 h before treating with zinc chromate. After 72 h zinc chromate treatment cells 
were transfected with Dharmafect kb transfection reagent (Horizon Discovery) per 
the manufacturer’s instructions. Final concentration of plasmids were 1 ug/ml and 
final Dharmafect kb was 3 ul/ml. After transfection cells were allowed to rest 48 h 
(total 120 h zinc chromate and 48 h plasmid treatment) and harvested for whole 
cell protein and immunofluorescence staining. 
RNAseq Analysis 
RNAseq is a genome wide expression profiling technique that uses next-
generation sequencing and can be used to identify expression profiles of different 




specifically to probe for miRNAs after treating WTHBF-6 cells with particulate 
Cr(VI). The goal was to identify which miRNAs are significantly upregulated or 
downregulated in response to Cr(VI) exposure, then identify the targets of those 
miRNAs, and which cellular pathways were targeted the most.  
RNA isolation and next generation sequencing  
WTHBF-6 cells were seeded, allowed to rest 48 h and treated with zinc 
chromate for 24, 72, or 120 h. At harvest cells were harvested with the mirVana™ 
miRNA Isolation Kit (Thermo cat: AM1560) using manufacturer’s instructions for 
the protocol to isolate total RNA. Briefly, cells were lysed directly in the culture 
plates and homogenized. RNA was extracted using acid-phenol:chloroform and 
the aqueous phase was transferred to filter cartridges. Total RNA was washed 
several times using ethanol and eluted into a fresh tube. 
Samples were sent to the University of Louisville CGeMM DNA Facility Core 
for analysis. Library prep was performed using the TruSeq Small RNA Library Prep 
Kit v2 (Illumina) with gel purification followed by library validation and quantification 
to create miRNA libraries from 0.5-2 ug total RNA. 1x75 bp sequencing was 
performed using NextSeq 500 High Output v2 (75 cycles) kit on the Illumina 
NextSeq500 instrument. Ten million reads per sample were generated. 
Bioinformatics  
RNA sequencing (RNA-Seq) reads were first filtered using fastx-toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/) (Hannon, 2010). Adaptor sequence 




that show a Phred score < 20 (i.e., base call error rate > 1%) were subsequently 
trimmed from both ends of a sequencing read to preserve the longest section of a 
high-quality sequence read. Finally, sequencing reads that show base call quality 
< 20 for over 25% of the remaining base calls were removed. For all data filter 
steps, sequencing reads with lengths < 15 nucleotides were discarded. Filtered 
sequencing reads were mapped to human non-coding RNA reference 
transcriptome (Ensembl GRCh38) using Bowtie2 (Kim et al., 2013) ‘end-to-end’ 
mode, followed by discarding transcriptome mapping results that yielded mapping 
score < 20 (i.e., > 1% error rate) using samtools (Li et al., 2009; Li and Durbin, 
2009). Expression profiles of all samples were next established using custom Perl 
scripts (Lu et al., 2017; Lu et al., 2018). Only transcripts identified as “miRNA” in 
Ensembl “transcript_biotype” database (Ensembl Version 98) were kept for further 
analyses. 
Differentially expressed miRNA analysis  
In order to identify differentially expressed miRNAs after Cr(VI) exposure 
raw read counts were normalized to fit a linear mixed effect model. miRNAs were 
removed from the analysis if the sum of the raw reads across all conditions was 
less than 10. Each raw read was divided by the sum of all the read counts in that 
sample and multiplied by 1,000,000 (i.e. gene 1 normalized read = raw read count 
of gene 1/(sum raw read of gene 1+2+3+…..n)*1,000,000. Adjusted p values were 
determined using the Benjamini-Hochberg false discovery rate (FDR)-controlling 
method for multiple hypothesis testing. miRNAs were considered significant if they 




Each treatment concentration (0.1, 0.2, 0.3 ug/cm2 zinc chromate) was 
compared to the 0 ug/cm2 zinc chromate control at its respective timepoint. These 
analyses were done using GraphPad Prism v8.4.2 to create volcano plots for each 
comparison. miRNAs were considered significantly up- or down-regulated for fold 
change if the -Log10(adjusted p-value) was greater than 2 and the Log2(Fold 
change) was less than Log2(-2) or greater than Log2(2).  
Venn diagrams were created to determine miRNAs significantly affected 
across treatment concentrations using the online tool Venny v2.1 
(https://bioinfogp.cnb.csic.es/tools/venny/) (Oliveros, 2007-2015).  
The Morpheus online data analysis tool 
(https://software.broadinstitute.org/morpheus/) (Broad Institute) was used to 
create heatmaps to visualize fold-change trends across treatments. miRNAs were 
included in this analysis if they had a p-value less than 0.01 and a fold change 
greater than 2 in at least one condition. Euclidean clustering using the average 
linkage method was applied. In a separate analysis Euclidean k-clustering using 
the average linkage method and a k =3 was applied.  
In some cases, the mean counts of miRNAs were reported as ‘0’ in the 
control or treated concentrations. Therefore, errors occur in the fold change 
calculations. To deal with this issue ‘0.1’ was added to all miRNA means (i.e. 0 + 
0.1 = 0.1; 20.2 + 0.1 = 20.3) for fold change analysis. Similarly, some adjusted p 
values are reported as 0 because of the software analysis reporting methods. This 




order to avoid calculation errors in the Log(adjusted p-value) calculations 0.0001 
was added to all the adjusted p-values. 
Pathway analysis 
For this analysis we performed a literature review of recent review papers 
on Cr(VI) to identify pathways involved in Cr(VI) carcinogenesis. Pathways 
involved in Cr(VI) carcinogenesis were then correlated to pathways identified in 
the Kyoto Encyclopedia of Genes and Genetics (KEGG) online database 
(https://www.genome.jp/kegg/). KEGG is an online resource used to understand 
high-level functions and relationships in biological systems. This database 
incorporates large-scale molecular datasets to identify relationships in biological 
systems to better understand interactions.  
For each condition lists of miRNAs that fit within the parameters set for the 
volcano plot analysis (adjusted p-value <0.01, fold change >2) were populated. 
The DIANA TOOLS mirPath v.3 (http://snf-515788.vm.okeanos.grnet.gr/) was 
used to analyze the lists of miRNAs for each concentration at each timepoint 
(Vlachos et al., 2015). mirPath is a web-based pathway analysis software that uses 
statistical analysis of predicted or experimentally validated datasets of miRNA-
gene interactions and associates those interactions with pathways. The analysis 
can be performed using the KEGG analysis function or gene ontology (GO) 
analysis function. We were focused on pathway analysis and so the KEGG 
analysis function was applied. The analysis can be performed using either Tarbase 
v7.0, microT-CDS (v5.0), or TargetScan databases. Tarbase v7.0 accesses more 




microT-CDS predicts miRNA Recognition Elements (MREs) in the CDS or 3’UTR 
regions of target genes. TargetScan is another predictive database that 
determines the biological targets of miRNAs including 8mer, 7mer, and 6mer sites 
matching the seed region of miRNAs and 3’ UTR sites on targets.  
In this analysis we chose to use TargetScan in the mirPath analysis. The 
annotations for each significantly up- or down-regulated miRNA at each 
concentration and time point were converted from Ensembl Gene IDs 
(ENSG00000283751) to the miRBase ID annotation (hsa-miR-xxx) using the 
Biomart ensembl tool (https://useast.ensembl.org/info/data/biomart/index.html) 
(Hunt et al., 2018). The miRBase annotations were linked to the miRBase 
webpage where the MIMAT annotation determined and recorded for each miRNA. 
The MIMAT annotation was used for uploading the miRNA lists to the mirPath web 
page for analysis. Then the species was set to human, and the Targetscan 
database was selected for the analysis. The p-value threshold was set to 0.05, the 
TargetScan Score Type was set to “Context +” with a score of -0.4, and false 
discovery rate (FDR) correction was selected. Hierarchical clustering and miRNA-
KEGG heatmaps were created using the “Significance Clusters/Heatmaps” 
function, which utilizes the exact significance levels generated in the analysis. The 
Fisher’s Exact Test (Hypergeometric Distribution) was applied as the enrichment 
analysis method and pathways were merged using the ‘pathways union’ function.  
The pathways targeted by miRNAs in each timepoint and concentration in 
the mirPath results were cross-referenced with the pathways of Cr(VI)-





Figure 2.2. mirPath analysis settings. 
Target gene analysis 
Analysis was performed to assess miRNAs identified in the RNA seq 
analysis that affect RAD51. The online web software, miRSystem 
(http://mirsystem.cgm.ntu.edu.tw/index.php) was used to identify miRNAs that 
target RAD51 (Tzu-Pin et al., 2012). This database uses both miRNA target gene 
prediction programs (DIANA, miRanda, miRBRidge, PicTar, PITA, rna22, and 
TargetScan) and validated experimental data programs (TarBase and miRecords) 
to determine miRNA-gene associations. miRSystem has the ability to search data 
from miRNAs to target genes or target genes to miRNAs. For this analysis we used 
the “target genes to miRNAs” function to search for miRNAs that target RAD51. 
The results were downloaded which include all the miRNAs that regulate the target 
based on the 7 predictive programs and 2 experimental validation programs. The 
list of miRNAs from miRSystem was compared to the list of differentially expressed 
miRNAs determined in the RNA seq analysis at each time point and concentration. 
The list was separated by up- or down-regulated miRNAs.  
We sought to characterize how well miRNAs significantly upregulated by 




platform, (http://www.microrna.org/microrna/home.do), which determines miRNA 
target sites on mRNA transcripts using the miRanda algorithm (Koppal et al., 2008, 
Enright et al., 2005) and mirSVR scores to determine the likelihood of binding 
(Koppal et al., 2010).  
siRNA transfections 
Small interfering RNAs (siRNAs) are short, non-coding RNA molecules 
usually about 20-25 base pairs in length that interfere in expression within the RNA 
interference pathway in cells. This mechanism has been adapted as a molecular 
technology developed to allow for testing the effects of loss of a target on cellular 
function. As a molecular tool, siRNAs are designed to be complementary to a 
target mRNA sequence. The siRNA binds to mRNA transcripts of target genes 
promoting degradation and preventing translation. 
 
 





WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for 
48 h before siRNA transfection. Transfections were carried out per the 
manufacturer’s suggestions with slight modifications. Dharmafect transfection 
reagent 1 (Dharmacon, Lafayette, CO) and E2F1 ON-TARGET plus siRNA #09 
(Dharmacon; J-003259-09-0005), E2F1 ON-TAREGET plus siRNA #10 
(Dharmacon; J-003259-10-0005), E2F1 ON-TARGET plus siRNA #11 
(Dharmacon; J-003259-11-0005), E2F1 ON-TARGET plus siRNA #12 
(Dharmacon; J-003259-12-0005), and ON-TARGET plus non-targeting control 
siRNA #1 (Dharmacon; D-001810-01-05) were combined with serum-free and anti-
biotic free media 5 minutes separately. The siRNAs were then combined with the 
Dharmafect 20 minutes and added to the cells with antibiotic-free media. Final 
concentrations of Dharmafect and siRNAs were 2 ul/ml, and 25 nM, respectively. 
After 24 h media was replaced, and cells were treated with zinc chromate for 24 h 
(48 h total transfection time). Cells were harvested for total RNA, whole cell protein, 
and immunofluorescence staining.  
Sister chromatid exchange assay 
The sister chromatid exchange assay is used as an indirect measure of 
homologous recombination repair (Sonoda et al 1999). This method involves the 
incorporation of 5-bromodeoxyuridine (BrdU) into DNA to visualize the reciprocal 
exchange of DNA that occurs during the crossing over of sister chromatids in 
homologous recombination repair. As a result, cells that have gone through two 
rounds of replication have chromosomes with one sister chromatid with BrdU 




light while the sister chromatid without BrdU is stained visibly dark resulting in 
harlequin staining. If homologous recombination occurred there is reciprocal 
exchange of DNA between the two chromatids. This method has been validated 
as a measure of homologous recombination repair, although it does not represent 
all possible repair products of homologous recombination repair due to variations 
in the resolution of holiday junctions.  
For 24 h treatments PDGC9-1LU cells were seeded in 100 mm dishes with 
0.6 ug/ml BrdU. Cells were allowed to rest for 48 h before replacing the media with 
fresh, warm media (with 0.6 ug/ml BrdU also added fresh) and treating with 0, 0.1, 
0.15, 0.2, 0.3, and 0.4 ug/cm2 zinc chromate. For 120 h treatments PDGC9-1LU 
cells were seeded in 100 mm dishes and allowed to rest 48 h before replacing 
media with fresh, warm media and treating with 0, 0.1 0.15, 0.2, and 0.3 ug/cm2 
zinc chromate. No metaphases were observed at 0.4 ug/cm2 zinc chromate after 
120 h exposure and so was not included. BrdU (0.6 ug/ml) was added 72 h (0, 0.1 
and 0.15 ug/cm2 zinc chromate) and 96 h (0.2 and 0.3 ug/cm2 zinc chromate) 
before the end of treatment due to slowed growth rate at the higher concentrations.   
Four hours before the end of the treatment time demecolcine was added to 
arrest cells in metaphase. At harvest, the media was collected to avoid loss of any 
loosely attached mitotic cells. Cells were washed with PBS (without calcium and 
magnesium) and trypsin was added to lift cells off the dishes. Cells were collected 
and centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was aspirated, 
and the cell pellet was resuspended with 10 ml of 0.75 M KCl for 17 minutes. One 




by centrifugation 5 minutes at 4°C and 1000 rpm. The pellet was resuspended in 
10 ml fixative 20 minutes at room temperature, the fixative was changed twice, and 
cells were dropped onto wet microscope slides. Slides were dried overnight, 
soaked in PBS 5 minutes, and stained with 0.5 ug/ml Hoechst 33258 
trihydrochloride trihydrate solution (Sigma Aldrich) for 10 minutes at room 
temperature. Excess solution was tapped off and several drops of 25 ug/ml 
Hoechst 33258 trihydrochloride trihydrate solution was added and a coverslip was 
added. Slides were incubated under fluorescent lights (27 W) for 10-12 hours in a 
humidified chamber 5 cm from the light source. At the end of the incubation the 
coverslips were washed off with distilled water and incubated in 2X sodium 
chloride/sodium citrate solution 15 minutes at 60°C. Slides were rinsed with 
distilled water, stained with 4% Giemsa stain in Gurr’s buffer 6 minutes, and 
coverslips were added with mounting medium. The average number of sister 
chromatid exchanges per chromosome was analyzed in 50 diploid cells with 
harlequin staining per concentration per time point. 
Statistics 
Results in Aims 1 and 3 are expressed as the mean +/- SEM (standard error 
of the mean) of at least 3 independent experiments unless otherwise noted. 2-way 
ANOVA with Tukey post-hoc analysis was used to determine the significance of 
Cr(VI) concentrations between exposure times (i.e. 24 h 0.1 ug/cm2 vs. 120 h 0.1 
ug/cm2 zinc chromate) or between Cr(VI) concentrations within a single exposure 
time (i.e. 24 h 0 ug/cm2  zinc chromate vs. 24 h 0.1 ug/cm2 zinc chromate). When 




used. Statistical significance was set at p<0.5. Statistical analysis was performed 
using GraphPad Prism v8.4.2.   
In Aim 2, mean read counts are expressed as the mean of 3 independent 
experiments with 4 technical repeats resulting in an n = 12. A linear mixed effect 
model was fit in R (https://www.r-project.org/) with the ‘nlme’ package (R core 
team, 2013). The Benjamini-Hochberg FDR-controlling method for multiple 
hypothesis testing was applied to determine adjusted p-values. Statistical 
significance was set at adjusted p-value<0.01. Statistical analysis was performed 
in R using the ‘stats’ package.  
Total RNA Isolation and qPCR 
Quantitative real-time polymerase chain reaction (qPCR) is a technique 
used to quantify levels of RNA transcripts in a sample to better understand 
changes in expression. This technique requires isolating RNA, which is reverse 
transcribed to cDNA. The cDNA is then used in a polymerase chain reaction (PCR) 
to amplify the number of cDNA transcripts. One technique to quantitatively assess 
this PCR reaction is using Taqman tools. Taqman uses primer-probe assays that 
target specific sequences with attached fluorescent probes and a quencher 
inhibiting fluorescent signaling. During the amplification process the primer-probe 
binds its target sequence and after polymerization the fluorescent probe is cleaved 
and separated from the attached quencher resulting in a fluorescent signal. This 





WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for 
48h before treating with zinc chromate for 24, 72, or 120 h. Total RNA was isolated 
from WTHBF-6 cells using the mirVana™ miRNA Isolation Kit. The protocol for 
total RNA was applied. Briefly, cells were lysed directly in the culture plates and 
homogenized. RNA was extracted using acid-phenol:chloroform and the aqueous 
phase was transferred to filter cartridges. Total RNA was washed several times 
using ethanol and eluted into a fresh tube. RNA quality and concentration was 
measured using a NanoDrop ND-1000 spectrophotometer.   
cDNA synthesis was carried out using a High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Inc.) per the manufacturer’s instructions with 
slight modifications. Briefly, 2X RT master mix was prepared using random 
primers, combined with 2 ug total RNA (per 20 ul reaction), and loaded onto a 96-
well plate. A no reverse transcriptase control and no RNA control were included in 
each reverse transcription reaction. Reverse transcription was carried out as 
shown in Table 2.1. 
Table 2.1. Reverse Transcription Conditions 
 Step 1 Step 2 Step 3 Step 4 
Temperature 
(ºC) 
25 37 85 4 
Time 10 min 120 min 5 min ∞ 
  
qPCR analysis was carried out using the TaqMan RNA assays per the 
manufacturer’s instructions with slight modifications. Briefly, TaqMan RNA primers 




Hs02758991_g1) were combined with TaqMan™ Fast Advanced Master Mix 
(Thermo Fisher Inc.) and cDNA in triplicate in a 96 well plate. The no RNA and no 
reverse transcriptase controls from cDNA synthesis and a no cDNA control were 
included in all qPCR runs. qPCR was carried out using a StepOnePlus Real-Time 
PCR system (Applied Biosystems) using conditions shown in Table 2.2. The CT 
threshold was set by the instrument’s calculations and results are displayed as 
∆∆Ct values relative to the untreated (0 ug/cm2 zinc chromate) control for each 
time point, respectively. 
Table 2.2. qPCR Conditions 
 Cycle (40 cycles) 
 Hold Hold Denature Anneal/Extend 
Temperature 
(ºC) 
50 95 95 60 




CHAPTER 3: RESULTS 
 
Aim 1: Determine if E2F1 modulates the RAD51 response to particulate Cr(VI) 
exposure. 
Background 
Data show chromosome instability is a primary driver of Cr(VI) 
carcinogenesis (Chen et al., 2019; Rager et al., 2019; Wise et al., 2018). However, 
the mechanisms of Cr(VI)-induced structural chromosome instability are not fully 
elucidated. Cr(VI) induces DNA double strand breaks resulting in structural 
chromosome instability (Holmes et al., 2008). We showed Cr(VI) inhibits the 
effector step of homologous recombination repair by interfering with RAD51 (Qin 
et al., 2014; Browning et al., 2016; Browning et al., 2017a). Reduced protein 
expression is a key effect of particulate Cr(VI) exposure that at a fundamental level 
can affect other particulate Cr(VI)-induced RAD51 phenotypes including loss of 
nuclear foci formation. However, mechanisms of RAD51 protein loss after Cr(VI) 
exposure are not known.  
There are two possible mechanisms for reduced RAD51 protein levels – 
increased protein degradation or decreased protein production. Particulate Cr(VI) 
can induce increased protein degradation. Indeed, Bruno et al., 2016 found protein 
degradation pathways were deregulated following Cr(VI) exposure in BEAS-2B 




transcription. Numerous studies show Cr(VI) causes global downregulation of 
expression (Andrew et al., 2003; Wetterhahn and Hamilton, 1989; Ye et al., 2001). 
Downregulation of factors involved in DNA repair has been observed following 
Cr(VI) exposure (Hodges and Chipman, 2002; Hu et al., 2018). For example, Hu 
et al., 2018 found Cr(VI) exposure inhibited transcription of MGMT, XRCC1, 
ERCC3, and RAD51 in 16HBE cells.   
RAD51 expression is tightly regulated in normal cells. Studies show 
overexpression of RAD51 can lead to aberrant recombinase activity and RAD51 
binding to chromatin resulting in genomic instability (Raderschall et al., 2002). 
Meanwhile, adequate RAD51 protein levels must be maintained to enable a 
response to DNA double strand breaks from both endogenous and exogenous 
insults. Therefore, understanding transcriptional regulation of RAD51 is critical to 
understand how Cr(VI) is affecting RAD51 expression.  
Hasselbach et al., 2005 characterized the RAD51 promoter and identified 
transcription factors ETS1/PEA3, E2F,TP53, EGR1, and STAT5 bind to the 
RAD51 promoter. These transcription factors have different numbers of binding 
sites and are either activating or repressive (Table 3.1).  







ETS1/PEA3 Activating 1 
E2F Activating 4 
p53 Repressive 3 
EGR1 Activating 2 





RAD51 has a TATA-less and GC-rich promoter that ranges from base pairs -543 
to +204 (747 total base pairs) relative to the transcription start site. There are 3 
cis-sequence elements responsible for RAD51 transcription, 1 for basal 
expression and 2 that limit the expression. The core promoter element is located 
from base pairs -204 to -5 and shares a consensus sequence for transcription 
factor binding also found in the BRCA1 promoter that is specifically targeted by the 
E2F family of transcription factors (Bindra and Glazer 2007; Hegan et al., 2009; 
Xie et al., 2013) (Figure 3.1).  
 
Figure 3.1. Working model of the RAD51 promoter. This figure shows 
a model of the RAD51 promoter elements that regulate expression 
based on data from Hasselbach et al., 2005. It shows 3 cis-regulatory 
elements; one that may limit expression (-305 to -204) one that 
enhances expression (-204 to -58) and one that limits expression (-
58 to +204). It also shows the binding sites of each transcription 
factor identified.  
E2F1 is a transcription factor involved in the expression of RAD51 and in 
the recruitment and stability of DNA repair proteins at double strand breaks. 
Studies have identified E2F1 as the predominant transcription factor for RAD51 
and show knockdown of E2F1 results in loss of RAD51 protein, mRNA, and 




E2F1 is normally held in a transcriptionally inactive state by the retinoblastoma 
(RB) pocket protein. Phosphorylation of RB releases E2F1, which can then 
perform its transcriptional function (Liao et al., 2010; Rubin, 2013). In addition to 
release from RB, E2F1 is stabilized by post-translational modifications following 
genotoxic stress increasing E2F1’s ability to assist in DNA repair through 
transcription activation of DNA repair proteins, and direct involvement in the repair 
process (Glorian et al 2017; Ianari et al., 2004).  
E2F4 is a repressive member of the E2F family of transcription factors and 
has been shown to directly compete with E2F1 for promoter binding. Indeed, 
Bindra et al., 2007 showed E2F1 and E2F4 bind to the same region of the RAD51 
promoter. E2F4 is a part of the DREAM complex, which includes the pocket protein 
p130. Hypophospho-p130 binds to E2F4, which then translocates to promoters. 
The hypo-phosphorylation of p130 enhances the formation of the DREAM complex 
and is facilitated by p53. However, p53 has also been shown to directly repress 
RAD51 transcription by binding the promoter itself (Hine et al., 2014; Arias-Lopez 
et al., 2005; Hannay et al., 2007). The repressive DREAM complex can displace 
the activating E2F1 complex at promoters leading to transcriptional repression, 
although this mechanism is not well understood. Studies show the DREAM 
complex downregulates DNA repair and facilitates a G2 arrest following DNA 
damage (Fischer et al., 2014; Jaber et al., 2016).  
Other transcription factors have been less characterized for RAD51 
transcription. Hasselbach et al., 2005 reported ETS1/PEA3 was included as a 
transcription factor at the RAD51 promoter, but acknowledges this protein is often 




Hasselbach et al., 2005 suggested EGR1 may be inhibitory, Hine et al., 2014 found 
deletion of the EGR1 binding site reduced RAD51 expression by 40%. Hine et al., 
2014 also characterized the RAD51 promoter with slightly different results than 
Hasselbach et al., 2005. This may be due to the different cell types each used and 
preparation of the constructs in their experiments.  
Although studies have begun to characterize transcriptional control of the 
RAD51 promoter it is still unknown if RAD51 transcription is inhibited following 
Cr(VI) exposure. We determined if particulate Cr(VI)-induced reduction of RAD51 
protein is due to altered protein half-life or reduced expression (Objective 1). 
Because E2F1 is the predominant transcription factor for RAD51 we assessed the 
effects of particulate Cr(VI) exposure on E2F1 (Objective 2). Finally, to further 
explore the role of E2F1 in the RAD51 response we assessed if E2F1 could 
modulate RAD51 after particulate Cr(VI) exposure (Objectives 3-4). All 
experiments in this aim were done in WTHBF-6 cells.  
Results 
Objective 1: Particulate Cr(VI)-induced reduction of RAD51 protein is a result 
of inhibited expression  
We showed particulate Cr(VI) reduces RAD51 whole cell protein (Browning 
et al., 2016). We confirmed this effect using the cell-equivalence western blot 
method. Figure 3.2A shows representative western blots of whole cell RAD51 
protein. RAD51 whole cell protein is unaffected after 24 h particulate Cr(VI) 
exposure, but decreases after prolonged 72 and 120 h exposure in a 
concentration- and time-dependent manner (Figure 3.2B) consistent with previous 




increased then decreased RAD51 whole cell protein to 109, 90, and 81% of 
control. RAD51 whole cell protein was decreased to 70, 28, and 11% after 72 h 
and further to 40, 20, and 6% of control after 120 h at 0.1, 0.2 and 0.3 ug/cm2 zinc 
chromate, respectively. All zinc chromate concentrations RAD51 protein levels 
were significantly reduced compared to the control after prolonged 72 and 120 h 
exposure (p<0.0001). However, the small reductions observed after 24 h zinc 

















Figure 3.2. Prolonged exposure to particulate Cr(VI) reduces RAD51 
whole cell protein expression. This figure shows (A) representative 
western blot images of whole cell RAD51 and (B) RAD51 whole cell 
protein (relative to control) decreased with concentration and time 
after 72 and 120 h, but not 24 h exposure. GAPDH was used as a 
loading control. When comparing zinc chromate concentrations 
between time points all concentrations were statistically significant 
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represent the mean of three experiments. Error bars = standard error 



























RAD51 protein reduction after particulate Cr(VI) exposure could be due to 
an increase in protein degradation. One component of assessing protein 
degradation is protein half-life. To assess if Cr(VI) affects RAD51 protein half-life 
cells were treated with 0 or 0.2 ug/cm2 zinc chromate for 24 or 120 h and at the 
end of treatment a protein translation inhibitor, cycloheximide (CHX), was added 
and a 12 h time course was performed to harvest protein. Figure 3.3A shows a 
representative western blot for RAD51 whole cell protein after 24 or 120 h zinc 
chromate exposure and a 12 h CHX treatment time course. RAD51 whole cell 
protein levels decreased significantly beginning at 4 h after the addition of CHX 
after 24 h 0 and 0.2 ug/cm2 zinc chromate exposure compared to the 0 h time point 
(Figure 3.3B).  RAD51 protein was significantly reduced 4 and 6 h hours after the 
addition of CHX in 0 and 0.2 ug/cm2 zinc chromate treated cells, respectively 
(Figure 3.3C).  There was no difference in RAD51 protein half-life comparing 0.2 
ug/cm2 zinc chromate to the control or between exposure time points.  Table 3.2 
shows the calculated half-life of RAD51 after 24 or 120 h zinc chromate exposure 















Figure 3.3. Particulate Cr(VI) has little effect on RAD51 protein half-
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protein (relative to the 0 h CHX control for either the 0 or 0.2 ug/cm2 
zinc chromate condition) after 24 and 120 h zinc chromate exposure 
and 12 h CHX exposure. Data represent the mean of three 
experiments. Error bars = standard error of the mean. Exposure to 
(B) 24 and (C) 120 h zinc chromate has little effect on RAD51 protein 
half-life. GAPDH was used as a loading control. RAD51 whole cell 
protein significantly decreased compared to 0 h CHX following the 
addition of CHX in all conditions. Statistically different compared to 0 




















Table 3.2. RAD51 protein half-life 
Zinc chromate 
conc. (ug/cm2) 
24 h 120 h 
0 5.17 h 5.59 h 
0.2 4.35 h 5.92 h 
 
Table 3.2. shows RAD51 protein half-life in hours after 24 or 120 h 




















The RAD51 protein half-life data indicates protein degradation is not 
significantly contributing to the reduction of RAD51 protein observed after 
prolonged particulate Cr(VI) exposure suggesting the effect is on protein 
production. To test this possibility, we measured RAD51 mRNA levels using qPCR. 
Particulate Cr(VI) inhibited RAD51 mRNA moderately after 24 h 0.1, 0.2, and 0.3 
ug/cm2 zinc chromate exposure to 83, 73, and 62% compared to control although 
none were significant (Figure 3.4). Prolonged exposure of 72 and 120 h 0.1, 0.2 
and 0.3 ug/cm2 zinc chromate reduced RAD51 mRNA to 49, 31, and 16% and 53, 
21 and 24% of control, respectively. After prolonged exposure of both 72 and 120 
h RAD51 mRNA was significantly reduced at all concentrations compared to 











Figure 3.4. Particulate Cr(VI) inhibits RAD51 mRNA. This figure 
shows after prolonged 72 and 120 h exposure zinc chromate inhibits 
RAD51 mRNA levels. GAPD was used to normalize RAD51 mRNA 
levels. RAD51 mRNA level was significantly reduced at all 
concentrations after 72 and 120 h exposure compared to control 
(*p<0.05; ***p<0.0001). RAD51 mRNA at all zinc chromate-treated 
concentrations was significantly decreased after 72 and 120 h 
compared to the respective concentration at 24 h exposure. Data 
represent the mean of three experiments. Error bars = standard error 
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Objective 2: Particulate Cr(VI) inhibits E2F1 expression 
The combination of protein half-life and qPCR data suggests the reduction 
of RAD51 protein following particulate Cr(VI) exposure is primarily a result of 
inhibited transcription. We sought to further investigate how Cr(VI) inhibits RAD51 
expression. We chose to focus on E2F1, the predominant transcription factor for 
RAD51, to assess how particulate Cr(VI) exposure affects E2F1 expression.  
Figure 3.5A shows representative E2F1 whole cell western blots. Similar to the 
effects on RAD51, particulate Cr(VI) did not affect E2F1 whole cell protein levels 
after 24 h exposure (84, 103 and 88% of control), but decreased levels to 57, 48, 
and 41% and 43, 47, and 55 % after 72 and 120 h 0.1, 0.2, and 0.3 ug/cm2 zinc 
chromate exposure, respectively (Figure 3.5B). E2F1 whole cell protein was 
decreased significantly compared to the control after 72 h 0.3 ug/cm2 and 120 h 
0.1 ug/cm2 zinc chromate, however all zinc chromate treated concentrations are 
clearly repressed compared to control at these time points. 
E2F1 self-regulates its own transcription and we found prolonged 
particulate Cr(VI) exposure inhibits E2F1 protein expression (Johnson et al., 1994). 
We tested if particulate Cr(VI) inhibits E2F1 mRNA levels using qPCR following 
particulate Cr(VI) exposure. Particulate Cr(VI) inhibited E2F1 mRNA levels after 
24, 72, and 120 h exposure (Figure 3.6). After 24 h E2F1 mRNA was reduced to 
82, 55, and 56% of control following 0.1, 0.2, and 0.3 ug/cm2 zinc chromate, and 
further decreased to 45, 28, and 18% of control after 72 and h. E2F1 mRNA 
remained low after 120 h decreasing to 55, 26, and 36% of control. At all time 
points each concentration was significantly decreased compared to control except 

























Figure 3.5. Prolonged particulate Cr(VI) inhibits E2F1 whole cell 
protein. This figure shows E2F1 whole cell protein is reduces after 
prolonged 72 and 120 h exposure to zinc chromate. Data represent 
the mean of three experiments. Error bars = standard error of the 
mean. (A) Representative images of E2F1 whole cell protein western 
blots. GAPDH was used as a loading control. (B) E2F1 whole cell 
protein (relative to control). Statistically significant compared to 
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Figure 3.6. Particulate Cr(VI) inhibits E2F1 mRNA levels. This figure 
shows 24, 72 and 120 h zinc chromate exposure inhibits E2F1 
mRNA levels. GAPD was used as to normalize E2F1 mRNA levels. 
E2F1 mRNA level was significantly reduced at all concentrations 
compared to control except 24 h 0.1 ug/cm2 zinc chromate 
(***p<0.0001). E2F1 mRNA at all zinc chromate-treated 
concentrations was significantly decreased after 72 and 120 h 
compared to the respective concentration at 24 h exposure. Data 
represent the mean of three experiments. Error bars = standard error 
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Objective 3: E2F1 overexpression does not rescue Cr(VI)-induced RAD51 
failure 
Particulate Cr(VI) induces a normal RAD51 response after acute 24 h 
exposure and an abnormal response after 120 h exposure characterized by 
inhibited protein expression and RAD51 nuclear foci formation and increased 
RAD51 cytoplasmic accumulation (Browning et al., 2016; Qin et al., 2014). Here, 
we show particulate Cr(VI) inhibits RAD51 mRNA indicating RAD51 expression 
specifically is impaired following exposure (Figure 3.4). We also showed the 
expression of the predominant transcription factor for RAD51, E2F1, was also 
suppressed following particulate Cr(VI) exposure (Figure 3.6). Therefore, we 
wanted to connect the correlating data between RAD51 and E2F1 impairment 
following particulate Cr(VI) exposure. We sought to determine if overexpression of 
E2F1 could offset the Cr(VI-reduced E2E1 protein levels to rescue Cr(VI)-induced 
RAD51 failure after 120 h exposure. To test this connection, cells were treated with 
zinc chromate for 120 h. For the last 48 h of exposure cells were transfected with 
either a plasmid vector control (CMV500) or E2F1 overexpression plasmid. At 
harvest, cells were collected for protein or fixed for immunofluorescence staining. 
Figure 3.7 shows E2F1 was successfully transfected into WTHBF-6 cells. After 
120 h exposure to 0 and 0.2 ug/cm2 zinc chromate E2F1 protein was 6220 and 





Figure 3.7. Transfection with E2F1 overexpression plasmid 
increases E2F1 whole cell protein. This figure shows E2F1 protein 
increases following transfection with E2F1 overexpression plasmid 
compared to untransfected cells and the transfection control plasmid 
(CMV500). E2F1 protein was normalized to GAPDH as a loading 
control. Data represent the mean of two experiments. Error bars = 
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RAD51 cytoplasmic accumulation is a key phenotype observed after 
prolonged exposure to particulate Cr(VI), however, the function of RAD51 is in the 
nucleus. (Browning et al., 2016; Qin et al. ,2014). The mislocalization of RAD51 in 
the cytoplasm may inhibit RAD51 from participating in homologous recombination 
repair. We used immunofluorescence staining and confocal microscopy to analyze 
RAD51 cytoplasmic accumulation following 120 h particulate chromium exposure 
and E2F1 overexpression.  
Figure 3.8A shows representative images of WTHBF-6 cells exposed to 120 
h 0 or 0.2 ug/cm2 zinc chromate with or without transfection. Cells were considered 
positive for cytoplasmic accumulation if the cytoplasmic intensity was greater than 
95% of control cells. All conditions were compared to the untransfected 0 ug/cm2 
zinc chromate control. Following 120 h exposure to 0.2 ug/cm2 zinc chromate 43% 
of cells were positive for RAD51 cytoplasmic accumulation consistent with 
previously published data (Browning et al., 2016)(Figure 3.8B). If E2F1 rescued 
particulate Cr(VI)-induced RAD51 cytoplasmic accumulation we would expect to 
see lower cytoplasmic accumulation levels in the E2F1 overexpression-transfected 
cells compared to the CMV500 transfection control. However, the percent of cells 
with RAD51 cytoplasmic accumulation was decreased in both the CMV500 control 
and E2F1-transfected cells. Additionally, there was no difference between control 
and 0.2 ug/cm2 zinc chromate treated cells in either transfection condition. This 
indicates the transfection procedure itself, not E2F1 overexpression caused the 







Figure 3.8. E2F1 overexpression does not prevent particulate Cr(VI)-
induced RAD51 cytoplasmic accumulation. This figures shows E2F1 
does not rescue particulate Cr(VI)-induced RAD51 cytoplasmic 
accumulation. (A) Representative images of RAD51 subcellular 
localization. The yellow arrow points to a cytoplasmic RAD51 
aggregate. (B) Exposure to 120 h 0.2 ug/cm2 zinc chromate induces 
cytoplasmic accumulation of RAD51 in untransfected cells. However, 
no cytoplasmic accumulation was observed in the CMV500 
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represent the mean of three experiments. Error bars = standard error 

























RAD51 foci formation is an indicator of RAD51 function in homologous 
recombination repair at double strand breaks. Previous studies show RAD51 
nuclear foci formation is inhibited following prolonged but not acute exposure to 
particulate Cr(VI) (Browning et al., 2016; Qin et al., 2014). We tested if E2F1 
overexpression could rescue the loss of RAD51 nuclear foci following 120 h 
exposure to particulate Cr(VI). The baseline level of RAD51 nuclear foci is set at 
5% of cells with more than 10 foci per cell based on previous studies (Browning et 
al., 2016; Qin et al., 2014). In untransfected cells we saw the expected response 
finding RAD51 nuclear foci formation is inhibited after 120 h exposure to 0.2 ug/cm2 
zinc chromate consistent with our previous work (Browning et al., 2016; Qin et al., 
2014) (Figure 3.9). If E2F1 overexpression rescues particulate Cr(VI)-inhibited 
RAD51 nuclear foci formation we would expect those levels to increase. However, 
in both the CMV500 transfection control and E2F1-transfected cells, RAD51 foci 








Figure 3.9. Particulate Cr(VI)-inhibited RAD51 nuclear foci is not 
rescued by E2F1 overexpression. This figure shows after 120 h 
particulate Cr(VI) exposure E2F1 overexpression does not increase 
RAD51 nuclear foci formation. The untransfected control has 
inhibited RAD51 nuclear foci formation following exposure to 0.2 
ug/cm2 zinc chromate, and similar levels of RAD51 nuclear foci were 
observed in the CMV500 transfection control and E2F1-transfected 
cells. The horizontal dashed grey line at 5 percent of cells with more 
than 10 RAD51 foci represents baseline levels normally observed in 
untreated cells. Data represent the mean of three experiments. Error 
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The literature suggests the primary role of E2F1 in RAD51 regulation is 
currently as a transcription factor for RAD51 expression. There may be many 
mechanisms affecting the localization of RAD51 unrelated to E2F1. Although we 
did not find E2F1 overexpression rescues Cr(VI)-induced RAD51 mislocalization 
we wanted to test if RAD51 protein levels could be restored by overexpressing 
E2F1 after 120 h particulate Cr(VI) exposure. Figure 3.10A shows representative 
western blot images of E2F1 and RAD51 following 120 h exposure to 0.2 ug/cm2 
zinc chromate with or without transfection. In untransfected cells, particulate Cr(VI) 
reduced RAD51 whole cell protein levels to 50% of control after 120 h exposure to 
0.2 ug/cm2 zinc chromate consistent with our previous work (Browning et al., 2016; 
Qin et al., 2014) (Figure 3.10B). However, E2F1 overexpression did not increase 
RAD51 protein levels following 0 or 0.2 ug/cm2 zinc chromate exposure. RAD51 
protein increases slightly in E2F1-transfected cells compared to the CMV500 
transfection control (40% to 60%, respectively) in 0 ug/cm2 zinc chromate controls, 
but there was no difference after exposure to 0.2 ug/cm2 zinc chromate (both 30% 








Figure 3.10. E2F1 overexpression does not rescue particulate 
Cr(VI)-inhibited RAD51 protein expression. This figure shows 
RAD51 whole cell protein is inhibited following 120 h exposure to 0.2 
ug/cm2 zinc chromate in untransfected cells and this phenotype is 
not rescued by E2F1 overexpression. GAPDH was used as a loading 
control. (A) Representative western blot images. (B) RAD51 whole 
cell protein expression (all conditions are relative to the 
untransfected 0 ug/cm2 zinc chromate control). Data represent the 
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Objective 4: Loss of E2F1 does not induce RAD51 failure after acute 24 h 
particulate Cr(VI) exposure 
E2F1 overexpression did not rescue RAD51 failure following prolonged 120 
h particulate Cr(VI) exposure. However, we also wanted to test the possible 
connection by determining if knocking down E2F1 could inhibit RAD51 following 
acute 24 h particulate Cr(VI) exposure to recapitulate the 120 h exposure 
outcomes. RAD51 has a normal response following 24 h particulate Cr(VI) 
exposure characterized by unaffected protein expression, and increased nuclear 
localization, and foci formation at double strand breaks (Browning et al., 2016; 
Tamblyn et al., 2009; Qin et al., 2014). Studies show loss of E2F1 results in 
reduced RAD51 protein levels, nuclear foci formation and inhibited homologous 
recombination repair (Chen et al., 2011; Choi and Kim, 2019; Wu et al., 2014). We 
transfected cells with E2F1 siRNA for 48 h and treated with 0.2 ug/cm2 zinc 
chromate the last 24 h of the transfection. Cells were harvested for 
immunofluorescence staining, protein, and RNA.  
Figure 3.11 shows E2F1 was successfully knocked down following 
transfection with four different E2F1 siRNAs after 24 h exposure to 0 and 0.2 
ug/cm2 zinc chromate. This analysis was performed two ways. The observed 
effects of the transfection procedure on E2F1 expression, all conditions were 
normalized to the untransfected 0 ug/cm2 zinc chromate control. The transfection 
procedure reduced E2F1 protein levels (60%) compared to the untransfected 0 
ug/cm2 zinc chromate control (Figure 3.11A). However, 0.2 ug/cm2 zinc chromate 
reduced E2F1 expression to 70% in both the untransfected and non-targeting 




B). This reduction is the result we would expect after 24 h particulate Cr(VI) 
exposure. E2F1 protein was decreased significantly in all E2F1 siRNA conditions 
compared to the untransfected and non-targeting siRNA control. E2F1 was 





















Figure 3.11. Knockdown of E2F1 inhibits E2F1 protein levels. This 
figure shows E2F1 knockdown for 48 h leads to reduced E2F1 
protein levels. Data represent the mean of at least 5 experiments. 
Error bars = standard error of the mean. (A) E2F1 whole cell protein 
levels relative to the 0 ug/cm2 zinc chromate untransfected control. 
E2F1 decreased significantly after 0.2 ug/cm2 zinc chromate 
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non-targeting siRNA conditions (***p<0.0001), however, no 
difference in this comparison was observed in E2F1 siRNA 
conditions. E2F1 levels were significantly decreased in all E2F1 
siRNA conditions compared to the untransfected and non-targeting 
siRNA control (#p<.0.0001) (B) E2F1 protein levels relative to the 0 
ug/cm2 zinc chromate non-targeting siRNA control. E2F1 decreased 




















We analyzed RAD51 cytoplasmic accumulation after E2F1 knockdown and 
24 h particulate Cr(VI) exposure. The same measures used in the E2F1 
overexpression experiments for RAD51 cytoplasmic accumulation were applied. 
After 24 h particulate Cr(VI) exposure we would expect a normal RAD51 response 
and no increase in RAD51 cytoplasmic accumulation in untransfected cells. This 
outcome is confirmed in the results which show 0.2 ug/cm2 zinc chromate control 
did not increase RAD51 cytoplasmic accumulation in the untransfected control 
(Figure 3.12). We also observed no increase in RAD51 cytoplasmic accumulation 
in the E2F1 knockdown conditions after either 0 ug/cm2 or 0.2 ug/cm2 zinc 
chromate exposure. The highest level of RAD51 cytoplasmic accumulation in any 
condition was 12% compared to 4% in the control (Figure 3.12) and 43%, which 
was observed in untransfected cells exposed to 120 h 0.2 ug/cm2 zinc chromate 








Figure 3.12. E2F1 knockdown does not induce RAD51 cytoplasmic 
accumulation after 24 h particulate Cr(VI) exposure. This figure 
shows RAD51 cytoplasmic accumulation did not increase following 
E2F1 knockdown and 24 h particulate Cr(VI) exposure. Data 
represent the mean of three experiments for all conditions (E2F1 #9 
and #10; n=1). Error bars = standard error of the mean. No statistical 
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Since E2F1 knockdown did not induce cytoplasmic accumulation of RAD51, 
RAD51 protein may still be available in the nucleus to form foci at DNA double 
strand breaks. We measured RAD51 nuclear foci after E2F1 knockdown and 24 h 
particulate Cr(VI) exposure to test this possibility. Exposure to 24 h 0.2 ug/cm2 zinc 
chromate increased RAD51 foci in all conditions (Figure 3.13). These increases 
were significant in the untransfected and non-targeting siRNA control (21 and 26% 
of cells, respectively), and these results are consistent with our previous work 
(Browning et al., 2016; Qin et al., 2014). One of the four E2F1 siRNA conditions 
also had a significant increase in RAD51 foci (E2F1 #10, 15% of cells). There was 
no difference in RAD51 foci level in cells with no zinc chromate exposure across 
all conditions. This outcome is expected because untreated RAD51 foci levels are 
already below baseline level and without a stimulus to induce RAD51 foci formation 
no change would be observable. However, when comparing RAD51 foci levels 
after 0.2 ug/cm2 zinc chromate exposure, the percent of cells with RAD51 foci was 
significantly decreased in all E2F1 knockdown conditions (except E2F1 #10) 
compared to the non-targeting siRNA control. These data indicate loss of E2F1 





Figure 3.13. E2F1 knockdown decreases RAD51 nuclear foci after 
acute particulate Cr(VI) exposure. This figure shows the percent of 
cells with more than 10 RAD51 foci per cell following 24 h particulate 
Cr(VI) exposure and E2F1 knockdown (untransfected 0 ug/cm2 zinc 
chromate controls subtracted). Exposure to 24 h 0.2 ug/cm2 zinc 
chromate significantly increased RAD51 foci in the untransfected 
and non-targeting siRNA controls and the E2F1 #10 siRNA condition 
(*p<0.05; ***p,0.0001). RAD51 foci were significantly decreased in 
all E2F1 siRNA conditions (except E2F1 #10) after exposure to 0.2 
ug/cm2 zinc chromate compared to the non-targeting siRNA control 
(#p<0.05). Data represent the mean of at least 3 experiments (E2F1 
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We are proposing E2F1’s transcription factor function would inhibit RAD51 
expression. Less RAD51 protein may also explain the inhibited RAD51 nuclear foci 
response to acute 24 h particulate Cr(VI) exposure after E2F1 knockdown. To 
determine if RAD51 protein is suppressed following E2F1 knockdown and acute 
24 h particulate Cr(VI) exposure we measured RAD51 protein. Figure 3.14 shows 
representative western blot images of E2F1 and RAD51 after E2F1 knockdown 
and 24 h exposure to particulate Cr(VI). We assessed the effect of the transfection 
on RAD51 protein expression and found while the transfection decreased RAD51 
protein to 70% in the non-targeting siRNA condition compared to the untransfected 
condition, it was not significant (Figure 3.14B). In the untransfected and non-
targeting control we saw the expected result of no difference in RAD51 protein 
level between 0 and 0.2 ug/cm2 zinc chromate.  When we compared the E2F1 
knockdown conditions to the non-targeting siRNA control only E2F1 #9 reduced 
RAD51 protein levels (50% of control), and only in the 0 ug/cm2 zinc chromate 
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Figure 3.14. E2F1 knockdown does not inhibit RAD51 protein after 
24 h particulate Cr(VI) exposure. This figure shows E2F1 knockdown 
for 48 h does not affect RAD51 protein levels. Data represent the 
mean of at least 5 experiments. Error bars = standard error of the 
mean. (A) Representative image of E2F1 and RAD51 western blots. 
(B) RAD51 whole cell protein levels relative to the 0 ug/cm2 zinc 
chromate untransfected control. There was no change in RAD51 
protein level between 0 and 0.2 ug/cm2 zinc chromate in any of the 
conditions. RAD51 protein was decreased to 70% in the non-
targeting siRNA control compared to the untransfected control, but 
this was not significant. (C) RAD51 protein levels relative to the 0 
ug/cm2 zinc chromate non-targeting siRNA control. RAD51 protein 
level only decreased in one E2F1 siRNA condition (E2F1 #9; 
***p<0.001) compared to the non-targeting siRNA control, and only 












It is possible E2F1 knockdown inhibits RAD51 transcription, but not protein 
levels. To test this possibility, we determined the effect of E2F1 knockdown on 
RAD51 mRNA levels using qPCR. We confirmed E2F1 knockdown inhibits E2F1 
mRNA (Figure 3.15A). E2F1 mRNA was significantly inhibited in all E2F1 
knockdown conditions compared to the non-targeting siRNA control except E2F1 
#10 after 0.2 ug/cm2 zinc chromate exposure. Exposure to 24 h 0.2 ug/cm2 zinc 
chromate also decreased E2F1 mRNA in all conditions, although only significantly 
in the untransfected control. The E2F1 mRNA reduction is consistent with our 
previous results (Figure 3.6). 
Next, we evaluated RAD51 mRNA levels following E2F1 knockdown. Figure 
3.15B shows RAD51 mRNA is decreased by 24 h exposure to 0.2 ug/cm2 zinc 
chromate however, none of the changes in these levels are significant. For 
example, 0.2 ug/cm2 zinc chromate reduced RAD51 mRNA to 64% compared to 
control similar to our previous experiments evaluating RAD51 mRNA after 
particulate Cr(VI) exposure (Figure 3.4). RAD51 mRNA was reduced by E2F1 
siRNA #9 compared to the non-targeting control, but this reduction was not 
significant. E2F1 #10 increased RAD51 mRNA slightly compared to the non-






Figure 3.15. E2F1 knockdown does not consistently RAD51 mRNA 
expression. This figure shows E2F1 knockdown does not inhibit 
RAD51 mRNA expression after acute 24 h particulate Cr(VI) 
exposure. Data represent the mean of three experiments. Error bars 
= standard error of the mean. (A) E2F1 mRNA were successfully 
reduced following E2F1 knockdown (#p<0.05). Particulate Cr(VI) 
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in the untransfected control (***p<0.0001). (B) RAD51 mRNA was 
unaffected by 0.2 ug/cm2 zinc chromate exposure or E2F1 
knockdown. GAPD was used as to normalize E2F1 and RAD51 
























Alternative hypotheses for reduced RAD51 expression 
The literature shows loss of E2F1 results in RAD51 impairment after 
induction of DNA double strand breaks (Chen et al., 2011; Choi and Kim, 2019; 
Wu et al., 2014). It is well known exposure to particulate Cr(VI) induces DNA 
double strand breaks and the canonical repair of those breaks occurs through 
homologous recombination (Bryant et al., 2006; Gastaldo et al., 2007; Helleday et 
al., 2000; Stackpole et al., 2007). However, the data in objective 3 and 4 indicate 
E2F1 does not modulate the RAD51 response to particulate Cr(VI). We began to 
develop alternative hypotheses that may explain this outcome. Although we 
showed E2F1 whole cell protein was significantly inhibited following prolonged 
exposure to particulate Cr(VI) it is possible in this case available protein is 
accumulated in the nucleus in order to preserve critical functions. Therefore, we 
measured E2F1 nuclear protein levels following particulate Cr(VI) exposure. 
Figure 3.16A shows representative western lots of E2F1 nuclear protein. 
Particulate Cr(VI) had no effect on E2F1 nuclear protein levels after 24, 72, or 120 
h exposure. For example, exposure to 0.2 ug/cm2 zinc chromate resulted in 
nuclear E2F1 protein levels of 94, 92, and 65 % of control after 24, 72, and 120 h, 
respectively. E2F1 nuclear protein decreased with concentration after 120 h 
exposure resulting in 85, 65, and 55 % of control following 0.1, 0.2, 0.3 ug/cm2 zinc 
chromate, however these levels were not significant compared to control or each 
other. These data suggest although total levels of E2F1 are significantly 
suppressed following exposure to prolonged particulate Cr(VI) the levels of E2F1 






Figure 3.16. Particulate Cr(VI) does not affect E2F1 nuclear protein 
levels. This figure shows E2F1 nuclear protein is unaffected by 
exposure to particulate Cr(VI). (A) Representative western blots of 
E2F1 nuclear protein. (B) E2F1 nuclear protein levels (relative to 
control) are unaffected following exposure to 24, 72, and 120 h 
particulate Cr(VI). H3 was used as loading control. Data represent 
the mean of three experiments. Error bars = standard error of the 
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RAD51 expression is tightly regulated by a balance of transcriptional 
activators and repressors. We wanted to investigate if other transcription factors 
involved in RAD51 expression were affected by particulate Cr(VI) exposure. We 
considered another transcriptional activator of RAD51 transcription, EGR1. Figure 
3.17A shows representative western blots of whole cell EGR1 protein. EGR1 
whole cell protein is unaffected by acute 24 h exposure to particulate Cr(VI) but 
decreases after 120 h exposure with concentration (Figure 3.17). For example, 
EGR1 protein is only reduced to 87% of control after 24 h exposure to 0.3 ug/cm2 
zinc chromate but  to 81, 76, 65% of control after 120 h exposure to 0.1, 0.2 and 
0.2 ug/cm2 zinc chromate; these levels are not significant. These data indicate 
another activator of RAD51 expression is suppressed following prolonged 












Figure 3.17. Prolonged particulate Cr(VI) exposure decreases EGR1 
whole cell protein expression. This figure shows prolonged 120 h 
exposure to particulate Cr(VI) decreases whole cell EGR1 protein 
(relative to control). (A) Representative western blot images of whole 
cell EGR1 protein. (B) EGR1 whole cell protein expression after 
acute 24 and prolonged 120 h exposure to particulate Cr(VI) 
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mean of three experiments. Error bars = standard error of the mean. 

























Loss of the tumor suppressor p53 is commonly associated with 
carcinogenic mechanisms (Hamadeh et al., 1999; Shen et al., 2008; Wang, 1999). 
As previously mentioned p53 suppresses RAD51 transcription through at least two 
mechanisms. It indirectly suppresses RAD51 through the DREAM complex 
(Engeland et al., 2018). Second, p53 can directly bind to the RAD51 promoter 
repressing transcription (Hine et al., 2014; Arias-Lopez et al., 2005; Hannay et al., 
2007). We measured total p53 and phospho-p53 (Ser15), which indicates p53 
stabilization associated with DNA damage (Canman et al., 1997; Shieh et al., 
1997). Figure 3.18A shows representative of p53 western blots. Particulate Cr(VI) 
exposure increased total p53 expression after 24 h exposure and decreased 
expression after 120 h exposure (Figure 13.18B). For example, 24 h exposure to 
0.1, 0.2, and 0.3 ug/cm2 zinc chromate increased p53 total protein to 114, 139, and 
144% of control while 120 h reduced total p53 protein to 92, 79, and 69% of control. 
Neither the increase after 24 h nor the decrease after 120 h exposure were 
significant compared to control. Figure 3.18C shows while particulate Cr(VI) 
slightly alters total p53, phospho-p53 (Ser15) is unaffected. For example, 0.2 
ug/cm2 zinc chromate altered p-p53 protein to 107 and 77% of control after 24 and 
120 h, respectively. These data suggest p53 stabilization is unaffected by 
particulate Cr(VI) exposure, and the minimal effect of Cr(VI) on p53 may not be a 
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Figure 3.18. Particulate Cr(VI) does not affect p53. This figure shows 
particulate Cr(VI) exposure does not affect p53 or phospho-p53. (A) 
Representative western blot images of total p53 and phospho-p53 
(Ser15). (B) Particulate Cr(VI) modulates total p53 levels differently 
after 24 and 120 h exposure, however no statistical significance was 
observed. (B) Phospho-p53 (Ser15) was unaffected by exposure to 
acute 24 h or prolonged 120 h exposure to particulate Cr(VI). No 
statistical significance was observed. GAPDH was used as a loading 
control. Data represent the mean of four experiments. Error bars = 
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One mechanism of p53 repression of RAD51 expression is through the 
DREAM complex. We found p53 was not inhibited significantly by particulate Cr(VI) 
exposure. Downstream of p53 in the DREAM pathway p130 binds with E2F4 
resulting in repressed transcription (Engeland et al., 2018). Hypo-phosphorylation 
of p130 facilitates p130 binding E2F4, and this process is mediated by p53. We 
assessed total and phospho-p130 expression following particulate Cr(VI) 
exposure.  
Figure 3.19 shows representative western blot images of total and phospho-
p130. Particulate Cr(VI) decreased total p130 protein levels after 24 h and further 
decreases after 120 h exposure (Figure 3.19B). For example, exposure to 0.2 
ug/cm2 zinc chromate decreased total p130 protein levels to 85 and 51% of control 
after 24 and 120 h, respectively. Although total p130 was decreased following 
exposure to particulate Cr(VI) the hypo-phosphorylation of p130 facilitates its 
binding with the transcriptional repressor E2F4. Therefore, we also measured 
phospho-p130 levels following exposure to particulate Cr(VI). Figure 3.19C shows 
exposure to particulate Cr(VI) reduces phospho-p130 after 24 and 120 h. For 
example, exposure to 0.3 ug/cm2 zinc chromate reduces to 40 and 47% of control 
after 24 and 120 h, respectively. These data indicate, of the total p130 available 
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Figure 3.19. Particulate Cr(VI) decreases total and phospho-p130 
protein levels. This figure shows particulate Cr(VI) inhibits total and 
phospho-p130 whole cell protein levels. (A) Representative western 
blot images of total and phospho-p130 whole cell protein. Particulate 
Cr(VI) inhibits (B) p130 and (C) phospho-p130 after 24 h and further 
after 120 h exposure. GAPDH was used a loading control. Data 
represent the mean of two experiments. Error bars = standard error 




















Less phosphorylation increases the interaction of p130 with E2F4. E2F4 is 
a repressive transcription factor that directly competes with E2F1 for the same 
binding site at the RAD51 promoter. To begin to test if E2F4-induced suppression 
may play a role in the repression of E2F1-mediated transcription we measured 
E2F4 protein levels following particulate Cr(VI) exposure. Figure 3.20 shows 
representative western blots of E2F4 whole cell protein. Particulate Cr(VI) had no 
effect on E2F4 protein level after 24 or 120 h exposure. For example, E2F4 levels 
after 0.3 ug/cm2 zinc chromate were 104 and 110% of control (Figure 3.20B). 
These data show while exposure to particulate Cr(VI) inhibits E2F1 protein after 
prolonged exposure (Figure 3.5) E2F4 protein levels are unaffected. Engeland et 
al 2018 suggests the balance of activating E2F1 and repressive E2F4 controls 
expression. Specifically, Bindra et al., 2007 showed E2F1 and E2F4 compete for 
the same binding sequence on the RAD51 promoter. We looked at the ratio of 
E2F4 to E2F1 after acute and prolonged particulate Cr(VI) exposure. Figure 3.20C 
shows after 24 h there is no change in the ratio of E2F4 to E2F1, however, after 
120 h exposure the ratio increases. These data indicate the increase in the ratio 
of E2F4 to E2F1 after prolonged exposure to particulate Cr(VI) may inhibit E2F1-
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Figure 3.20. Particulate Cr(VI) increases the ratio of E2F4 to E2F1. 
This figure shows particulate Cr(VI) does not affect E2F4 protein 
levels after particulate Cr(VI) exposure, but increases the ratio of 
E2F4 to E2F1 after prolonged exposure. Data represent the mean of 
three experiments. Error bars = standard error of the mean. (A) 
Representative western blot images of E2F4. (B) E2F4 whole cell 
protein levels (relative to control) are unaffected by acute 24 or 
prolonged 120 h exposure to particulate Cr(VI). GAPDH was used 
as a loading control. No statistical significance was observed.  (C) 
The ratio of E2F4 to E2F1 increases after exposure to 120 h 


















In this Aim, we show the reduction in RAD51 protein after particulate Cr(VI) 
exposure is primarily a result of decreased transcription. We found RAD51 mRNA 
levels begin to decrease after 24 h exposure to particulate Cr(VI) and further 
decrease after 72 and 120 h. However, we did not find any considerable difference 
in RAD51 protein half-life after 24 or 120 h exposure. Considering the reduction of 
RAD51 protein is due to a transcriptional issue we investigated the effects of 
particulate Cr(VI) on E2F1, the predominant transcription factor for RAD51. We 
found particulate Cr(VI) decreased E2F1 whole cell protein levels after prolonged 
72 and 120 h exposure, and mRNA decreased beginning after 24 h and continued 
to decrease after 72 and 120 h.  
To connect the loss of E2F1 and RAD51 after particulate Cr(VI) exposure 
we tested if overexpressing E2F1 could rescue RAD51 failure induced by 
prolonged particulate Cr(VI) exposure. We analyzed three endpoints to assess 
RAD51 failure: RAD51 cytoplasmic accumulation, nuclear foci formation, and 
RAD51 whole cell protein expression. We found E2F1 overexpression did not 
inhibit RAD51 cytoplasmic accumulation or restore RAD51 nuclear foci and protein 
levels after prolonged particulate Cr(VI) exposure.  
We also tried to confirm the connection by recapitulating 120 exposure 
outcomes after 24 h exposure. We knocked down E2F1 after acute particulate 
Cr(VI) exposure to test if loss of E2F1 could inhibit the RAD51 response to 
particulate Cr(VI) when the RAD51 response is usually normal. We found loss of 
E2F1 did not induce RAD51 cytoplasmic accumulation and did not reduce RAD51 




inhibition did not recapitulate most 120 h exposure outcomes. However, we did 
find loss of E2F1 inhibited RAD51 foci formation after 24 h particulate Cr(VI) 
exposure when foci formation usually increases.  
We demonstrated the reduction of RAD51 protein is due to a transcriptional 
issue, however, RAD51 expression was not modulated by E2F1 in response to 
particulate Cr(VI). Therefore, we explored alternative hypotheses. While 
particulate Cr(VI) knocked down E2F1 whole cell protein we found nuclear protein 
was unaffected potentially explaining the results of our E2F1 overexpression and 
knockdown experiments. We also assessed how other mediators of RAD51 
transcription were affected by particulate Cr(VI) exposure. The transcriptional 
activator, EGR1, was slightly decreased by particulate Cr(VI) exposure after 24 h 
exposure and further decreased after 120 h exposure. The transcriptional 
repressor p53 increased slightly after 24 h and decreased after 120 h exposure, 
however, p53 stability was unaffected. Finally, we assessed the transcriptional 
repressor, E2F4, and its binding partner p130 and found while p130 levels 
decreased after particulate Cr(VI) exposure, phosphorylation also decreased. 
E2F4 protein was unaffected by particulate Cr(VI) exposure, and this resulted in 
an increase in the ratio of E2F4 to E2F1 following prolonged particulate Cr(VI) 
exposure. This result, in part, may explain inhibited RAD51 expression following 







Aim 2: Identify particulate Cr(VI)-altered miRNAs involved in RAD51 
regulation and homologous recombination repair 
Background 
Cr(VI) causes permanent-heritable phenotypes, but induces low rates of 
mutations in key oncogenes and tumor suppressors (Ewis et al., 2001; Wetterhahn 
and Hamilton, 1989; Katabami et al., 2000; Kondo et al., 1997; Wise et al., 2018). 
Additionally, Cr(VI) is known to alter global gene expression, however, the 
mechanisms of this effect are unknown (Andrew et al., 2003; Izzotti et al., 2002; 
Ye and Shi, 2001). The field of Cr(VI) research is increasingly finding epigenetic 
modifications may play a significant role in Cr(VI) carcinogenesis contributing to 
the permanent-heritable phenotypes and global changes in gene expression 
following Cr(VI) exposure (Rager et al., 2019).  
Specifically related to our study, Cr(VI) has been shown to downregulate 
expression of DNA repair genes (Andrew et al., 2003; Clancy et al., 2012, Wu et 
al., 2012). Aim 1 shows RAD51 transcription is decreased following particulate 
Cr(VI) exposure. Aim 1 also shows the primary transcription factor of RAD51, 
E2F1, does not modulate RAD51 expression following particulate Cr(VI) exposure. 
Additionally, while alternative transcription factors of RAD51 were investigated, 
they cannot fully explain particulate Cr(VI)-inhibited RAD51 expression. Based on 
these data and the general consensus from the literature that epigenetic 
mechanisms play a role in altered gene expression and Cr(VI) carcinogenesis, we 
investigated how miRNAs may play a role in inhibited RAD51.  
miRNAs are short non-coding RNA sequences with an average 22 base 




exported out of the nucleus to the cytoplasm where they are processed to 
precursor-miRNA (pre-miRNA) before finally being converted into mature miRNA 
(O’Brien et al., 2018; Perron, 2008). Mature miRNAs target mRNA sequences to 
regulate expression through the RNA-induced silencing complex (RISC) 
(MacFarlane and Murphy, 2010). miRNAs usually target to the 3’ UTR site of 
mRNA (Ha and Kim, 2014). The binding location on the mRNA transcript and the 
homology of the sequence of the miRNA to the mRNA transcript play a role in the 
effectiveness of the miRNA effect on either target degradation or translation 
inhibition (Finnegan and Matzke, 2003; McGeary et al., 2019). For example, 
miRNAs with perfect sequence matches in the 3’ UTR region of an mRNA 
transcript leads to mRNA degradation (Rhoades et al., 2002). However, imperfect 
matches have been shown to only inhibit translation of an mRNA transcript, which 
may only delay the translation process, or have no effect (Martin et al., 2014; 
Saxena et al., 2003). These, perfect and imperfect matches mostly refer to the 
seed region of the 3’ UTR of an mRNA target. However, they can also bind to other 
regions of the mRNA transcript contributing to the complexity of miRNA-mRNA 
target analysis (Betel et al., 2010; Broughton et al., 2016).  
Single miRNAs may target mRNA transcripts from many different genes, 
and any given mRNA transcript may be regulated by many different miRNAs. It 
has been challenging to determine how the balance of miRNAs may affect the 
expression of specific genes. One approach to understanding how the altered 
balance of miRNAs plays a role in gene expression is using RNAseq analysis. 




RNAseq to evaluate miRNAs provides hypothesis-driving data about how miRNAs 
may contribute to a pathogenic endpoint.  
Studies have evaluated the effects of Cr(VI) exposure on limited miRNAs, 
but none considered particulate Cr(VI) (Chandra et al., 2015; He et al., 2013; Li et 
al., 2014; Li et al., 2016; Pratheeshkumar et al., 2017; Wang et al., 2019, Wang et 
al., 2020; Zhang et al., 2020). Cr(VI)-altered miRNAs have specifically been linked 
to DNA damage in cell culture and epidemiology studies (Chandra et al., 2016; Li 
et al., 2014). For example, Li et al., 2014 found miR-3940-5p was associated with 
genetic damage in the blood of workers exposed to Cr(VI).  
To date, five studies have evaluated miRNAs in lung cells after Cr(VI) 
exposure (He et al., 2013; Li et al., 2016; Pratheeshkumar et al., 2017; Wang et 
al., 2019; Wang et al., 2020). However, only one evaluated miRNAs in relation to 
DNA repair (Li et al., 2016). In general, there is very limited data available on the 
effects of miRNAs on pathways of Cr(VI) carcinogenesis. This is partly due to the 
fact only one genome-wide study has been done to evaluate Cr(VI)-altered miRNA 
expression, and this was done in the radish plant (Raphanus sativus L.) (Liu et al., 
2015). No global expression data is available to evaluate Cr(VI) altered miRNAs in 
humans, let alone in the lung, which is the primary target of Cr(VI) exposure. 
In Aim 2 we performed a global analysis of miRNA expression using 
RNAseq in human lung cells following particulate Cr(VI) exposure. We 
characterized particulate Cr(VI)-altered miRNA expression patterns to assess how 
particulate Cr(VI) up- or down-regulates miRNA expression (Objective 1). We are 
specifically interested in how miRNAs affect pathways of Cr(VI) carcinogenesis. 




Cr(VI)-altered miRNAs involved in pathways of Cr(VI) carcinogenesis (Objective 
2). To focus more closely on homologous recombination repair and RAD51 we 
identified Cr(VI)-altered miRNAs that specifically regulate targets in the 
homologous recombination pathway and RAD51 (Objective 3).  
Results  
Objective 1: Particulate Cr(VI) alters global expression of miRNAs 
This is the first study to evaluate global miRNA expression after Cr(VI) 
exposure in human cells. The primary target of particulate Cr(VI) exposure is the 
lung. We evaluated how particulate Cr(VI) altered miRNA expression in human 
lung cells after acute and prolonged exposures. Our first goal was to assess 
changes in miRNA expression patters after particulate Cr(VI) exposure. In our 
analysis, 956 unique miRNAs were identified across all conditions. Of these, table 
3.4 shows the total number of significantly altered (adjusted p-value<0.01) miRNAs 
affected by particulate Cr(VI) exposure. In Table 3.3 the numbers of upregulated 
and downregulated miRNAs are included. In some conditions, a miRNA was only 
expressed in a treated condition indicating that miRNA was ‘turned on’, or 
alternatively a miRNA may only have been expressed in the control and therefore, 
‘turned off’. miRNAs that were turned off or on are listed distinctly from the up- or 








Table 3.3 Distribution of significantly altered miRNAs by particulate Cr(VI) 
exposure. 
 
Table 3.3 shows the number of significantly (adjusted p-value<0.01) 
up- or down-regulated miRNAs, the number of miRNAs turned on or 
off, and the total for each (Total Upregulated = upregulated + turned 
on; total downregulated = downregulated + turned off). For each 
condition the total number of miRNAs significantly altered by 
particulate Cr(VI) exposure is listed as the “Total altered” for each 
column. Data represent the mean of three independent experiments 












0.1 0.2 0.3 0.1 0.2 0.3 0.1 0.2 0.3
Upregulated 20 146 63 17 17 51 33 48 47
Downregulated 12 46 46 69 99 105 110 122 136
Turned on 3 8 2 2 2 4 2 4 7
Turned off 3 9 1 1 1 2 0 1 2
Total upregulated 23 154 65 19 19 55 35 52 54
Total downregulated 15 55 47 70 100 107 110 123 138





To determine trends in expression changes after particulate Cr(VI) 
exposure we visualized the data in Table 3.3 as bar graphs in Figure 3.21. Figure 
3.21A shows higher concentrations of particulate Cr(VI) increase the number of 
upregulated miRNAs at all time points. However, there is a spike in upregulated 
miRNA after 24 h exposure to 0.2 ug/cm2 zinc chromate. Figure 3.14B shows the 
number of downregulated miRNAs increase with time and concentration after 
exposure to particulate Cr(VI). For example, exposure to 0.2 ug/cm2 zinc chromate 
resulted in a total of 55, 100, and 138 miRNAs downregulated after 24, 72 and 120 
h exposure, respectively. It is also notable more miRNAs were downregulated 
compared to those that were upregulated. For example, after 120 h exposure to 
0.3 ug/cm 2 zinc chromate only 54 miRNAs were upregulated while 138 miRNAs 
were downregulated. Downregulation of protein-coding gene expression is 
associated with Cr(VI) exposure. These data show for the first time Cr(VI) also 








Figure 3.21. Particulate Cr(VI) exposure increases global 
downregulation of miRNAs. This figure shows particulate Cr(VI) 
significantly (adjusted p-value<0.01) upregulated or downregulated 
miRNAs compared to control. Data represent the mean of three 
independent experiments and four technical replicates. (A) 
Particulate Cr(VI) significantly upregulated miRNAs at all zinc 
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a spike after 24 h exposure to 0.2 ug/cm2 zinc chromate. (B) 
Particulate Cr(VI) significantly downregulated miRNAs in a time-and 
























We visualized these data using volcano plots to assess the distribution and 
scattering of miRNAs according to two measures: significance and fold change. All 
956 miRNAs were included in each analysis. The volcano plots visualize the 
distribution of up- or -downregulated miRNAs, their significance, and whether the 
fold change was greater than two (Figure 3.22). The fold change parameter was 
set to provide some biological relevance to the changes in expression in this global 
analysis. It is notable that under each condition there are miRNAs with a fold 
change greater than 2 that did not reach our significance cut-off of an adjusted p-
value<0.01. In addition, there were also changes is expression that were 
significant, but were less than 2-fold that are also not included. From these data 
we can see the number of significantly up- or -downregulated miRNAs with a fold 
change greater than two for each condition. These values are listed in table 3.4. 
For example, 0.3 ug/cm2 zinc chromate resulted in 12, 18 and 45 miRNAs 
downregulated and 14, 30 and 19 miRNAs upregulated after 24, 72, and 120 h 
exposure, respectively.  
These data are presented as bar graphs in Figure 3.23 to assess trends 
across concentrations and time. There is a spike in significantly upregulated 
miRNAs (fold change >2) after 24 h exposure to 0.2 ug/cm2 zinc chromate, which 
reflects the spike seen in all upregulated miRNAs under this condition (Figure 
3.21). There is also a large increase in upregulated miRNAs after 72 h exposure 
to 0.3 ug/cm2  zinc chromate (30 miRNAs) compared to 0.1 and 0.2 ug/cm2 zinc 
chromate, which only had 7 significantly upregulated miRNAs with a fold change 
greater than 2 each. After 120 h the number of significantly upregulated miRNAs 




0.1, 0.2 and 0.3 ug/cm2 zinc chromate 8, 17, and 19 miRNAs were upregulated, 
respectively. Figure 3.21B shows particulate Cr(VI) increased the number of 
downregulated miRNAs in a concentration and time-associated manner after 
prolonged exposure (72 and 120 h) For example, 120 h exposure to 0.1, 0.2 and 
0.3 ug/cm2 zinc chromate resulted in 15, 37 and 45 significantly downregulated 
miRNAs (fold change >2), respectively. Notably, after 24 h exposure there was a 
spike in significantly downregulated miRNAs (fold change >2) after 0.2 ug/cm2 zinc 
chromate (29 miRNAs) compared to 0.1 and 0.2 ug/cm2 zinc chromate (11 and 12 






Figure 3.22. Particulate Cr(VI) alters the expression of miRNAs. This 
figure shows the -Log10(adjusted p-value) and Log2(fold change) of 
all miRNAs identified in the RNAseq analysis after 24 h (A, B, C - 0.1, 
0.2, and 0.3 ug/cm2 zinc chromate compared to control), 
respectively, 72 h (D, E, F - 0.1, 0.2, and 0.3 ug/cm2 zinc chromate 
compared to control, respectively), and 120 h (G, H, I - 0.1, 0.2, and 
0.3 ug/cm2 zinc chromate compared to control, respectively).  All 
miRNAs above the grey horizontal grey dashed line were 




value<0.01). These miRNAs are signified by orange or red dots. All 
miRNAs to the right of the vertical grey dashed line on the x-axis set 
at 1 were upregulated with a fold change greater than 2. All miRNA 
to the left of the vertical grey dashed line set at -1 were 
downregulated with a fold change greater than 2. Data represent the 





















Table 3.4 Number of significantly up- or down-regulated miRNAs with a fold 
















Figure 3.23. miRNAs significantly altered by particulate Cr(VI) with a 
fold change greater than 2. This figure shows particulate Cr(VI) 
increases the number of miRNAs significantly up- or down-regulated 
(adjusted p-value<0.01) with a fold change greater than 2 compared 
to control. Data represent the mean of three independent 
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by particulate Cr(VI) exposure relative to control. (B) miRNAs 

























This broad general view of particulate Cr(VI) altered miRNAs in Table 3.5 
and Figure 3.23 does not indicate how many of the same miRNAs were affected 
between conditions. To better understand the number of miRNAs upregulated or 
downregulated by particulate Cr(VI) exposure across concentrations we visualized 
the data using Venn diagrams. Each Venn diagram shows the crossover of 
miRNAs significantly affected (either up- or down-regulated) by particulate Cr(VI) 
within a time point (Figure 3.22). Very few of the same miRNAs were significantly 
upregulated (fold change >2) in both the 0.1 and 0.3 ug/cm2 zinc chromate 
conditions at all time points. For example, no significantly upregulated miRNAs 
were the same between 0.1 and 0.3 ug/cm2 zinc chromate after 24 and 72 h, 
respectively, and only 0 and 1 downregulated miRNAs were shared between these 
two time points. However, after 120 h exposure there were 5 downregulated and 








Figure 3.24. Venn diagrams of up- and down-regulated miRNAs 
across particulate Cr(VI) concentrations. This figure shows how 
many miRNAs were significantly up- or down-regulated (fold change 
>2) after particulate Cr(VI) exposure between concentrations 
compared to control. Data represent the mean of three independent 
experiments and four technical replicates. A, B, and C show Venn 
diagrams of miRNAs upregulated by 0.1, 0.2 and 0.3 ug/cm2 zinc 
chromate after 24, 72, and 120 h exposure, respectively. D, E, and 
F show Venn diagrams of miRNAs downregulated by 0.1, 0.2 and 
0.3 ug/cm2 zinc chromate after 24, 72, and 120 h, respectively 





To better understand how particulate Cr(VI) affected expression across 
different miRNAs we generated heatmaps using fold change data. Figure 3.25 
shows Euclidean hierarchical clustering of miRNAs after 24 (A), 72 (B), and 120 h 
(C) exposure to particulate Cr(VI). These heatmaps cluster together miRNAs using 
the Euclidean hierarchical model, which clusters units based on direct lines of 
relatedness. In this case, the closer in color of the unit, the more similar the fold 
change of the miRNA compared to the control. For example, after 120 h exposure 
miR-200A, miR-194-1 and miR-194-2 clustered closely to one another and were 
all significantly upregulated. We can see distinct clustering of up- or down-
regulated miRNAs in these heatmaps, but this clustering is especially prominent 
after prolonged 72 and 120 h exposure where the top halves of the heatmaps are 
almost exclusively orange (upregulated) and the bottom halves are almost 
exclusively blue (downregulated). This distinction is less obvious after 24 h 
exposure to particulate Cr(VI). The difference between the 24 h and 72 or 120 h 
distinctions in clustering reflects our other data that show the 24 h response to 
particulate Cr(VI) is different than the 72 and 120 h responses. Additionally, the 
larger number of miRNAs in the 24 h heatmap shows more miRNAs were 
significantly affected (fold change >2) than after 72 or 120 h exposure. However, 
this likely reflects the spike of upregulated miRNAs after 24 h exposure to 0.2 
ug/cm2 zinc chromate presented earlier (Figure 3.23). It is noteworthy that of the 
large number of miRNAs in the 24 h heatmap many of them have light-colored 
units (white correlating to a fold change of 0) indicating a low fold change in 
expression. The heatmaps were also clustered using k-clustering to show 




the miRNAs using Euclidean k-clustering. A k-cluster n = 3 was used in the 
analysis, and clearly clusters the miRNAs by expression patterns. In Figure 3.26A 
we can clearly see the distinction between miRNAs with higher fold change 
patterns and those with low fold change. There is also a stronger distinction across 
all the time points between the clusters of up- and down-regulated miRNAs. Similar 
to the hierarchical clustering, the 72 and 120 h heatmaps are more distinct than 









Figure 3.25. Euclidean hierarchical clustering of miRNAs altered by 
particulate Cr(VI) exposure. This figure shows hierarchical clustering 
of significantly altered miRNAs after particulate Cr(VI) exposure 
compared to control. Data represent the mean of three independent 
experiments and four technical replicates. Clustering of miRNAs was 
performed after 24 (A), 72 (B), and 120 h (C) exposure to particulate 
Cr(VI). The average linkage method was applied. Data are 
represented as fold change relative to control. miRNAs were 
included if they were significantly affected (adjusted p-value<0.01, 
fold change >2) in at least one condition for each individual time point 
compared to control. Upregulated miRNAs are coded orange while 








Figure 3.26. K-clustering of miRNAs altered by particulate Cr(VI) 
exposure. This figure shows the k-clustering of miRNAs significantly 
affected by particulate Cr(VI) exposure compared to control. Data 
represent the mean of three independent experiments and four 
technical replicates. K-clustering of miRNAs was performed after 24 
(A), 72 (B), and 120 h (C) exposure to particulate Cr(VI). The average 
linkage method was applied. Data are represented as fold change 
relative to control. miRNAs were included if they were significantly 
affected (adjusted p-value<0.01, fold change >2) in at least one 
condition for each individual time point. Upregulated miRNAs are 
coded orange while downregulated miRNAs are coded blue. A k-
cluster of 3 was applied and grouped the miRNAs by red, orange, or 














Objective 2: Particulate Cr(VI) alters miRNAs involved in pathways of Cr(VI) 
carcinogenesis 
The data in Objective 1 provide the first analysis of global miRNA 
expression after Cr(VI) exposure in human cells. We found particulate Cr(VI) 
increased the number of miRNAs significantly up- or down-regulated and identified 
trends in the analyses. We are specifically interested in the role of miRNAs in 
Cr(VI) carcinogenesis. While the global analysis is informative about trends of 
Cr(VI)-altered miRNAs we wanted to know how they may be involved in the 
mechanisms of Cr(VI) carcinogenesis. We performed a literature search for recent 
review papers on Cr(VI) to identify pathways proposed to be involved in Cr(VI) 

















Table 3.5. Articles used to populate pathways of Cr(VI) carcinogenesis. 
Paper Title Citation 
Molecular and epigenetic mechanisms of Cr(VI)-induced 
carcinogenesis 
Chen et al., 2019  
Oxidative stress and metabolic reprogramming in Cr(VI) 
carcinogenesis 
Clementino et al., 2018 
Mechanisms of chromium-induced toxicity DesMarias and Costa, 2019 
Imbalance of oxidative and reductive species involved in 
chromium(VI)-induced toxic effects 
Hu et al., 2017 
Review of transcriptomic responses to hexavalent 
chromium exposure in lung cells supports a role of 
epigenetic mediators in carcinogenesis 
Rager et al., 2019 
Current status on chromium research and its implications 
for health and risk assessment 
Speer and Wise, 2018 
Metal carcinogen exposure induces cancer stem cell-like 
property through epigenetic reprograming: A novel 
mechanism of metal carcinogenesis 
Wang and Yang, 2019 
Carcinogenicity of chromium and chemoprevention: a brief 
update 
Wang et al., 2017 
Metal carcinogenesis and DNA damage: A case study 
using hexavalent chromium 













We correlated the pathways of Cr(VI) carcinogenesis identified in the 
literature with pathways in the KEGG database. We identified 5 networks and 13 
sub-networks that pathways of Cr(VI) carcinogenesis applied to (Table 3.6). The 5 
networks include 4 involved in cell mechanisms, and 1 related to human disease. 
All the human disease sub-networks are related to cancer. Of those networks 
related to cellular mechanisms, 3 are related to environmental information 
processing, genetic information processing, and metabolism while one is related 
to cellular processes.  Upon looking at the sub-networks many are expectedly 
associated with carcinogenesis including signaling transduction, energy 
metabolism, and replication and repair. Thirty-six distinct KEGG pathways were 
identified within these networks to be involved in Cr(VI) carcinogenesis. These are 
















Table 3.6. KEGG networks of Cr(VI) carcinogenesis. 
Network Sub-Network 
Cellular Processes Cell growth and death 
Environmental information processing Transport and catabolism 
Environmental information processing Signal transduction 
Environmental information processing Signaling molecules and interactions 
Genetic information processing Folding, sorting, degradation 
Genetic information processing Replication and repair 
Genetic information processing Transcription 
Metabolism Carbohydrate metabolism 
Metabolism Energy Metabolism 
Metabolism Xenobiotics biodegradation and metabolism 
Human disease Cancer: overview 
Human disease Cancer: specific types 















We populated lists of significantly up-or down-regulated miRNAs (fold 
change >2) for each condition and uploaded them to the web-based analysis 
system mirPath, which identified KEGG pathways affected by sets of miRNAs 
(Vlachos et al .,2015). These pathways were then cross-referenced with the KEGG 
pathways identified through our Cr(VI) literature search to determine how many 
genes within a pathway was affected by particualte Cr(VI)-upregulated miRNAs 
and how many miRNAs targeted each pathway. We focused on upregulated 
miRNAs because upregulation of miRNAs leads to the downregulation of gene 
expression. We partitioned the pathways by their relevance to one another 
resulting in 4 groupings: Cancer related (Table 3.7A-B), signaling (Table 3.8A-B), 
cellular processes (Table 3.9A-B), and DNA repair (Table 3.10A-B). We can see 
the number of particulate Cr(VI)-upregulated miRNAs predicted to target pathways 
of Cr(VI) carcinogenesis and the number of genes targeted increase with time or 
concentration. For example, the number of predicted genes targeted by particulate 
Cr(VI)-upregulated miRNAs in the pathways in cancer pathway are 64, 87, and 93 
after 24, 72, and 120 h. In all these tables, we can see an increase after 24 h 0.2 
ug/cm2 zinc chromate consistent with the earlier data showing a spike at under this 
condition (Figure 3.23). Of all of the pathways involved in signaling the PI3K-AKT 
pathway had the most predicted genes targeted by Cr(VI)-upregulated miRNAs. 
Of the ‘cellular processes’ pathways, apoptosis, cell cycle, and ubiquitin-mediated 
proteolysis were the most targeted. For example, 10, 20 and 23 genes in the cell 
cycle pathway were predicted to be targeted by particulate Cr(VI)-upregulated 
miRNAs after 0.3 ug/cm2 zinc chromate after 24 , 72, and 120 h, respectively. The 




particulate Cr(VI)-upregulated miRNAs and the number of miRNAs that targeted 
those pathways. For example, the fanconi anemia pathway, nucleotide excision 
repair, and homologous recombination had 8, 7, and 5 genes predicted to be 
targeted by particulate Cr(VI)-upregulated miRNAs, after 24 , 72, and 120 h 






















Table 3.7A. Number of genes targeted by Cr(VI)-upregulated miRNAs in cancer 
related pathways. 
 
Table 3.7B. Number of Cr(VI)-upreguated miRNAs targeting genes in cancer 
related pathways. 
 






Table 3.8B. Number of Cr(VI)-upreguated miRNAs targeting genes in signaling. 
 
Table 3.9A. Number of genes targeted by Cr(VI)-upregulated miRNAs in cellular 
processes pathways. 
 






Table 3.10A. Number of genes targeted by Cr(VI)-upregulated miRNAs in DNA 
repair pathways. 
 












We compared how many genes were predicted to be targeted by particulate 
Cr(VI) up- or down-regulated miRNAs using 0.3 ug/cm2 zinc chromate as a 
representative concentration (Figure 3.27). For most pathways the number of 
genes predicted to be targeted by downregulated miRNAs was lower than the 
number of genes predicted to be targeted by upregulated miRNAs (24h: 9 out of 
29, 72h: 6 out of 29, 120h: 18 out of 29). The increase of genes predicted to be 
targeted by particulate Cr(VI)-downregulated miRNAs after 120 h reflects the 
global downregulation of miRNA expression induced by particulate Cr(VI) 
exposure. It is noteworthy, although particulate Cr(VI) induces downregulation of 
more miRNAs than those that are upregulated, genes in more pathways of Cr(VI) 













Figure 3.27. Comparison of the number of genes targeted by 
particulate Cr(VI)-up or down-regulated miRNAs in pathways of 
Cr(VI) carcinogenesis. This figure shows the number genes targeted 
by up- or down-regulated miRNAs in pathways of Cr(VI) 
carcinogenesis after exposure to 0.3 ug/cm2 zinc chromate 
compared to control (adjusted p-value<0.01, fold change >2). Data 




technical replicates. Genes targeted after 24 (A), 72 (h), and 120 h 


























Similarly, in Figure 3.28 we show the numbers of particulate Cr(VI) up- and 
down-regulated miRNAs predicted to target genes in pathways of Cr(VI) 
carcinogenesis. We found for most pathways the number of downregulated 
miRNAs affected by particulate Cr(VI) exposure was relatively low after 24 h (10 
out of 29 pathways) and 72 h (5 out of 29). However, after 120 h 24 out of 29 
pathways had more miRNAs downregulated by particulate Cr(VI) exposure than 
those that were upregulated. This accurately reflects the global downregulation of 
miRNAs by particulate Cr(VI) exposure we showed earlier (Figure 3.23). After 120 
h exposure to particulate Cr(VI) only the apoptosis, non-homologous end joining, 
mismatch repair, and oxidative phosphorylation pathways had more miRNAs 
upregulated than downregulated. It is notable after 24 and 72 h exposure the 
number of upregulated miRNAs in the ubiquitin mediated proteolysis pathway is 6 
and 7 times higher than the number of downregulated miRNAs in that pathway, 













Figure 3.28. Comparison of the number of particulate Cr(VI)-up or 
down-regulated miRNAs targeting genes in pathways of Cr(VI) 
carcinogenesis. This figure shows the number of up- or down-
regulated miRNAs targeting genes in pathways of Cr(VI) 
carcinogenesis after exposure to 0.3 ug/cm2 zinc chromate 
compared to control (adjusted p-value<0.01, fold change >2). Data 




technical replicates. miRNAs altered after 24 (A), 72 (h), and 120 h 

























Objective 3: Particulate Cr(VI) alters miRNAs that target homologous 
recombination and regulate RAD51 expression 
In Objective 2 of Aim 2 we began to investigate Cr(VI)-altered miRNAs 
involved in pathways of Cr(VI) carcinogenesis. To further narrow down the focus, 
we wanted to look closer at how miRNAs significantly induced by particulate Cr(VI) 
affect the homologous recombination pathway, and ultimately, RAD51. We further 
analyzed the mirPath data correlating significantly particulate Cr(VI)-upregulated 
miRNAs (fold change >2) with the KEGG pathway of homologous recombination. 
For each particulate Cr(VI)-upregulated miRNA at each condition we identified 
gene targets in the homologous recombination pathway. Table 3.11 shows the 
specific particulate Cr(VI)-upregulated miRNAs and their predicted targets in the 
homologous recombination pathway. Comparing across time points miRNAs 
targeting RPA2 and RPA1 are upregulated. After 24 h exposure miRNAs predicted 
to target XRCC3 were upregulated at all concentrations. Similarly, after 72 h 
miRNAs predicted to target RPA1 and RPA2 were upregulated after 0.1 and 0.3 
ug/cm2 zinc chromate (none were observed after 0.2 ug/cm2 zinc chromate). After 
120 h exposure miRNAs predicted to target RPA2 and RAD52 were upregulated 
at all concentrations.   
This breakdown also allows us to see which miRNAs were significantly 
upregulated under all 9 of the conditions (3 time points and 3 concentrations). After 
24 and 72 h no miRNAs were upregulated at all concentrations. However, after 
120 h exposure miR-210-5p and miR-210-3p were upregulated at all 




zinc chromate, and miR-210-3p and miR-210-5p were upregulated after 24 h 

























Table 3.11. Particulate Cr(VI)-upregulated miRNAs and their targets in the 









miRNAs found to 
target pathway Gene Targeted




miRNAs found to 
target pathway Gene Targeted
miR-3064-5p XRCC3 miR-6797-5p RPA1 miR-210-5p RPA2
miR-3136-3p RPA3 miR-2276-5p RPA2 miR-210-3p RAD52
miR-3193 MUS81 miR-6882-3p RAD54B
miR-3689c RAD51B miR-6880-5p POLD3
miR-6880-3p 	TOP3A
miR-4695-5p XRCC2 miR-210-5p RPA2
miR-6824-5p RPA1 miR-7109-5p RPA1 miR-210-3p RAD52
miR-6827-5p POLD4 miR-210-5p RPA2 miR-1249-5p RPA1
miR-210-5p RPA2 miR-7846-3p RAD52
miR-6789-3p TOP3A miR-210-3p RAD52 miR-6825-5p RAD51B, SSBP1
miR-7108-3p POLD1, XRCC3 miR-6089 TOP3A miR-486-3p POLD1
miR-4786-3p POLD3 miR-3195 RAD51D miR-210-5p RPA2
miR-6840-3p MRE11A miR-6087 RAD51C miR-210-3p RAD52
miR-210-3p RAD52
miR-4642 BLM






























Regulators of RAD51 and RAD51 homologs were predicted to be targeted 
by miRNAs significantly upregulated by particulate Cr(VI) exposure (fold change 
>2). However, we did not want to overlook particulate Cr(VI)-upregulated miRNAs 
predicted to target RAD51. In our next analysis we included all miRNAs 
significantly upregulated by particulate Cr(VI) exposure (adjusted p-value<0.01). 
We used an online database called mirSystem to identify miRNAs predicted to 
target RAD51 (Lu et al., 2012). Using this platform, 126 miRNAs were identified 
that target RAD51. Then we cross-referenced RAD51 targeting miRNAs with 
significantly upregulated miRNAs in our RNAseq dataset. We found particulate 
Cr(VI) upregulated 37 unique miRNAs out of the 126 that target RAD51. Figure 
3.29 shows the total number of particulate Cr(VI) upregulated miRNAs that target 
RAD51. We can see the number of particulate Cr(VI) upregulated miRNAs 
increased to 24 and 14 after 24 h exposure after 0.2 and 0.3 ug/cm2 zinc chromate, 
respectively. After 72 h exposure to 0.3 ug/cm2 zinc chromate there were 11 
upregulated miRNAs that target RAD51 and this level remained elevated after 120 





Figure 3.29. Particulate Cr(VI) upregulates miRNAs that target 
RAD51. This figure shows the number of significantly (adjusted p-
value<0.01) upregulated miRNAs that target RAD51 after particulate 
Cr(VI) exposure compared to control.  Upregulated miRNA targeting 
RAD51 increase after 24, 72 and 120 h exposure. Data represent the 
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We considered each miRNA that targets RAD51 to see if there were any 
trends in the upregulation across concentration or time. Figure 3.30 shows the 
RAD51-targeting miRNAs and under each condition they were significantly 
upregulated. Several miRNAs were significantly upregulated after 24 h exposure 
to 0.2 and 0.3 ug/cm2 zinc chromate including miR-320a, miR-134-5p, miR-136-
5p, and miR-432-5p. miR-134-5p was also upregulated at all concentrations after 
72 and 120 h exposure. miR432-5p and miR-194-5p were significantly upregulated 
after 72h exposure to 0.2 and 0.3 ug/cm2 zinc chromate and at all concentrations 
after 120 h exposure. miR-26b-5p was significantly upregulated after 72 h 
exposure to the highest concentration and the two highest concentrations after 120 
h exposure. miR-411-5p and miR-30b-5p were significantly upregulated after both 
72 and 120 h at the highest concentration. All these miRNAs show either a trend 
in concentration or time and should be further considered in the regulation of 














Figure 3.30. This figure shows trends in the fold change of 
expression of miRNAs predicted to target RAD51 altered by 
particulate Cr(VI) exposure. miRNAs were included if at least one 
miRNA was significantly upregulated at any condition. The color 




scheme represents the Log2(fold change). Units with black boarders 

























We find particulate Cr(VI) significantly upregulates miRNAs predicted to 
target the RAD51 mRNA transcript. However, studies show the quality of the 
binding between a miRNA and its target mRNA plays a role in the efficacy and fate 
of these interactions (Martin et al., 2014; Rhoades et al., 2002; Saxena et al., 
2003). We evaluated the binding characteristics of the miRNAs predicted to target 
RAD51 significantly upregulated by particulate Cr(VI) exposure. This analysis was 
done using microRNA.org which is an online database that allows you to search 
for an mRNA target and view the binding location, mirSVR score, and exact 
nucleotide pairing of each miRNA that binds it. Table 3.13 shows the total number 
of binding sites for each miRNA on the mRNA transcript, their mirSVR score, and 
the number of nucleotides in the 3’ UTR region the miRNA had a perfect match to 
on the RAD51 mRNA transcript. The mirSVR score is assigned based on a 
regression model to determine the likelihood of mRNA target downregulation and 
the lower the score, the more likely it is the miRNA will result in the downregulation 
of a target (Betel et al., 2010). All the miRNAs on the list have mirSVR scores less 
than -1 except 2 indicating the likelihood of binding is high. However, we found 
several miRNAs have more than one predicted binding site to RAD51 mRNA. For 
example, miR-130b-3p has 2 predicted binding sites, while miR-148b-5p has 4 
predicted binding sites.  
For those miRNAs with more than one prediced binding site, one is 
preferable over the others. For example, the first binding site of miR-130b-3p has 
a mirSVR score of -0.005 and has 6mer binding compared to the second binding 
site with a mirSVR of -0.0933 which has 8mer binding. A 6mer is a perfect 6 




7mer and 8mer binding (Grimson et al., 2007). We can see all the miRNA binding 
sites with the lowest mirSVR scores are 6mers. For example, the 6mers miR-532-
3p and miR-30b-5p have mirSVR score of -0.0007 and -0.0015, respectively while 
8mers miR-130a-3p and miR-320a have mirSVR scores of -0.1015 and -1.0068, 
respectively. The miRNAs with perfect 6mer binding and low mirSVR scores are 
the best candidates for targeting RAD51 mRNA for degradation. We found 17 of 
the 37 miRNAs significantly upregulated by particulate Cr(VI) exposure have a 
6mer binding site. These data suggest RAD51 targeting miRNAs significantly 
upregulated by particulate Cr(VI) exposure are likely to bind the RAD51 mRNA 

















Table 3.12. RAD51 mRNA binding site information of significantly upregulated 
miRNAs by particulate Cr(VI) exposure. 
 
Table 3.12 shows significantly upregulated (adjusted p-value<0.01) miRNAs by 
particulate Cr(VI) exposure that target RAD51. The total binding sites are shown 




3’ UTR of RAD51 for all binding sites for each miRNA. Numbers in parenthesis 



























In Aim 2 we present the first study to evaluate global expression of miRNAs 
after Cr(VI) exposure in human cells. We show particulate Cr(VI) significantly alters 
the expression of miRNAs. The number of significantly increased miRNAs 
increased with particulate Cr(VI) exposure at all time points, and these levels were 
higher at higher concentrations of zinc chromate. We also observed when 
comparing the number of significantly upregulated miRNAs to the number of 
downregulated miRNAs at each condition, more miRNAs were downregulated by 
particulate Cr(VI) exposure. These are the first data to show Cr(VI) alters global 
miRNA expression, and more miRNAs are downregulated.  
We also compared the altered expression of miRNAs after particulate Cr(VI) 
expression by narrowing the parameters by evaluating significantly altered 
miRNAs with a fold change greater than 2. Such a large dataset allowed us to 
focus on miRNAs that may have the largest biological relevance for global effect 
analysis. We visualized the scattering of miRNAs based on these criteria using 
volcano plots and found not all miRNAs with a fold change greater than 2 were 
significant (adjusted p-value<2). We also found the number of significantly 
upregulated miRNAs (fold change >2) increased almost 7-fold after 24 h exposure 
to 0.2 ug/cm2 zinc chromate compared to 0.1 0r 0.3 ug/cm2 zinc chromate at this 
this time point. After 72 and 120 h more miRNAs were significantly upregulated at 
higher zinc chromate concentrations. The number of significantly downregulated 
miRNAs (fold change >2) also increased with concentration and time, although 
there was a spike in the 24 h 0.2 ug/cm2 zinc chromate condition. We also included 




concentration. This analysis was also used to generate heat maps showing the 
clustering of miRNAs based on their fold change values to better understand how 
patterns of miRNA expression altered by particulate Cr(VI) exposure.  
In Objective 2 we focused the analysis on particulate Cr(VI)-altered miRNAs 
that target genes in pathways of Cr(VI) carcinogenesis. We generated a list of 
KEGG pathways involved in Cr(VI) carcinogenesis and performed analysis 
comparing the KEGG pathways list with KEGG pathways targeted by particulate 
Cr(VI)-altered miRNAs at each of our conditions. We found particulate Cr(VI)-
altered miRNAs target pathways of Cr(VI) carcinogenesis. We further analyzed 
these data to compared the number of up- or down-regulated miRNAs that target 
each pathway of Cr(VI) carcinogenesis and the number of genes targeted by 
miRNAs up- or down-regulated by particulate Cr(VI) exposure.  
In Objective 3 we focused in on how particulate Cr(VI)-upregulated miRNAs 
affect the homologous recombination pathway and specifically RAD51. We 
identified miRNAs at each time point and particulate Cr(VI) concentration that 
target specific proteins in the homologous recombination pathway. We found 
trends in predicted target genes and the miRNAs that affect their expression. 
Finally, we analyzed all significantly up-regulated miRNAs from the RNAseq 
analysis that predicted to target RAD51. Using an online database 126 miRNAs 
were predicted to target the RAD51 mRNA transcript. Of those 37 unique miRNAs 
were upregulated by particulate Cr(VI) exposure. We evaluated each of these 37 
miRNAs under each treatment condition and identified trends in expression 
associated with time and concentration. Lastly, we assessed the quality of each 




result in a biological effect. We found all but two of the Cr(VI)-upregulated miRNAs 
have a high likelihood of binding and 17 out of the 37 had perfect match binding in 
the seed region.  
Aim 3: Characterize the effects of particulate Cr(VI) on homologous 
recombination in leatherback sea turtle lung cells. 
Background 
Cr(VI) is a global environmental pollutant and can affect both humans and 
wildlife. The One Environmental Health approach is a research perspective that 
incorporates human, wildlife, and ecosystem health to better understand how 
toxicants affect the overall health of the environment (Perez and Wise, 2018). We 
are investigating the effects of particulate Cr(VI) cells from both human and wildlife 
species. We showed particulate Cr(VI) does not induce the same response to 
particulate Cr(VI) in whale cells that is observed in human cells (Browning et al., 
2017; Li Chen et al., 2009a; Li Chen et al., 2009b; Li Chen et al., 2012; Wise et al. 
2015). In this study we focus on another marine species, leatherback sea turtles.  
Leatherback sea turtles are a large (up to 1200 lbs) and long-lived (~45 
years) marine reptile that spend the entirety of their lives in the ocean. The 
extended amount of time leatherbacks spend in the ocean exposes them to 
pollutants and contaminants in the water, air, or food sources (Godley et al., 1999; 
Guirlet et al., 2008; Perrault et al., 2013; Storelli and Marcotrigiano, 2003). These 
exposures may lead to detrimental health impacts including immune and 
reproductive failure (Guirlet et al., 2010; Stewart et al., 2011a). Furthermore, 
leatherbacks may bioaccumulate environmental contaminants exacerbating health 




Several studies have investigated metal levels in leatherback sea turtles 
around the world and found their tissues may accumulate metals such as mercury, 
cadmium, lead, and arsenic (Guirlet et al., 2010; Kunito et al., 2008; Stewart et al., 
2011b). To our knowledge only one study has investigated Cr levels in 
leatherbacks but did not measure Cr levels in lung tissue (Poppi et al., 2012). 
However, one study showed in tissues of adult and young loggerhead sea turtles 
(Caretta caretta) Cr accumulated in the highest concentrations in the lung (Storelli 
et al., 1998). These studies demonstrate leatherbacks are exposed to Cr(VI) in the 
environment.  
It is important to study the potential effects of environmental contaminants 
such as Cr(VI) in leatherbacks to understand the potential impact on the health of 
their population, the health of the environment, and to gain insight into human 
health. Previously, we have shown particulate and soluble Cr(VI) is cytotoxic and 
genotoxic in leatherback sea turtle lung cells (Speer et al., 2017). Additionally, we 
found human and leatherback lung cells has similar levels of cytotoxicity and 
genotoxicity although there were some observable differences between the two 
species (Speer et al., 2018). No studies have investigated DNA damage or repair 
in leatherbacks, and it is unknown how Cr(VI) causes genotoxicity in leatherback 
cells.  
In Aims 1 and 2 of this dissertation we investigated mechanisms of 
particulate Cr(VI) induced loss of homologous recombination repair in human lung 
cells. In Aim 3 we investigate key endpoints of particulate Cr(VI) exposure in 
leatherback lung cells to begin to understand the mechanisms of particulate Cr(VI) 




in leatherback cells and impair DNA repair based on our previous studies of Cr(VI) 
in leatherback lung cells. We tested this hypothesis my measuring DNA double 
strand breaks and homologous recombination repair in primary leatherback lung 
cells.  
Results 
Objective 1: Particulate Cr(VI) induces DNA damage in leatherback lung cells. 
We observed particulate Cr(VI) induced genotoxicity in leatherback lung 
cells after acute and prolonged exposure as a measure of structural chromosome 
instability (Speer et al., 2017; Speer et al., 2018). Induction of DNA double strand 
breaks is a primary driver of structural chromosome instability. We measured DNA 
double strand breaks in leatherback lung cells using two measures. We used the 
neutral comet assay to measure of DNA double strand breaks in leatherback lung 
cells. We found particulate Cr(VI) did not increase comet tail intensity in 
leatherback lung cells after 24 or 120 h exposure (Figure 3.31). For example, 24 h 
exposure to 0.1 or 0.4 ug/cm2 zinc chromate resulted in a tail intensity of 1 and 1.2 
relative to control, respectively, while 120 h exposure resulted in a tail intensity of 








Figure 3.31. Particulate Cr(VI) does not increase DNA damage. This 
figure shows tail intensity as a measure of DNA double strand breaks 
does not increase after 24 or 120 h exposure to particulate Cr(VI). 
Data represent the mean of at least 3 independent experiments. 
Error bars = standard error of the mean. No statistical significance 
was observed.  (A) Representative images of comets after exposure 
to particulate Cr(VI) in leatherback lung cells. (B) Particulate Cr(VI) 
does not increase comet tail intensity in leatherback lung cells after 












































We also measured DNA double strand breaks using gamma-H2AX nuclear 
foci. The histone variant, H2AX is phosphorylated (gamma-H2AX) in response to 
DNA double strand breaks as a signaling method to initiate repair (Khanna and 
Jackson, 2001).  
Figure 3.32A shows representative images of gamma-H2AX foci in leatherback 
lung cells. We found particulate Cr(VI) increased the percent of cells with >10 foci 
after 24 and 120 h exposure (Figure 3.32B). For example, 24 h exposure to 0.1 or 
0.4 ug/cm2 zinc chromate resulted in 8.7 and 27.3 percent of cell with >10 gamma-
H2AX foci, respectively, while 120 h exposure resulted in 11.3 and 24.7 percent of 
cells with >10 gamma-H2AX foci, respectively. Only 24 h exposure to 0.4 ug/cm2 
zinc chromate was significant from control (*p<0.05), but there is a clear increasing 
trend in the percent of cells with >10 gamma-H2AX foci after 24 h exposure. We 











Figure 3.32. Particulate Cr(VI) increases gamma-H2AX foci in 
leatherback lung cells. This figure shows the percent of leatherback 
lung cells with >10 gamma-H2AX foci increases with concentration 
after 24 and 120 h exposure. Data represent the mean of three 
independent experiments. Error bars = standard error of the mean. 































































cells. The nucleus is stained blue with DAPI. gamma-H2AX foci are 
stained pink. (B) The percent of cells with >10 gamma-H2AX foci 
after 24 and 120 h exposure increased with increasing zinc chromate 
concentrations. The percent of cells with >10 gamma-H2AX foci was 
significantly higher after 24 h exposure to 0.4 ug/cm2 zinc chromate 
compared to control (*p<0.05). The percent of cells with >10 gamma-
H2AX foci increased after 120 h exposure to 0.1, 0.3, and 0.4 ug/cm2 



















Objective 2: RAD51 but not homologous recombination is impaired after prolonged 
particulate Cr(VI) exposure 
In Objective 1 we found induction of DNA double strand breaks increased 
after particulate Cr(VI) exposure in leatherback lung cells using gamma-H2AX as 
a measure. However, there appeared to be no increase in DNA double strand 
breaks in the comet assay analysis. To better understand this result and to 
determine if particulate Cr(VI) affects DNA repair in leatherback lung cells we first 
assessed homologous recombination repair by measuring RAD51 nuclear foci.  
Figure 3.33A shows representative images of RAD51 foci in leatherback lung cells. 
We found RAD51 nuclear foci increase after 24 h exposure to particulate Cr(VI) 
(Figure 3.33B). For example, exposure to 0.1, 0.2, 0.3, and 0.4 ug/cm2 zinc 
chromate resulted in 9.3 15.3, 18, and 18.3% of cells with >10 RAD51 foci. The 
0.2, 0.3 and 0.4 ug/cm2 concentrations were significant compared to control 
(*p<0.05 and **p<0.01). However, after 120 h exposure to particulate Cr(VI) 
RAD51 nuclear foci increase at lower concentrations and then decreased at the 
higher concentrations. For example, 0.1 and 0.2 ug/cm2 zinc chromate increase 
the percent of cells with >10 RAD51 foci to 8 and 11, respectively, while after 0.3 
and 0.4 ug/cm2 zinc chromate the percent of cells with >10 RAD51 foci is only 2.8 
and 1.5, respectively. The increase was only significant after 0.2 ug/cm2 zinc 
chromate (*p<0.5). The percent of cells with >10 RAD51 foci was significantly 
lower after 120 h exposure to 0.3 and 0.4 ug/cm2 zinc chromate compared to 24 h 






Figure 3.33. RAD51 nuclear foci increase after acute but not 
prolonged particulate Cr(VI) exposure in leatherback lung cells. Data 
represent the mean of at least three independent experiments. Error 
bars = standard error of the mean.  (A) Representative images of 
RAD51 foci in leatherback lung cells. The nucleus is stained blue 
with DAPI. yH2AX foci are stained red. (B) The percent of cells with 
>10 RAD51 foci (controls subtracted) in leatherback lung cells. 

































































after 24 h in leatherback lung cells compared to control (*p<0.05, 
**p<0.01). While the percent of cells with >10 RAD51 foci increases 
after 120h exposure to 0.1 and 0.2 ug/cm2 zinc chromate (*p<0.05) 
it decreases after 0.3 and 0.4 ug/cm2 zinc chromate. The percent of 
cells with >10 RAD51 foci is significantly lower after 120 h compared 





















 RAD51 nuclear foci were decreased after 120 h exposure to particulate 
Cr(VI) compared to 24 h. Sister chromatid exchanges were used as a measure of 
homologous recombination repair in leatherback lung cells. Figure 3.34A shows 
representative images of leatherback lung cells metaphases with sister chromatid 
exchanges. We found the ratio of sister chromatid exchanges to chromosome 
number increased significantly after 24 and 120 h exposure to all concentrations 
of particulate Cr(VI) (**p<0.01; ***p<0.001). For example, 24 h exposure to 0.1 and 
0.3 ug/cm2 zinc chromate increased the ratio of sister chromatid exchanges to 
chromosome number to 0.1 and 0.2, respectively. This ratio was higher after 120 
h exposure resulting in a ratio of 0.2 and 0.4 after exposure to 0.1 and 0.4 ug/cm2 
zinc chromate, respectively. The ratio of sister chromatid exchanges to 
chromosome number was significantly higher after 120 h exposure to 0.15, 0.2, 
and 0.3 ug/cm2 zinc chromate compared to 24 h (###p<0.001). No metaphases 
were observed after 120 h exposure to 0.4 ug/cm2 zinc chromate consistent with 






Figure 3.34. Particulate Cr(VI) induces sister chromatid exchanges 
in leatherback lung cells. This figure shows after 24 and 120 h 
exposure sister chromatid exchanges increase with particulate 











































































exchanges in leatherback lung cells. (B) Ratio of sister chromatid 
exchanges to chromosome number. Sister chromatid exchanges 
were increased in each zinc chromate concentration (**p<0.01; 
***p<0.001). Sister chromatid exchanges were significantly higher 
after 120 h exposure to 0.15, 0.2, and 0.3 ug/cm2 zinc chromate 
(###p<0.001). After 120 h exposure to 0.4 ug/cm2 zinc chromate no 
metaphases (NM) were observed. Results represent the mean of at 
least three independent experiments. Error bars = standard error of 




















In objective 2 we investigated DNA damage and repair in leatherback lung 
cells after acute and prolonged exposure to particulate Cr(VI). We found DNA 
double strand breaks did not increase with particulate Cr(VI) concentration after 
24 or 120 h exposure using the comet assay. However, gamma-H2AX foci 
increased with concentration to similar levels after both 24 and 120 h particulate 
Cr(VI) exposure. The difference between the comet assay and gamma-H2AX foci 
analysis could be the result of differences in the two measurements or signify 
double strand breaks are being partially repaired in leatherback lung cells after 
exposure to particulate Cr(VI). 
After measuring DNA repair in leatherback lung cells we saw prolonged 
exposure to particulate Cr(VI) inhibited RAD51 foci at higher concentrations of 
particulate Cr(VI), but homologous recombination repair was not inhibited. These 
data indicate while RAD51 may be inhibited after prolonged exposure, homologous 
recombination is still available to leatherback lung cells and may be partially 
protective. 
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CHAPTER 4: DISCUSSION 
Overview 
Homologous recombination is a high-fidelity DNA repair mechanism critical 
in maintaining genomic stability (Bryant et al., 2006; Stackpole et al., 2007). 
Studies show the homologous recombination pathway is involved in the repair of 
DNA double strand breaks induced by several metals including Cr(VI), arsenic, 
cadmium, lead, and nickel (Bryant et al., 2006; Gastaldo et al., 2007; Helleday et 
al., 2000; Stackpole et al., 2007). When homologous recombination repair is 
unavailable the cell must resort to low-fidelity repair mechanisms increasing the 
rate of chromosome instability. Indeed, we have shown Cr(VI) induces DNA double 
strand breaks while inhibiting homologous recombination repair resulting in 
chromosome instability (Browning et al., 2016, Qin et al., 2014; Wise et al., 2003; 
Wise et al., 2002; Xie et al., 2009) 
A critical factor in homologous recombination repair is the protein RAD51, 
which is involved in carrying out the effector step in this pathway. RAD51 is 
inhibited after prolonged exposure to particulate Cr(VI) illustrated by inhibited 
RAD51 monofilament formation and nuclear foci, cytoplasmic accumulation of 
RAD51 protein, and inhibited RAD51 protein expression (Browning et al., 2016; 
Qin et al., 2014). Decreased RAD51 protein is a key event that may underlie the 
other RAD51 phenotypes observed after prolonged Cr(VI) exposure. The 
transcription factor, E2F1, is predominantly responsible for RAD51 expression, 
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and studies show loss of E2F1 inhibits RAD51 expression and foci formation as 
well as homologous recombination repair (Chen et al., 2011; Choi and Kim, 2019; 
Wu et al., 2014). However, there are no studies investigating RAD51 expression 
and the mechanisms controlling RAD51 expression after Cr(VI) exposure. 
In Aim 1 we tested if E2F1 mediates the RAD51 response to particulate 
Cr(VI) exposure. We demonstrated the decrease in RAD51 protein is likely due to 
inhibited expression and not protein degradation. We focused on the predominant 
transcription factor for RAD51, E2F1, to determine if E2F1 was critical for 
expression of RAD51 after particulate Cr(VI) exposure. We found E2F1 
overexpression does not rescue RAD51 failure induced by prolonged particulate 
Cr(VI) exposure. This result indicates E2F1 alone does not modulate the RAD51 
response to particulate Cr(VI). This conclusion was supported by our data that 
shows knocking down E2F1 does not inhibit RAD51 expression. While we began 
to investigate the potential role of alternative transcription factors in particulate 
Cr(VI)-inhibited RAD51 expression, these results could not fully explain the 
decrease of RAD51 expression. 
In Aim 2 we performed a global RNAseq analysis to investigate how 
particulate Cr(VI) alters the expression of miRNAs. miRNAs are key regulators of 
gene expression, and studies show Cr(VI) causes global changes in gene 
expression. However, limited studies have evaluated changes in miRNA 
expression following Cr(VI) exposure, and none focused on homologous 
recombination repair or RAD51. We investigated the effects of acute and 
prolonged exposure to particulate Cr(VI) on miRNAs and characterized their 
expression profiles. We found particulate Cr(VI) significantly altered miRNA 
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expression and caused global down regulation of miRNAs. Additionally, we found 
miRNAs altered by particulate Cr(VI) target genes in pathways of Cr(VI) 
carcinogenesis. RAD51 expression is a focus of this study and we characterized 
which particulate Cr(VI)-altered miRNAs predicted to target RAD51 and the 
likelihood of their potential to bind to the RAD51 mRNA transcript. Together these 
data provide insight into how particulate Cr(VI) alters global expression of miRNAs 
and how they may play a role in pathways of Cr(VI) carcinogenesis. 
To complement our investigation in the mechanisms of particulate Cr(VI)-
induced homologous recombination failure we applied the One Environmental 
Health approach by evaluating key endpoints in leatherback sea turtle lung cells. 
Previous studies using this approach have identified differences in the response 
to Cr(VI) exposure that may serve as protective mechanisms in one species over 
another (Browning et al., 2017a; Li Chen et al., 2009a; Li Chen et al., 2009b; Li 
Chen et al., 2012; Wise et al. 2015). Therefore, in aim 3 we investigated DNA 
damage and repair in leatherback lung cells. Using the comet assay we found 
particulate Cr(VI) did not induce DNA damage. However, when we measured 
gamma-H2AX foci, there was an increase after acute and prolonged particulate 
Cr(VI) exposure. When we investigated repair, we found RAD51 foci increased 
after 24 h, but was inhibited after 120 h exposure indicating RAD51 is impaired. 
Alternatively, the breaks could be resolved. Even though RAD51 was decreased, 
homologous recombination repair was active indicated by the increase of sister 
chromatid exchanges. These data indicate homologous recombination repair is 
available in leatherback lung cells to repair double strand breaks. 
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The conclusions of these aims are supported by the data in this dissertation. 
Below, we discuss the results in detail. 
Particulate Cr(VI) inhibits expression of RAD51 and E2F1 
RAD51, the key protein in the effector step of homologous recombination, 
is impaired after prolonged exposure to particulate Cr(VI) while earlier steps in the 
pathway remain functional (Qin et al., 2014). Loss of RAD51 was characterized by 
inhibited nuclear foci and monofilament formation, increased cytoplasmic 
accumulation, and inhibited protein expression (Browning et al., 2016; Qin et al., 
2014).  Browning et al., 2017a further investigated mechanisms of cytoplasmic 
accumulation of RAD51 after prolonged Cr(VI) exposure, however how particulate 
Cr(VI) inhibits RAD51 protein expression is unknown and was a major focus of this 
investigation. 
We confirmed RAD51 protein expression decreased following prolonged, 
but not acute particulate Cr(VI) exposure consistent with previous studies 
(Browning et al., 2014, Qin et al., 2014). Decreased levels of protein could result 
from either increased protein degradation or decreased production of the protein. 
Bruno et al., 2016 characterized ubiquitin-mediated protein degradation as an 
important pathway of Cr(VI) exposure leading to deleterious cellular effects. 
However, our data show particulate Cr(VI) exposure had minimal effect on RAD51 
protein half-life indicating protein degradation likely plays a minor role in the 
decrease of RAD51 protein levels. We did not apply additional methods to 
investigate RAD51 protein degradation in our analysis, however, it is unlikely to be 
a major contributor based on our protein half-life results. Thus, degradation may 
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be an overall important pathway for Cr(VI), but it does not appear to have a major 
contribution to this specific protein. 
By contrast, we did find a reduction in processes underlying protein 
production, specifically RAD51 transcription. RAD51 mRNA expression decreased 
slightly after 24 h (not significant) but notably, and significantly decreased after 72 
and remained low after 120 h exposure to particulate Cr(VI). While Bruno et al., 
2016, suggests protein degradation is increased following Cr(VI) exposure our 
mRNA expression data suggest inhibited transcription is the primary mechanism 
responsible for the decrease of RAD51 protein, specifically. This result is 
supported by Manning and Patierno, 1992 who demonstrated Cr(VI) inhibits 
transcription. Our data are the first to describe RAD51 mRNA expression following 
Cr(VI) exposure, for both particulate and soluble Cr(VI) compounds. These results 
are consistent with studies showing Cr(VI) downregulates expression of DNA 
repair genes and correlate with the trend in RAD51 protein levels previously 
reported after acute and prolonged Cr(VI) exposure (Browning et al., 2016; Hodges 
et al., 2002; Hu et al., 2018; Pritchard et al., 2007; Qin e al., 2014; Takahashi et 
al., 2004). 
Although we found decreased levels of RAD51 mRNA it is possible RAD51 
protein reduction after prolonged particulate Cr(VI) exposure is also due to 
inhibited translation. Several studies have shown Cr(VI) inhibits protein translation 
(Blankenship et al., 1994; Gunaratnam and Grant, 2008; Shumilla and 
Barchowsky, 1999) Gunaratnam and Grant, 2008 showed Cr(VI) inhibited DNA, 
RNA, and protein synthesis, but the most significant effect was on protein 




result of several mechanisms including inhibited transcription, RNA degradation, 
and inhibited translation as the end product of gene expression. Specific 
mechanisms of inhibited protein translation involving transcriptional machinery 
after Cr(VI) exposure have not been investigated. However, one emerging 
mechanism is the involvement of miRNAs in mRNA degradation and inhibited 
translation. We will discuss this possibility further below. 
RAD51 is a key protein in homologous recombination repair and thus its 
transcriptional control has been investigated. Control of RAD51 expression is 
tightly regulated. E2F1 is the predominant transcription factor for RAD51 and loss 
of E2F1 inhibits RAD51 protein and nuclear foci formation (Chen et al., 2011; Choi 
and Kim, 2019; Wu et al., 2014). These results correlate with the RAD51 response 
after prolonged particulate Cr(VI) exposure. Studies show E2F1 is inhibited 
following exposure to other metals including arsenic and cadmium (Lam et al., 
2014; Lam et al., 2015; Li et al., 2008; Wu et al., 2013). However, only one study 
investigated E2F1 after Cr(VI) exposure and found 24 h exposure increased E2F1 
expression (Permenter et al., 2011). Prolonged exposures have not been 
investigated. We investigated the effects of particulate Cr(VI) on E2F1 to determine 
if particulate Cr(VI)-induced loss of E2F1 may underlie reduced RAD51 
expression. Our data show E2F1 protein expression is unaffected after 24 
exposure but decreases after 72 and 120 h exposure. We observe significant 
decrease of RAD51 mRNA after prolonged exposures correlating with prolonged 
Cr(VI)-inhibited E2F1 protein expression. E2F1 mRNA also decreased after 24 h 
and further decreased after 72 and 120 h exposure to particulate Cr(VI) consistent 
with the E2F1 protein levels. E2F1 self regulates its own transcription. Therefore, 
197 
the loss of E2F1 protein after prolonged exposure may explain reduced E2F1 
mRNA. RAD51 and E2F1 mRNA begin to decrease after 24 h suggesting 
transcription may be inhibited earlier than the decrease in protein is detected and 
indicates there may more than one mechanism for decreased mRNA levels at this 
time point. The mechanism underlying the loss of mRNA is currently unknown. 
One possible mechanism that may explain our results is miRNAs target the mRNA 
for degradation, and we will address this possibility below. miRNA-induced loss of 
mRNA does not explain why RAD51 and E2F1 protein levels are not affected after 
24 h particulate Cr(VI) exposure. One explanation is the cell recognizes the need 
for RAD51 and E2F1 protein after acute particulate Cr(VI)-induced DNA damage 
and protects available protein. Indeed, studies show E2F1 protein is stabilized 
following DNA damage (Biwas and Johnson, 2012; Ianari et al., 2004; Lin et al., 
2001). 
E2F1 does not mediate the RAD51 response to particulate Cr(VI) 
We observed particulate Cr(VI) affected RAD51 and E2F1 mRNA and 
protein expression in a similar temporal manner suggesting loss of E2F1 after 
prolonged particulate Cr(VI) exposure may be responsible for loss of RAD51. To 
confirm this connection, we attempted to rescue the RAD51 response by 
overexpressing E2F1 after prolonged particulate Cr(VI) exposure. We found 
overexpression of E2F1 did not rescue RAD51 as the reduced protein levels, 
inhibited foci formation and aberrant cytoplasmic accumulation remained despite 
elevated E2F1 levels. RAD51 protein levels were inhibited in our untransfected 
control after 120 h exposure to particulate Cr(VI) consistent with previous data 
(Browning et al., 2016; Qin et al., 2014). However, while RAD51 protein levels 
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increased after E2F1 overexpression in the cells untreated with particulate Cr(VI), 
after 120 h exposure to 0.2 ug.cm2 zinc chromate RAD51 protein did not increase 
compared to the transfection control. These data show that while E2F1 
overexpression may increase RAD51 protein levels, it does not rescue prolonged 
particulate Cr(VI)-induced reduction in RAD51 protein. When we examined RAD51 
nuclear foci we did not find E2F1 rescued prolonged particulate Cr(VI)-inhibited 
RAD51 foci formation observed in our untransfected control. This result indicates 
E2F1 may not directly affect RAD51 nuclear foci formation. One explanation for 
this result may be E2F1 overexpression does not abrogate prolonged particulate 
Cr(VI)-induced RAD51 cytoplasmic accumulation and RAD51 is not available in 
the nucleus. However, when we examined RAD51 cytoplasmic accumulation after 
E2F1 overexpression we did not find RAD51 cytoplasmic accumulation was 
inhibited after prolonged particulate Cr(VI) exposure. These data suggest E2F1 is 
not involved in RAD51 nuclear localization. 
The regulation of RAD51 expression and localization in the cell are 
controlled by complex mechanisms. Our data showing E2F1 increased RAD51 
protein expression in cells untreated with particulate Cr(VI) is consistent with the 
literature. However, RAD51 protein levels were not modulated by E2F1 after 
particulate Cr(VI) exposure. Alternative repressive mechanisms may prevent the 
excess amount of E2F1 in the cells from expressing RAD51 explaining this result. 
Failure of E2F1 overexpression to rescue particulate Cr(VI)-inhibited RAD51 foci 
formation may be explained by the fact that RAD51 protein was not restored. 
Alternatively, RAD51 nuclear foci are formed as a result of RAD51 loading onto 
single-stranded DNA at sites of DNA double strand breaks in part by BRCA2 and 
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RAD51C, and this process may be unaffected by E2F1 (Amunugama et al., 2013; 
Forget and Kowalczykowski, 2010; Jensen et al., 2010). 
Inhibited RAD51 nuclear foci may also be attributed to our result showing 
E2F1 overexpression did not abrogate particulate Cr(IV)-induced RAD51 
cytoplasmic accumulation rendering RAD51 unavailable in the nucleus. This 
outcome was unexpected as Ketchap et al., 2010 found histone deacetylase 
inhibitors affected RAD51 through E2F1-mediated mechanisms. One endpoint 
they confirmed was the induction of RAD51 cytoplasmic accumulation. The 
difference in our results may be due to the histone deacetylase inhibitors 
themselves used in Katchap et al., 2010 and not the loss of E2F1 directly. Katchap 
et al., 2010 used a histone deacetylase inhibitor that targets both class I and class 
II histone deacetylases, which can target non-histone proteins (Glozak et al., 
2005). It is possible the inhibitor in this study affected post-translational 
modifications on proteins important for RAD51 localization. 
RAD51 has no nuclear localization signal and thus must bind to other 
proteins, BRCA2 and RAD51C, to be transported into the nucleus (Gildemeister et 
al., 2009; Jeyasekharan et al., 2013). These proteins interact with nuclear pore 
complexes to mediate transport of RAD51 into the nucleus (Christie et al., 2016). 
Indeed, Browning et al., 2017a showed RAD51 nuclear transport mediated by 
BRCA2 and RAD51C was inhibited. It is possible E2F1 does not affect these 
mechanisms and that is why we did not see E2F1 overexpression rescue RAD51 
cytoplasmic accumulation of RAD51 after prolonged particulate Cr(VI) exposure. 
It is notable that RAD51 cytoplasmic accumulation was decreased to low levels in 




any observable effect of E2F1 overexpression and may have artifactually masked 
the result. This result indicates the transfection procedure itself affected RAD51 
cytoplasmic accumulation, although the mechanisms underlying this possibility 
have not been investigated.  
An alternative explanation for why E2F1 overexpression did not rescue any 
particulate Cr(VI)-induced RAD51 phenotypes is due to off-target effects directly 
related to E2F1 overexpression. Previously, overexpression of E2F1 was found to 
lead to activation of cell death pathways in fibroblasts (Kowalik et al., 1995). 
Therefore, it is possible E2F1 overexpression induced off-target effects that 
interfered with normal DNA repair mechanisms. Although we did not measure cell 
death, if cell death pathways were activated after E2F1 overexpression, it is likely 
less resources would be allocated to DNA repair mechanisms. This points to the 
delicate balance of factors in the cell and how they respond to genotoxic insult.  
It may be that complications of the E2F1 overexpression paradigm 
prevented us from determining if E2F1 mediates the RAD51 response to 
particulate Cr(VI). Therefore, we tried to connect E2F1 with the RAD51 response 
by knocking down E2F1 after acute exposure to particulate Cr(VI) when RAD51 is 
normally active to try an recapitulate the prolonged exposure response. Previous 
studies were successful showing loss of E2F1 inhibits RAD51 (Chen et al., 2011; 
Choi and Kim, 2019; Wu et al., 2014). We found knockdown of E2F1 did not inhibit 
RAD51 mRNA or protein expression or induce RAD51 cytoplasmic accumulation 
but did inhibit RAD51 nuclear foci formation. RAD51 protein levels were unaffected 
by E2F1 knockdown in three out of the four E2F1 siRNAs tested after exposure to 
acute 24 h particulate Cr(VI). Although one E2F1 siRNA inhibited RAD51 protein 
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levels, it is possible this siRNA has an off-target effect on RAD51 expression 
inconsistent with the other siRNAs. These data indicate E2F1 does not modulate 
RAD51 protein levels in WTHBF-6 cells in response to particulate Cr(VI) consistent 
with our E2F1 overexpression data. Similarly, when we investigated RAD51 mRNA 
after E2F1 knockdown we found RAD51 mRNA were not consistently affected. 
While RAD51 mRNA was decreased slightly after E2F1 knockdown with one 
siRNA, it was slightly increased by another siRNA correlating with the RAD51 
protein data after E2F1 knockdown. When we examined RAD51 localization, we 
found E2F1 knockdown did not induce RAD51 cytoplasmic accumulation observed 
after prolonged particulate Cr(VI) exposure indicating E2F1 does is not involved in 
mechanisms regulated RAD51 nuclear localization. These data are consistent with 
our E2F1 overexpression analysis. The cytoplasmic accumulation result is 
contrary to our finding that E2F1 knockdown inhibited RAD51 nuclear foci 
formation after only acute 24 h exposure to particulate Cr(VI). This result suggests 
E2F1 may affect RAD51 localization or stability at DNA double strand breaks but 
not nuclear localization. 
The results of our E2F1 knockdown experiments may be explained by the 
complex nature of the involvement of E2F1 in RAD51 expression and function. 
Only one of the four E2F1 siRNA transfection resulted in decreased RAD51 protein 
expression and was only significant in the condition with no particulate Cr(VI) 
exposure. An explanation for this result may be that in this condition E2F1 was 
knocked down to 10% while the other E2F1 knockdowns E2F1 was only knocked 
down to between 20-30%. This difference could explain why we do not observe 
the decrease of RAD51 reported by others in the literature. However, within our 
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study mechanism, particulate Cr(VI) does not reduce E2F1 protein to these levels. 
In fact, the largest effect on E2F1 protein loss is after 72 h exposure to 0.3 ug/cm2 
zinc chromate resulting in 41% E2F1 protein levels relative to control. Therefore, 
it may be possible E2F1 knockdown inhibits RAD51, but only at levels not reached 
after particulate Cr(VI) exposure. 
E2F1 is responsible for the transcription of RAD51. However, we found 
E2F1 knockdown did not inhibit RAD51 mRNA expression consistently after acute 
particulate Cr(VI) exposure. Other studies have found E2F1 knockdown inhibits 
RAD51 mRNA expression (Choi and Kim, 2019; Wu et al., 2014). These papers 
are inconsistent with our results showing E2F1 knockdown did not significantly 
impact RAD51 mRNA. The levels of E2F1 in our study may not low enough to 
induce the RAD51 effect observed in other studies. Similar to the RAD51 protein 
expression results the E2F1 siRNA condition where E2F1 was knocked down to 
10% reduced RAD51 mRNA, while in the other E2F1 siRNA condition E2F1 was 
knocked down to 20-30% and slightly increased RAD51 mRNA. An alternative 
explanation is we found nuclear E2F1 protein levels only decreased after 120 h 
exposure. Although total E2F1 protein is significantly decreased after 72 and 120 
h particulate Cr(VI) exposure, it appears what E2F1 protein is available is shuttled 
into the nucleus. Another explanation is alternative transcription factors may be 
compensating for the loss of E2F1 in the expression of RAD51. Consistent with 
these results and our E2F1 overexpression data we found E2F1 knockdown did 
not induce RAD51 cytoplasmic accumulation after only acute exposure to 
particulate Cr(VI). This result may be because E2F1 simply is not involved in the 




It is also possible the timing of the experiment did not allow for the 
development of RAD51 cytoplasmic accumulation or the reduction in RAD51 
mRNA and protein. For example, we knocked down E2F1 for a total of 48 h and 
treated with particulate Cr(VI) the last 24 h of the transfection. In initial testing, we 
found WTHBF-6 cells did not tolerate longer E2F1 knockdown transfection times 
well. This timing issue may have inhibited our ability to detect the RAD51 
phenotypes investigated that may require longer to develop. It is also possible 
knocking down E2F1 had off-target effects in the cells that affected these 
endpoints. 
Although RAD51 protein and mRNA expression and cytoplasmic 
accumulation were unaffected by E2F1 knockdown, we did find RAD51 nuclear 
foci were inhibited. This result is consistent with studies showing loss of E2F1 
reduces RAD51 nuclear foci at double strand breaks and inhibits DNA repair. For 
example, Chen et al., 2011 showed E2F1 knockout cells had increased DNA 
damage and inhibited repair indicated by the comet assay and gamma-H2AX foci 
while also reducing RAD51 nuclear foci. RAD51 nuclear foci normally increase in 
response to acute particulate Cr(VI) exposure (Browning et al., 2014; Qin et al., 
2014). Our data show loss of E2F1 inhibited RAD51 nuclear foci formation after 
acute particulate Cr(VI) exposure. These data indicate E2F1 may play a role in 
RAD51 loading onto single-stranded DNA at double strand breaks, or affect 
proteins involved in this process. E2F1 can localize to DNA double strand breaks 
and plays a role in the signaling and stability of DNA repair proteins (Chen et al., 
2011; Choi and Kim, 2019; Liao et al., 2010; Lin et al., 2001). It is possible E2F1 
facilitates RAD51 nuclear foci formation directly or through the regulation of 
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mediator proteins. This direct involvement at DNA double strand breaks may 
explain why E2F1 knockdown affected RAD51 nuclear foci but not the other 
endpoints we assessed. This result does not explain why we did not see E2F1 
overexpression rescue prolonged particulate Cr(VI)-inhibited RAD51 nuclear foci 
formation. However, as previously discussed the overexpression procedure may 
have had off-target effects affecting the result. Further work is required to 
determine the role of E2F1 in RAD51 foci formation after particulate Cr(VI) 
exposure. 
Alternative RAD51 transcription factors may play a role in RAD51 expression 
after particulate Cr(VI) exposure 
While we found E2F1 may affect RAD51 nuclear foci formation, RAD51 
expression was unaffected by modulating E2F1. We explored alternative 
mechanisms that may explain these results focusing on alternate proteins involved 
in RAD51 transcription however there is little data on the regulation of RAD51 by 
other transcription factors. EGR1 is a proposed transcriptional activator of RAD51 
(Hine et al., 2014). We found EGR1 was unaffected after 24 h but had a modest 
decrease after 120 h exposure. For example, 120 h exposure to 0.1, 0.2, and 0.3 
ug/cm2 zinc chromate decreased EGR1 to 81, 76, and 64% of control, respectively, 
although these results were not significant.  We have not investigated the modest 
decrease in EGR1 after prolonged particulate Cr(VI) exposure thus far and how it 
may contribute to loss of RAD51 expression. 
We considered the opposite scenario, that rather than RAD51 activators 
being decreases, perhaps transcription was low because inhibitors were 
increased. It is possible transcriptional repressors modulate RAD51 expression 
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after particulate Cr(VI) exposure. Indeed, Engeland, 2018 suggests the balance of 
activating and repressive complexes are important in gene expression. P53 is a 
direct and indirect transcriptional repressor of RAD51 (Buchop, 1997; Toledo, 
1998). However, we found p53 protein increased after 24 h and decreased slightly 
after 120h exposure to particulate Cr(VI), which does not support a conclusion that 
p53 was repressing RAD51 transcription. We further found p53 stabilization was 
not altered. These data suggest p53 may not play a significant direct role in the 
expression of RAD51 after particulate Cr(VI) exposure. Our observations that 
stability is unaffected would allow p53 to participate in indirect regulation of RAD51 
expression. For example, p53 facilitates hypo-phosphorylation of p130, and hypo-
p130 binds to E2F4 facilitation the formation of the repressive DREAM complex 
(Engeland, 2018). 
The DREAM complex is thought to displace activating complexes 
containing E2F1. Indeed, Bindra et al., 2007 showed E2F1 and E2F4 compete for 
the same binding location at the RAD51 promoter. We found while p130 protein 
decreased after particulate Cr(VI) exposure, phospho-p130 was further deceased. 
These data indicate of the p130 available after particulate Cr(VI) exposure, more 
is in the hypo-phosphorylated form, which may then complex with E2F4. We found 
E2F4 protein to be slightly elevated level after acute and prolonged exposure to 
particulate Cr(VI).  This outcome indicates while E2F1 is inhibited following 
particulate Cr(VI) exposure E2F4 is unaffected, which would shift the balance of 
the two transcription factors towards the repressive E2F4. Based on the literature 
this imbalance may be responsible for the repressed RAD51 expression (Bindra 




might initially seem to contradict the hypothesis that the balance of E2F1 to E2F4 
is responsible for RAD51 repression after particulate Cr(VI) exposure. However, 
the complexity of this process may need to be further investigated to better 
delineate the mechanism. Indeed, there is not much known about how the 
repressive DREAM complex displaces the transcriptional activating complex 
containing E2F1.  
Particulate Cr(VI) upregulates miRNAs targeting RAD51 expression 
Our data exploring transcriptional control of RAD51 do not fully explain loss 
of RAD51 mRNA and protein after particulate Cr(VI) exposure. miRNAs play a 
significant role in regulating gene expression by targeting mRNA for degradation 
or inhibition of translation. Only a few studies have evaluated changes in miRNAs 
after Cr(VI) expression, however, these only focused on a few miRNAs each, and 
none in connection to RAD51 (Chandra et al., 2015; Li et al., 2014; Li et al., 2016). 
We performed a global analysis of miRNAs using RNAseq after exposure to acute 
and prolonged particulate Cr(VI) exposure in human lung cells and identified 
miRNAs upregulated by particulate Cr(VI) that target RAD51.  
We found particulate Cr(VI) upregulated miRNAs targeting RAD51 mRNA. 
Of the 126 miRNAs predicted to target RAD51, we found 37 to be significantly 
upregulated by particulate Cr(VI) exposure. Thirty-five of these miRNAs targeted 
RAD51 with high likelihood of binding according to their mirSVR scores. Seventeen 
out of the 37 total miRNA targeting RAD51 had perfect 6mer binding, which 
indicates many of the particulate Cr(VI) upregulated miRNAs targeting RAD51 




We observed trends in concentration and time associated with several 
miRNAs. For example, miR-432-5p and miR-194-5p were upregulated after 72 and 
120 h exposure at all concentrations of particulate Cr(VI). These miRNAs have 
7mer binding to the RAD51 mRNA transcript. miR-30b was significantly 
upregulated after 120 h exposure at the highest concentration and has perfect 
6mer binding to the RAD51 mRNA transcript. We observed significant upregulation 
of RAD51-targeting miR-186 after 24 h exposure to particulate Cr(VI) with 3 
predicted binding sites on the RAD51 mRNA transcript (one with a perfect 6mer 
match). This miRNA was also found to induce chromosome instability following 
arsenic exposure although this study did not consider the implications of miR-186 
targeting RAD51 in their analysis (Wu et al., 2019). miR-186 and those RAD51-
targeting miRNAs upregulated after prolonged exposure would be excellent 
candidates for further evaluation of their effect on RAD51 expression and 
chromosome instability after particulate Cr(IV) exposure.  
No previous studies evaluated miRNAs altered by Cr(VI) in relation to 
RAD51. However, RAD51 itself has been the target of therapeutic studies for 
interference by miRNAs. For example, Huang et al., targeted RAD51 using miR-
103 and miR-107 although we did not see these miRNAs affected by particulate 
Cr(VI) exposure. Several other studies also identified RAD51-targeting miRNAs in 
relation to cancers or therapeutic use, but none overlapped with particulate Cr(VI)-
upregulated miRNAs targeting RAD51 in our results (Lai et al., 2016; Gasparini et 
al., 2014; Li et al., 2016).  
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Particulate Cr(VI) upregulates miRNAs that target homologous 
recombination genes 
RAD51 is a key protein in the homologous recombination pathway and we 
found particulate Cr(VI) upregulated miRNAs predicted to target RAD51. However, 
Cr(VI) may upregulate miRNAs targeting additional proteins in the homologous 
recombination pathway affecting RAD51. We identified individual miRNAs 
significantly upregulated (fold change >2) by particulate Cr(VI) under each 
experimental condition and their gene targets in the homologous recombination 
pathway. It is notable RAD51 was not included in this list. This is because of our 
stringent cut-off of a fold change >2 for this specific analysis. However, the analysis 
shows many of the genes targeted are RAD51 homologs or involved in loading 
RAD51 onto the single-stranded DNA at double strand breaks. For example, 
XRCC2, RAD52, RAD51D, RAD51C, and RAD51B were all targeted by particulate 
Cr(VI)-upregulated miRNAs. Specifically, we observed several trends across 
concentration and time including miR-210 (which targets RAD52), which was 
upregulated at all time points.  RAD52 is involved in loading RAD51 onto the single-
stranded DNA at double strand breaks. Few genes in the earlier steps of 
homologous recombination repair were affected consistent with our previous 
reports showing it is the downstream steps in homologous recombination affected 
by particulate Cr(VI) exposure (Browning et al., 2016; Browning et al., 2017a; Qin 
et al., 2014). For example, early proteins in the homologous recombination 
pathway RAD50, ATM, and NBS1 were not predicted to be targeted by particulate 
Cr(VI)-upregulated miRNAs. We have not investigated the effect of Cr(VI) on NBS1 




breaks with NBS1 (MRN complex) was unaffected by prolonged Cr(VI) exposure 
(Qin et al., 2014). The MRN complex is important for signaling of DNA double 
strand breaks, and our previous study also shows downstream signaling by ATM 
remains functional after prolonged Cr(VI) exposure (Qin et al., 2014). This is 
consistent with the RNAseq data showing ATM was not a predicted target by 
particulate Cr(VI) upregulated miRNAs. In contrast, RPA proteins, which coat 
single-stranded DNA were targeted under all particulate Cr(VI) conditions. RPA 
nuclear foci levels are decreased after prolonged particulate Cr(VI) exposure 
compared to acute exposure indicating a possible inhibitory effect correlating with 
our RNAseq data (data not published, Cynthia Browning). However, RPA 
expression has not been measured. RPA is involved in many processes including 
cell cycle, DNA damage checkpoints, DNA replication, and most DNA repair 
pathways (Zou et al., 2006). Further work is needed to understand if the miRNAs 
predicted to target RPA in our analysis have a significant impact on homologous 
recombination repair.  
Particulate Cr(VI) alters miRNAs that target pathways of Cr(VI) 
carcinogenesis 
We identified particulate Cr(VI)-upregulated miRNAs that target RAD51 and 
other proteins involved in homologous recombination repair, which is known to be 
an important in the mechanism of Cr(VI) carcinogenesis. Carcinogenesis is a 
complex process and involves many different pathways, and it is unknown how 
Cr(VI)-altered miRNAs affect other pathways of Cr(VI) carcinogenesis. To date this 
is the only study to evaluate global changes in miRNAs after Cr(VI) exposure. 




miRNAs. To address this gap in the literature, we identified up- or down-regulated 
miRNAs significantly affected by particulate Cr(VI) exposure then assessed them 
in the context of pathways of Cr(VI) carcinogenesis.  
Particulate Cr(VI) increased the number of significantly (adjusted p-
value<0.01) up- and down-regulated miRNAs compared to the control in all 
conditions. Increased expression of miRNAs is often associated with decreased 
translation of their mRNA targets. Therefore the upregulation of miRNAs by 
particulate Cr(VI) may increase the chance of those miRNAs binding to their target 
mRNA transcripts resulting in downregulation of translation. Conversely, the 
downregulation of miRNAs by particulate Cr(VI) may result in increased translation 
of their target mRNAs. The balance of up-and down-regulated miRNAs is a 
complex process. For example, the upregulation of a miRNA targeting an activator 
of a pathway may decrease activity in that pathway. Alternatively, the 
downregulation of a miRNA targeting a repressor may result in increased activity 
of that repressor’s target.  
In our analysis we observed a significantly higher number of miRNAs 
upregulated after 24 h exposure to 0.2 ug/cm2 zinc chromate compared to all other 
particulate Cr(VI) concentrations at any time point. In our previous studies on 
particulate Cr(VI) exposure we have found a different response after 24 h 
compared to prolonged 72 or 120 h exposure (Browning et al., 2016; Browning et 
al., 2017a; Holmes et al., 2006; Martino et al., 2015; Qin et al., 2014). However, 
the reason for the specific concentration effect after 24 h exposure to 0.2 ug/cm2 
zinc chromate is unknown. Apart from this anomaly, we found the total number of 
downregulated miRNAs under each condition was greater than the number of 
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upregulated miRNAs. For example, after 120 h exposure particulate Cr(VI) 
downregulated more than twice the number of miRNAs that were upregulated. This 
result suggests Cr(VI) causes more downregulation than upregulation of miRNAs 
and is the first assessment to show global expression of non-coding RNAs affected 
by Cr(VI) exposure. Indeed, studies show exposure to Cr(VI) alters global gene 
expression (Andrew et al., 2003; Izzotti et al., 2002; Wetterhahn and Hamilton, 
1989; Ye and Shi, 2001). One explanation for how Cr(VI) alters global expression 
may be Cr(VI) affects miRNAs targeting the transcriptional machinery in cells, 
however, further investigation of this possibility is required. 
Due to the large dataset we characterized the miRNAs significantly 
(adjusted p-value<0.01) affected by particulate Cr(VI) exposure. A stringent fold-
change cut-off of 2 was applied to focus on miRNAs that may have a more 
impactful biological responses in the cell. Analysis of miRNAs shared between 
treatment concentrations of up- or down-regulated revealed not many miRNAs 
were shared between the lowest and highest particulate Cr(VI) concentrations 
tested. This result indicates different concentrations of particulate Cr(VI) modulate 
expression of different sets of miRNAs. There are no studies addressing the impact 
of this effect. However, this result could have implications in the mixture of miRNAs 
available at any given concentration of particulate Cr(VI) exposure and affect how 
cells respond. 
Using Euclidean clustering to create heatmaps, we determined which 
miRNAs were up- or down-regulated with similar patterns across particulate Cr(VI) 
exposure conditions. We found strong clustering between miRNAs similarly 
affected by particulate Cr(VI) exposure. One endpoint considered was how the 
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miRNAs clustered after acute or prolonged particulate Cr(VI) exposure. When 
comparing the 24 h clustering to the 72 or 120 h clustering the 24 h clustering looks 
less similar to the 72 and 120 h clustering. This difference seems to be in part due 
to a large number of miRNAs with low fold change values in the 24 h data indicating 
they may not have a significant impact. It is also notable in the 24 h data there are 
more miRNAs included in the heatmap than 72 or 120 h, however, this likely 
reflects the spike in the total number of upregulated miRNAs after 24 h exposure 
to 0.2 ug/cm2 zinc chromate previously discussed. We also observed miRNAs in 
the 24 h data with a switch in expression patterns that was only observed in one 
miRNA in the 72 h dataset and not at all in the 120 h data set. For example, 
miRNAs went from being upregulated at 0.1 ug/cm2 zinc chromate to 
downregulated at 0.2 ug/cm2 zinc chromate, and then upregulated again at 0.3 
ug/cm2 zinc chromate or vice versa. These data indicate the trends in 
concentration-response were stronger after prolonged 72 and 120 h exposure than 
after 24 h exposure to particulate Cr(VI). This difference in the analysis at 24 h 
compared to prolonged 72 or 120 h exposure is consistent with trends in our 
previous data and highlights the different effects of acute verses prolonged Cr(VI) 
exposure (Browning et al., 2016; Browning et al., 2017a; Holmes et al., 2006; 
Martino et al., 2015; Qin et al., 2014). 
When we used this analysis to look closer at specific miRNA effects we 
found miR-194-1 was significantly upregulated after 72 h and after 120 h exposure 
had the highest fold change increase at that time point. Upregulation of miR-194-
1 was also reported in the liver of rats treated with arsenic although gene targets 




share similar mechanisms of carcinogenesis (Chen et al., 2019). Studies have 
begun to investigate how carcinogenic metals such as cadmium and arsenic alter 
global miRNA expression, but none have been done following Cr(VI) exposure (Liu 
et al., 2015; Ren et al., 2015). Hou et al., 2011 summarized a set of studies 
evaluating the effect of environmental chemicals including cadmium, arsenic, 
cigarette smoke, and metal-rich particulate matter on miRNA expression and found 
miR-210 was downregulated by arsenic trioxide (Cao et al., 2011). We also found 
miR-210 was downregulated after 24 h exposure to 0.3 ug/cm2 zinc chromate in 
our study. Additional studies comparing how metals alter miRNA expression may 
be insightful to their role in carcinogenesis. 
We used this differential miRNA expression data to identify and characterize 
pathways of Cr(VI) carcinogenesis targeted by particulate Cr(VI)-altered miRNAs. 
Pathways of Cr(VI) carcinogenesis were identified through a literature search of 
recent papers on this topic and aligning those pathways with pathways in the 
KEGG database. We noted trends in the number of genes predicted to be targeted 
by Cr(VI)-altered miRNAs in each pathway and identified which pathways were 
targeted by the most Cr(VI)-altered miRNAs. Of the cellular processes pathways 
cell cycle and apoptosis were two of the pathways predicted to have the most 
targeted genes. Cr(VI) is known to alter cell cycle and cell death mechanisms 
contributing to carcinogenesis (Gavin et al., 2007; O’Brien et al., 2002; Russo et 
al., 2005; Wise et al., 2006b). For example, Wise et al., 2006b showed prolonged 
exposure to particulate lead chromate induced spindle assembly checkpoint 
bypass altering cell cycle in WTHBF-6 cells. These cells also exhibited numerical 
chromosome instability, a hallmark of lung cancers. Russo et al., 2005 showed 
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Cr(VI) increased pro-apoptotic genes, however, this was only after acute 24 h 
exposure to high concentrations of soluble Cr(VI). It is currently unclear how 
subsets of Cr(VI)-exposure cells evade apoptosis to develop into malignant cells. 
Our miRNA analysis may provide insight into this mechanism. 
The pathway analysis also shows which pathways have bigger differences 
in the number of genes per pathway targeted by up- or down-regulated miRNAs 
and the total number of up- or down-regulated miRNAs predicted to target each 
pathway. For example, in the ubiquitin mediated proteolysis pathway after 24 h 
exposure to 0.3 ug/cm2 zinc chromate 16 genes were predicted to be targeted by 
downregulated miRNAs and 20 genes were targeted by upregulated miRNAs while 
only 2 downregulated miRNAs targeted genes in this pathway and 12 upregulated 
miRNAs targeted genes in this pathway. One consideration is that the number of 
predicted targets identified in any given KEGG pathways may play a role in our 
analysis. For example, we observed the PI3K-AKT pathway had the most genes 
targeted my Cr(VI)-upregulated miRNAs (13, 20, and 18 after 24, 72, and 120 h 
exposure to 0.3 ug/cm2 zinc chromate, respectively). While the PI3K-AKT pathway 
is extensive (354 genes), it is still worth noting this result to investigate further. This 
analysis demonstrates the complex dynamics of the relationship between miRNAs 
and their targets and highlights the need to better understand how miRNA-
regulated gene expression is controlled. 
Pathway analysis revealed correlations between these results and those of 
several studies that have investigated smaller sets of miRNAs. For example, Li et 
al., 2014 identified miR-3940-5p was altered by Cr(VI) exposure in human plasma 
and associated it with regulation of a gene in involved in homologous 
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recombination repair, a pathway targeted by Cr(VI)-altered miRNAs. However, we 
found miR-3940 was significantly increased, but only after 24 h exposure. 
Similarly, miR-4741 and miR-590 were reported as significantly down- and up-
regulated, respectively, in the Cr(VI) plasma study. In our RNAseq results we found 
miR-4741 was also downregulated after 24 h exposure to particulate Cr(VI) 
consistent with the plasma miRNA report. However, miR-590 was upregulated 
after 120 h exposure in our RNAseq data set contrary to being upregulated by 
Cr(VI) exposure in the blood. These results may be due to many factors including 
the source of the miRNAs (human plasma of people exposed to potassium 
chromate vs. cultured lung cells exposed to zinc chromate) and different study 
methods (microarray vs. RNAseq). In future studies these analyses can be used 
to further investigate miRNAs involved in pathways of Cr(VI) carcinogenesis 
providing a road map of affected targets. 
Our data support a recent analysis of pathways of Cr(VI) carcinogenesis 
suggesting Cr(VI)-altered epigenetic mechanisms lead to genomic instability as a 
key driver of Cr(VI) carcinogenesis (Rager et al., 2019). This hypothesis is 
supported by data showing Cr(VI) induces low-rates of point mutations while 
causing inheritable phenotypes (Ewis et al., 2001; DeFlora and Wetterhahn, 1989; 
Katabami et al., 2000; Kondo et al., 1997; Wise et al., 2018). Specifically, Cr(VI)-
altered miRNAs have been proposed to downregulate DNA repair factors 
ultimately leading to genomic instability. Our data support this hypothesis and it 
will be important to investigate how miRNAs contribute to the multiple mechanisms 




Leatherback lung cells are resistant to particulate Cr(VI)-inhibited 
homologous recombination repair 
Leatherback sea turtles are an excellent candidate for the One 
Environmental Health approach. Leatherbacks are a large marine reptile with a 
long lifespan and may be exposed to environmental contaminants throughout their 
life. Few studies have evaluated Cr levels in tissues of leatherback (Guzman et al,. 
2020; Perrault et al., 2019; Poppi et al., 2012). However, Guzman et al., 2020 
found Cr levels in leatherback eggs considered unsafe for humans. Cr was 
measured in another marine species, sperm whales (Physeter macrocephalus) 
and their tissues had Cr levels as high as levels found in human lung tissue from 
workers who died of chromate-induced lung cancer (Wise et al., 2009). These 
studies confirm Cr is a threat to marine species.  
While Cr(VI) induces chromosome instability in whale cells, the levels are 
far lower than those observed in human cells demonstrating a difference in 
response (Li Chen et al., 2009a; Li Chen et al., 2009b). We used this same 
approach to show Cr(VI) induces chromosome instability in leatherback sea turtle 
lung cells at similar levels to those observed in human lung cells although some 
differences in response were observed (Speer et al., 2018; Speer et al., 2019). 
Browning et al., 2017b began to investigate the mechanisms of chromosome 
instability in whale cells and showed RAD51 increases after both acute and 
prolonged Cr(VI) exposure in whale cells, but these levels were higher after acute 
Cr(VI) exposure. RAD51 and homologous recombination repair have not been 




We measured RAD51 foci after acute and prolonged exposure to particulate 
Cr(VI) in leatherback lung cells. We found RAD51 nuclear foci increased after 
acute 24 h exposure to particulate Cr(VI). However, after prolonged 120 h 
exposure RAD51 nuclear foci increased at lower concentrations slightly, then 
decreased to baseline levels at the higher concentrations. These data suggest 
RAD51 is inhibited after prolonged exposure to particulate Cr(VI) in leatherback 
lung cells and are consistent with results in human data (Browning et al., 2016; Qin 
et al., 2014).  
Homologous recombination repair is protective against Cr(VI)-induced 
genomic instability in human cells (Bryant et al., 2006; Stackpole et al., 2007). As 
we found RAD51 foci were decreased after prolonged particulate Cr(VI) exposure, 
we also assessed homologous recombination repair using the sister chromatid 
exchange assay. We found sister chromatid exchanges increase after 24 h with 
increasing particulate Cr(VI) concentration and increase further after prolonged 
120 h exposure. This result suggests homologous recombination repair is available 
to repair DNA double strand breaks after both acute and prolonged particulate 
Cr(VI) exposure.  
This result initially seems contradictory to our RAD51 outcomes we 
observed in turtle cells. It is tempting to suggest that Cr(VI) might be inducing sister 
chromatid exchanges not by inducing homologous recombination repair, but 
instead by inhibiting topoisomerase II. Historically, some data in the literature 
suggest topoisomerase II inhibitors can increase sister chromatid exchanges 
(Dillehay et al., 1989; Pommier et al., 1988). However, this possibility seems is 
unlikely to be a major contributor to our effect. First, the hypothesis that 
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topoisomerase inhibitors induce sister chromatid exchanges is controversial many 
reports show they do not increase sister chromatid exchanges (Fantini et al., 1998; 
Lim et al., 1986).  Secondly, topoisomerase II inhibitors ultimately cause DNA 
double strand breaks and these breaks can be repaired by homologous 
recombination repair. Thus, the most likely explanation for topoisomerase II inhibit-
induced sister chromatid exchanges is the induction of homologous recombination 
repair and not some homologous recombination repair-independent mechanism. 
Furthermore, the breaks after topoisomerase II inhibitors are predominately 
repaired by non-homologous recombination repair (Adachi et al., 2003, Kantidze 
and Razin, 2006; Terasawa et al., 2014). If Cr(VI) was inhibiting topoisomerase II, 
one would expect the breaks to be repaired by non-homologous end joining 
resulting in reduced sister chromatid exchanges and reduced RAD51 foci, but we 
did not find this outcome. Therefore, it seems unlikely that topoisomerase II 
inhibitions would explain this outcome. 
Another explanation for the difference between the RAD51 foci and sister 
chromatid exchange data is that homologous recombination repair in leatherbacks 
may differ than that in human cells where RAD51 is necessary for successful 
repair. RAD51 is highly conserved across species (Khoo et al., 2009). However, it 
is possible slight differences in the RAD51 protein may have affected the sensitivity 
of human RAD51 antibodies in the leatherback cells. Browning et al., 2017b also 
found RAD51 nuclear foci increased to lower levels after prolonged exposure then 
was observed after acute exposure, however, sister chromatid exchanges 
increased). This is consistent with the pattern of our result in leatherback lung cells. 
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Structural chromosome instability increases with Cr(VI) exposure in 
leatherback lung cells (Speer et al., 2018; Speer et al., 2019). Induction of DNA 
double strand breaks is a key event of structural chromosome instability, however, 
we found homologous recombination repair was active after prolonged particulate 
Cr(VI) exposure in leatherback lung cells. When we investigated DNA damage in 
leatherback lung cells we found no increase in DNA double strand breaks after 24 
or 120 h exposure to particulate Cr(VI) using the neutral comet assay in 
leatherback lung cells. However, we did observe an increase in gamma-H2AX foci 
after both 24 and 120 h exposure to particulate Cr(VI). The gamma-H2AX data 
indicate particulate Cr(VI) induces DNA double strand breaks after both acute and 
prolonged exposure, but these data do not correlate with our sister chromatid 
exchange data showing an increase in homologous recombination repair after 
acute and prolonged exposure to particulate Cr(VI). In contrast, our comet analysis 
does support the sister chromatid exchange data. There are several explanations 
that may explain the difference between the comet assay analysis and gamma-
H2AX data. One explanation may be due to assay sensitivity. The sensitivity of the 
comet analysis may not have been high enough to detect a significant change in 
DNA double strand breaks after particulate Cr(VI) exposure. In contrast, at least 
25% of cells had elevated levels of gamma-H2AX foci after the highest 
concentration of particulate Cr(VI) at both time points. Alternatively, the timing of 
the detection of gamma-H2AX compared to the detection of double strand breaks 
by comet assay may play a role in the different response. Future investigation is 
necessary to assess DNA repair dynamics in leatherbacks to determine how the 
timing of repair in leatherbacks may affect our results. 
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These data do not fully explain the increase in chromosome damage seen 
after prolonged particulate Cr exposure in leatherback lung cells (Speer et al., 
2019). Chromosome breakage during mitosis can induce structural chromosome 
instability contributing to higher levels of chromosome damage however, this 
mechanism has not been investigated after Cr(VI) exposure (Bayani et al., 2007). 
In conclusion, we have shown RAD51 was inhibited after prolonged exposure, 
however homologous recombination repair is uninhibited by prolonged particulate 
Cr(VI) exposure demonstrated by our sister chromatid exchange data. These 
results provide the first mechanistic data on how Cr(VI) causes chromosome 
instability in leatherback sea turtle cells. 
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FUTURE DIRECTIONS 
This study provides data contributing to the mechanistic insight of Cr(VI)-
induced carcinogenesis. It provides the first analysis of transcriptional regulation 
of RAD51 following Cr(VI) exposure and the role of E2F1 in this process. We also 
present the first global analysis of miRNAs after Cr(VI) exposure in human cells 
using RNAseq analysis. These data were applied to identify miRNAs targeting 
pathways of Cr(VI) carcinogenesis, and specifically homologous recombination 
and RAD51. We also demonstrated for the first-time mechanisms involved in DNA 
repair in leatherback cells. However, these data generated many new ideas and 
hypotheses to investigate in the future. 
First, while we showed E2F1 did not modulate RAD51 expression after 
particulate Cr(VI) exposure directly it would be important to test E2F1 binding the 
RAD51 promotor and its ability to transcribe the RAD51 gene. Investigating this 
possibility could be accomplished using the ChIP assay and a gene reporter 
system. It is possible other proteins involved in E2F1-mediated transcription are 
affected by Cr(VI) exposure, and thus, are required for successful expression of 
RAD51. Specifically, the release of E2F1 from the retinoblastoma protein is 
required for E2F1 to perform its transcriptional function. E2F1 must also associate 
with its dimerization protein to enhance transcription. These functions could be 
tested using proximity ligation assay as well as the ChIP assay. In lung cells E2F1 
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may be more important for RAD51 localization at double strand breaks than 
transcription. This hypothesis could be tested using immunofluorescence assays. 
Knocking down E2F1 in a direct repeat green fluorescent protein (DR-GFP) 
reporter system for homologous recombination repair may elucidate if E2F1 is 
essential for homologous recombination repair after Cr(VI) exposure. Additionally, 
we showed E2F4 may play a role in RAD51 repression. It would be interesting to 
pursue this hypothesis by overexpressing E2F4 or knocking it down to test the 
effect on RAD51 and homologous recombination repair. Using the ChIP assay to 
investigate if Cr(VI) displaces E2F1 with E2F4 would provide insight into regulation 
of RAD51 transcription specifically. 
In Aim 2, we provided extensive hypothesis-driving data. It will be interesting 
to compare the results of Cr(VI)-altered miRNAs with miRNAs altered by other 
metals to better understand mechanisms of metal carcinogenesis. Additionally, 
looking closer at the miRNAs with the highest fold-change in expression and their 
targets in more detail warrant further investigation. Validation of some of the 
differentially expressed miRNAs identified in the RNAseq analysis using qPCR 
would confirm their change in expression after particulate Cr(VI) exposure. 
Additionally, using miRNA mimics of specific miRNAs from the analysis can be 
used to confirm effects on targets of select miRNAs, and specifically of RAD51. 
While we investigated specific genes in the homologous recombination pathway 
predicted to be targeted by Cr(VI)-upregulated miRNAs this type of analysis would 
be insightful for other pathways in Cr(VI) carcinogenesis as well. 
Finally, further investigation into the mechanisms of genotoxicity in 
leatherback lung cells warrant further investigation to elucidate differences in DNA 
223 
damage and repair. It will be important to perform cell cycle analysis to determine 
if Cr(VI) induces cell cycle arrest. Additionally, measuring RAD51 using western 
blot analysis may provide a more clear image of how Cr(VI) affects RAD51 in 
leatherback lung cells. Additionally, performing time course analysis of DNA repair 
to characterize the time it takes for leatherback lung cells to repair double strand 
breaks would be insightful to the dynamics of repair. These data might also explain 
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at the World Marine Mammal Science Conference, Barcelona, Spain, December, 2019. 
 
22.  Isusi, I.M., Speer, R.M., Toyoda, J.H., and Wise, Sr., J.P. The Characterization of the 
Toxicologic Effects of Particulate Hexavalent Chromium in Female and Male Fin Whale 
Cells. Presented at the World Marine Mammal Science Conference, Barcelona, Spain, 
December, 2019. 
 
23.   Speer, R.M., Zhou, X., Liu, K.J., Browning, C.L., Kondo, K., Wise, Sr., J.P. Chromate-
Induced Loss of E2F1 Inhibits RAD51 Response in Homologous Recombination Repair. 
Presented at the Ohio Valley Chapter of the Society of Toxicology (OVSOT) annual 
meeting, October, 2019.  
 
24.  Meaza, I., Speer, R.M., Toyoda, J.H. Wise, J.P., Sr. Particulate Hexavalent Chromium 
Induces Cytotoxicity and Genotoxicity in Female and Male Fin Whale Primary Fibroblasts. 
Presented at the Ohio Valley Chapter of the Society of Toxicology (OVSOT) annual 
meeting, October, 2019. 
 
25. Wise, J.P., Jr., Lu, H., Meaza, I., Wise, S.S., Croom-Perez, T., Speer, R.M., Toyoda, 
J.H., Ali, Abdulmehdi, Cai, L., Liu, K.J., Wise, J.T.F., Young, J.L., Wise, J.P., Sr. An 
Environmental Toxicology Assessment of Heavy Metal Accumulation in American 
Alligators in Florida. Presented at the Ohio Valley Chapter of the Society of Toxicology 
(OVSOT) annual meeting, October, 2019. 
 
26. Meaza, I.M., Speer, R.M., Toyoda, J.H., Wise, Sr., J.P. Particulate Hexavalent 




Official abstract for the Society of Toxicology annual meeting, March 2020 (Canceled – 
Covid-19). 
 
27. Speer, R.M., Zhou, X., Liu, K.J., Browning, C.L., Kondo, K., Wise, Sr., J.P. Chromate-
Induced Loss of E2F1 Inhibits RAD51 Response in Homologous Recombination Repair. 
Official abstract for the Society of Toxicology annual meeting, March 2020 (Canceled – 
Covid-19).  
 
28. Lu, H., Browning, C.L., Wise, S.S., Speer, R.M., Lu, K.J., Wise, Sr., J.P. How 
Chromium Induces Genomic Instability: Lessons from Human and Whale Cells. Presented 
at the Sixteenth International Symposium on Recent Advances in Environmental Health 
Research, March, 2020 (Postponed – Covid-19). 
 
University Student Research Day Presentations 
1.  Speer, R.M., The, T., and Wise, Sr., J.P. The Cytotoxicity and Genotoxicity of 
Particulate and Soluble Cobalt in Human Urothelial Cells. Presented at 
Research!Louisville, University of Louisville, 2015. 
 
2.  Speer, R.M., Young, J.L., Martin Bras, M., Barandiaran, M. Marquez-D’Acunti, L. and 
Wise, Sr., J.P. A Comparison of the Cytotoxicity and Genotoxicity of Particulate and 
Soluble Hexavalent Chromium Leatherback Sea Turtle (Dermochelys coriacea) Lung 
Cells. Research!Louisville, 2016. 
 
3.  Rossman, J., Speer, R.M., Wise, S.S. and Wise, Sr., J.P. Cytotoxic Effects of Chromate 
Exposure on Alligotr Skin and Bronchial Cells. Presented at Research!Louisville, 
University of Louisville, 2016. 
 
4.  Speer, R.M., Browning, C.L. and Wise, Sr., J.P. Chromate-Induced Suppression of 
E2F1 and RAD51 in the Homologous Recombination Response. Presented at 
Research!Louisville, University of Louisville, 2017. 
 
5.  McBride, D.E., Perez, A.A., Raph S.M., Speer R.M., Croom-Perez T.J., Wise S.S. and 
Wise, Sr., J.P. A One Health Case Study: Comparison of DNA Damage Response to 
Hexavalent Chromium in Alligator and Human Lung Fibroblasts. Presented at 
Research!Louisville, University of Louisville, 2017. 
 
6.  Toyoda, J.H., Martino, J., Speer, R.M., and Wise, Sr., J.P. Mechanisms of Hexavalent 
Chromium-Induced Centriole Disengagement and Centrosome Amplification. Presented 
at Research!Louisville, University of Louisville, 2017. 
 
7.  Speer, R.M., Young, J.L., Wise, S.S., Raph, S.M., Martin Bras, M., Barandiarin, M., 
Marquez-D’Acunti, L., and Wise, Sr., J.P. Using Leatherback Sea Turtles (Dermochelys 
coriacea) as a Model Species for Metal Toxicology Research and Public Education in 
Vieques, Puerto Rico. Presented at the Graduate Student Regional Research 
Conference, University of Louisville, 2018. 
 
8.   Speer, R.M., Browning, C.L, and Wise, Sr., J.P. Suppression of E2F1 and RAD51 in 






9.  Speer, R.M., Zhou, X., Liu, K.J., Browning, C.L., Kondo, K., Wise, Sr., J.P. Chromate-




10.  Wise, S.S., Miller, E., Daniel, S., Meaza, I., Toyoda, J.H., Lu, H., Speer, R. M., Young, 
J. L., Isakov, R., Jaggers, H., Wise, Jr., J. P., Croom-Perez, T. J., Cai, L., Hoyle, G., Wise, 
Sr., J. P. Effects of Chronic Exposure to Particulate Chromate in Rat Lungs. Presented at 
Research!Louisville, 2019. 
 
Seminars/Oral Presentations  
2019 Tox on the Clock, Three Minute Thesis Competition, Ohio Valley Regional Chapter 
of the Society of Toxicology (OVSOT) annual meeting, Cincinnati, Ohio. 
 
2019 Speer, R.M., Browning, C.L., Wise, J.P., Sr. “The Role of E2F1 in Chromate-
Induced RAD51 Suppression” Graduate Student Research Conference, University 
of Louisville, Louisville, KY.  
 
2019 Speer, R.M., Wise, C.F., Wise, S.S., Martin Bras, M., Barandiaran, M., Marquez, 
L., Bermudez, E., Wise, J.P., Sr. Environmental Impacts on Leatherback Sea 
Turtle Health: Using a One Health Approach to Study Metal Pollution in Wildlife. 
International Sea Turtle Symposium, Charleston, SC. 
 
2019 Speer, R.M. “Methods to Characterize and Assess Genotoxicity in Leatherback 
Sea Turtles.” Environmental Contaminants in Sea Turtles Workshop, International 
Sea Turtle Symposium, Charleston, SC. 
 
2018 “Mechanisms of E2F1 Suppression of RAD51 in Chromate-Induced Failure of 
Homologous Recombination.” 20th Annual Midwest DNA Repair Symposium, 
Columbus, OH. May, 2018. 
 
2017 “A Comparison of the Cytotoxicity and Genotoxicity of Particulate and Soluble 
Hexavalent Chromium in Human and Leatherback Sea Turtle (Dermochelys 
coriacea) Lung Cells.” 8th Meeting of Aquatic Animal Models of Human Disease, 
University of Alabama, Birmingham, AL. January, 2017. 
 
2016 “Developing a Thesis: The Role of E2F1 in Cr(VI)-Induced Carcinogenesis.” 
Cancer Center Colloquia Series, University of Louisville, Louisville, KY. April, 2016. 
 
2014 “Cytotoxicity and Genotoxicity of Particulate and Soluble Cobalt in Human 
Urothelial Cells.” Department of Applied Medical Sciences Seminar Series. 
University of Southern Maine, Portland, ME.  
 
Public Presentations 
2018 “One Environmental Health: Investigating Toxicology with Sea Turtles and 
Humans.” Vieques Conservation and Historical Trust Speaker Series, Vieques, 
Puerto Rico.  
 
2017 “The What, How, and What Now of Toxicology.” Future Problem Solvers Mentor 





2016 “Wise Laboratory Research in Vieques: Implications and Future Directions.” 
Vieques Conservation and Historical Trust Speaker Series, Vieques, Puerto Rico.  
 
Field Work 
2018 Conducted alligator sampling expedition at Kennedy Space Center, Lake 
Woodruff and Lake Apopoka, Florida. 
 
2017 Conducted sample collecting in the Gulf of California (Sea of Cortez), 
Mexico during the spring season. Biopsies were taken from fin, humpback, 
minke, Bryde’s, blue, pilot and sperm whales. 
2017-Present Conducted sample collecting in the Gulf of Maine during the fall season. 
Biopsies were taken from fin, humpback and minke whales. 
 
2015-Present Conducted alligator sampling expeditions at Kennedy Space Center, 
Florida. 
2015-Present Developed a marine field research laboratory in Vieques, Puerto Rico. 
Conducted sampling programs for fish and sea turtles. 
 
Committees 
2018-Present Policy Coordinator, Science Policy and Outreach Group, University of 
Louisville 
 
2019-2020 Member, FUTURE Committee, Society of Toxicology 
 
2019-2020 Member, Programming Subcommittee, Graduate Student Leadership 
Committee, Society of Toxicology 
 
2018-2020 Metals Specialty Section Graduate Student Representative 
 
2018-2019 President of the Pharmacology and Toxicology student body, Department 
of Pharmacology and Toxicology, University of Louisville 
 
2018-2019 Research Grant Review Committee, Graduate Student Council, University 
of Louisville 
 
2018-2019 Member, Continuing Education Committee Graduate Student 
Representative, Society of Toxicology  
 
2018-2019 Member Professional Development Subcommittee, Graduate Student 
Leadership Committee, Society of Toxicology 
 
2017-2018 President of third year graduate student class, Department of 
Pharmacology and Toxicology, University of Louisville 
 
Continuing Education Coursework 
2020 Professional Development Webinar, “Navigating the K99/R00 Grant Process,” 
American Society for Cell Biology. 
 
2020 Professional Development Webinar, “Transitioning to Independence Webinar 
Series Part 3: How to Get the Most out of Your Mentoring Relationships,” 





2019 Continuing Education Course, “Assay Development Principles and Good 
Research Practices for Rigor and Reproducibility in In Vitro Toxicology,” Society of 
Toxicology. 
 
2018 Superfund Seminar Series, “Superfund Research Program Progress in Research 
Webinar Part 2: University of Louisville, University of New Mexico, and University 
of Washington,”  
 
2018 Superfund Seminar Series, “Superfund Research Program Progress in Research 
Webinar Part 3: Columbia University, Massachusetts Institute of Technology, and 
University of Rhode Island,”  
 
2018 Superfund Seminar Series, “Superfund Research Program Progress in Research 
Webinar Part 4: Boston University, Texas A&M University, and University of 
California, Davis,” 
 
2017 Webinar, “Defining a cancer cell-specific mechanism of resistance to 
Topoisomerase I poisons,” Society of Toxicology Webinar. 
 
2017 Webinar, “Finding Your Dream Job in Regulatory Toxicology,” Society of 
Toxicology Webinar. 
 
2017 Continuing Education Course, “Basic Principles of Human Risk Assessment,” 
Society of Toxicology. 
 
2014 Webinar, “New Frontiers in Chemical Carcinogenesis, Association of Scientists of 
Indian Origin,” Society of Toxicology. 
2014 Webinar, “Increasing Your Visibility and Participation in SOT as an Early Career 
Toxicologist, SOT Postdoctoral Assembly,” Society of Toxicology. 
 
2014 Webinar, “Postdoctoral Representative Fall Webinar,” SOT Postdoctoral 
Assembly, Society of Toxicology. 
 
Professional Memberships & Societies: 
2020-Present Graduate Student Member, Society of Environmental Toxicology and 
Chemistry 
 
2017-Present Graduate Student Member, Women in Toxicology Special Interest Group, 
Society of Toxicology 
 
2016-Present Graduate Student member, National Postdoctoral Association  
 
2015-Present Graduate Student Member, Science Policy and Outreach Group  
 
2015-Present Graduate Student Member, American Association for the Advancement of 
Science,  
 






2014-Present Graduate Student Member, Society of Toxicology 
 
2014-Present Graduate Student Member, Carcinogenesis Specialty Section, Society of     
Toxicology 
 
2014-Present Graduate Student Member, Metals Specialty Section, Society of 
Toxicology 
 
2014-2015 Northeast Regional Chapter, Society of Toxicology 
 
Volunteer and Community Work 
2020 Head Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville, 
KY. 
 
2019 Activity Leader, Girls Rule STEM+Health Summit, Speed School of Engineering, 
University of Louisville, Louisville, KY.  
 
2019 Event Leader, Louisville Regional Science and Engineering Fair Advocacy Day at 
the Capital, Frankfort, KY. 
 
2019 Head Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville, 
KY.  
 
2018 Project Mentor, Central High School Students for Kentucky Science Fair, Kentucky 
Science Center, Louisville, KY.  
 
2018 Presenter and Program Organizer, Manta Environmental Summer Education 
Programs, Vieques Conservation and Historical Trust, Vieques, Puerto Rico.  
 
2017 Program Organizer, Future Problem Solver’s Competition Preparation Workshop, 
Kentucky Association for Academic Competition, University of Louisville, 
Louisville, KY.  
 
2017 Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville, KY.  
 
2017 Program Assistant, Manta Environmental Summer Education Program, Vieques 
Conservation and Historical Trust, Vieques, Puerto Rico.  
 
2016 Volunteer, U.S. Fish and Wildlife Service beach clean-up program, Vieques, 
Puerto Rico. 
 
2016 Program Assistant, Manta Environmental Summer Education Program, Vieques 
Conservation and Historical Trust, Vieques, Puerto Rico.  
 
2016 Head Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville, 
KY. Judged posters for middle school students. 
 
2015 Program Assistant, Manta Environmental Summer Education Program, Vieques 





2015 Project Mentor, Science Fair Student Mentoring Session, Science Policy and 
Outreach Group, University of Louisville and Kentucky Science Center, Louisville, 
KY.  
 
2015 Project Assistant, Research!Louisville High School Student Graduate School 
Information Session, Science Policy and Outreach Group, University of Louisville 
and Kentucky Science Center, Louisville, KY.  
 
2014 Event Volunteer, Annual Wild & Scenic Film Festival, Friends of Casco Bay, 
Portland, ME.  
 
Volunteer, Annual beach clean-ups, Environmental Health and Toxicology Club, 
University of Southern Maine, Portland, ME. 
